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Investigating the Safety and Efficacy of Regenerative Medicine Therapies 
in Mouse Models of Kidney Disease, by Lauren Scarfe 
Acute kidney injury (AKI) and chronic kidney disease (CKD) are serious health problems with 
high morbidity and mortality. There are currently no specific treatments available to patients 
with AKI or CKD, and many patients require renal replacement therapy to survive. Cell-based 
regenerative medicine therapies have shown potential for treating AKI and CKD in preclinical 
models, however conventional methods of measuring kidney function and tracking 
exogenously administered cells are not ideal. Novel imaging-based methods provide an 
alternative approach, allowing kidney function and cell biodistribution to be monitored 
longitudinally, without sacrificing many animals at multiple time points. The work in this 
thesis aimed to evaluate the use of two novel methods for assessing kidney function in mice, 
and apply them in the assessment of cell therapy efficacy in two preclinical models of kidney 
disease. Furthermore, preclinical imaging approaches were used to track cell biodistribution 
in vivo, in order to gain insights into the mechanism of action of cell therapy, and long-term 
safety.  
Two novel methods of measuring kidney function were assessed: 1) transcutaneous 
measurement of FITC-sinistrin clearance, and 2) photoacoustic imaging of IRDye clearance 
kinetics. The transcutaneous measurement of FITC-sinistrin clearance was found to be a 
superior method of measuring kidney function in mice, correlating more strongly with 
histological assessment of structural damage compared with traditional biochemical 
techniques in the adriamycin model of CKD, and the ischemia-reperfusion model of AKI. 
Photoacoustic imaging of IRDye clearance kinetics was also found to correlate better with 
histology in the adriamycin model, however the transcutaneous method was preferred for 
subsequent studies due to practical considerations including shorter anaesthesia time, higher 
throughput data collection, and ease of data handling.  
The efficacy of human kidney-derived cells (hKCs) was assessed following early and late 
administration in the adriamycin model. It was found that the hKCs induced a trend towards 
improved kidney function when administered on day one, but there was no effect when 
treatment was delayed until day 15, after overt proteinuria was established. Furthermore, 
bioluminescence imaging of luciferase+ hKCs demonstrated that intravenously administered 
hKCs remained trapped in the lungs, where they promptly died and did not migrate to the 




and suggest that efficacy may be absent or diminished when treatment is administered later 
in the course of the disease. 
The efficacy of hKCs was also assessed in the ischemia-reperfusion model, and was compared 
with human mesenchymal stromal cells derived from either bone marrow or the umbilical 
cord. These results were unexpected, as it was found that none of the cell types tested had 
any effect on kidney structure or function, and furthermore, the cells did not die in the lungs 
within 24h of administration. These results may allude to a potential role of cell death in the 
mechanism of action of cell therapy, however this requires a great deal of further 
investigation.  
Finally, preclinical imaging techniques were used to optimise an intracardiac method of cell 
administration, and to compare the short- and long-term biodistribution of cells following 
intravenous and intracardiac administration. Intracardiac administration was shown to 
deliver cells to all organs of the body, including the kidney, and a multi-modal imaging 
approach enabled whole-body imaging of live cells by bioluminescence imaging, in 
conjunction with detailed organ-specific imaging of intra-organ biodistribution with magnetic 
resonance imaging. Longitudinal bioluminescence imaging demonstrated the effect of route 
of administration on tumour development, with intracardiac administration leading to more 
aggressive tumour development compared with intravenous administration. These results 
highlight the value of preclinical imaging in the assessment of regenerative medicine 
therapies, and show the importance of longitudinal monitoring of the safety of a cell therapy. 
Overall, the results of this thesis demonstrate the use of novel imaging-based methods of 
assessing kidney function and cell biodistribution in preclinical assessment of the safety and 
efficacy of cell-based regenerative medicine therapies. These minimally-invasive methods 
are more reliable than traditional analyses, and allow individual animals’ responses to be 
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1.1 The Kidney: Structure and Function 
The kidneys perform various functions in the body and are essential organs for life. The 
primary function of the kidneys is to act as a filter for the blood; removing waste products 
and excreting them from the body via urine, in addition to maintaining the volume, pH, and 
ion homeostasis of blood. When the kidneys do not function correctly, waste products and 
fluid build up in the body, and abnormal pH and electrolyte levels interfere with the function 
of various other organs of the body, and thus kidney dysfunction can be fatal.  
1.1.1 The Structure of the Kidney and Urine Production1 1,2 
Kidneys exist in pairs, and are located by the posterior abdominal wall, with the left kidney 
having a slightly higher position in the body than the right. The kidney is enclosed in a fibrous 
capsule, and surrounded by a protective layer of perirenal fat. The kidneys are supplied by 
the renal arteries, which branch off from the abdominal aorta. Together, the kidneys receive 
approximately 20% of the cardiac output3. The nephron (Fig. 1.1) is the functional unit of the 
kidney: there are typically one million nephrons in each human kidney, although this varies 
considerably between individuals, from just 250,000 to over 2.5 million nephrons per kidney, 
and this is strongly correlated with birth weight4. Each nephron comprises a renal corpuscle, 
consisting of a glomerulus and Bowman’s capsule, and a renal tubule, consisting of a proximal 
tubule (straight and convoluted portions), the loop of Henle, and a distal tubule (straight and 
convoluted portions), which empties into a collecting duct. 
The parenchyma of the kidney is divided into the cortex and the medulla: the nephron begins 
with the renal corpuscle and the proximal tubule located in the cortex, the loop of Henle then 
dips into the medulla, and the distal tubule returns the nephron back to the cortex. The 
human kidney contains multiple renal pyramids within the medulla, whereas the kidney of 
small mammals, such as the mouse, only has one renal pyramid5. The medulla can be divided 
into an outer and inner zone, and the outer zone can be further divided into an outer and 
inner stripe. The outer stripe of the outer medulla (OSOM) contains the straight portions of 
the proximal and distal tubules, the thick ascending limb of the loop of Henle, and the 
collecting ducts. The inner stripe of the outer medulla (ISOM) contains the thick ascending 
limb and the thin descending limb of the loop of Henle, and the collecting ducts.
                                                          
1 Two book chapters, Halgrimsson et al., (2003) and McBride et al., (2016), provided the information 









The inner medulla contains the thin ascending and descending limbs of the loop of Henle and 
larger collecting ducts which empty into the renal pelvis. 
Two types of nephrons exist, classified according to their starting location and length of the 
tubules. Cortical nephrons are the most abundant, making up approximately 85% of all 
nephrons. The glomeruli of cortical nephrons are located in the outer portion of the cortex 
and have shorter loops of Henle, generally extending only to the ISOM. Juxtamedullary 
nephrons have glomeruli located in the inner cortex, close to the border between the cortex 
and medulla, and tend to have much longer tubules, with the loop of Henle extending deep 
into the inner medulla.  
The Renal Corpuscle 
The renal corpuscle is comprised of the glomerulus and the Bowman’s capsule, which is 
continuous with the proximal tubule and surrounds the glomerulus. The space between 
these two structures is known as the Bowman’s space. The glomerulus is a tightly packed tuft 
of capillaries which selectively filters components of the blood through its filtration barrier, 
to produce an ultrafiltrate. The filtration barrier is comprised of1,6: 
1) Highly fenestrated endothelial cells of the glomerular capillaries, which serve as a size-
specific barrier to cells and large macromolecules within the blood, only permitting the 
filtration of water and small molecules through the fenestrations. 
2) The glomerular basement membrane (GBM), which consists of type IV collagen, 
fibronectin, laminin, and proteoglycans. The GBM provides structural support to the 
glomerulus and protects the filtration barrier from the hydrostatic pressure generated 
within the glomerular capillaries. 
3) Podocytes, which are highly specialised epithelial cells formed from the visceral layer 
of the Bowman’s capsule, form the final component of the filtration barrier. Podocytes 
have a large cell body and extend long cytoplasmic processes which wrap around the 
glomerular capillaries. These lead to secondary processes called pedicels, which 
interdigitate with the pedicels of adjacent podocytes, forming a network of narrow 
filtration slits between the glomerular capillaries and the Bowman’s space. The 
filtration slits are bridged by the slit diaphragm, which is a filamentous, porous sheet 
that serves as an additional size-specific barrier to macromolecules.  
Additionally, the renal corpuscle also contains mesangial cells, located between the capillary 




provide structural support to the GBM, and also function to phagocytose any 
macromolecules trapped within the GBM.  
Blood enters the kidney via the renal artery, which branches to form the afferent arteriole 
that enters the glomerulus at the vascular pole of the renal corpuscle, and leaves the 
glomerulus via the efferent arteriole. The hydrostatic pressure from blood flowing through 
the glomerular capillaries forces water and small solutes, such as amino acids, salts, urea, 
creatinine, and glucose, out of the plasma. In addition to filtering based on the size of 
molecules, the glomerular filtration barrier also selects molecules based on charge. Many 
components of the filtration barrier are negatively charged, and this therefore prevents 
negatively charged molecules, such as plasma proteins, from crossing the barrier. 
Importantly, while large proteins such as albumin are generally blocked by the filtration 
barrier, approximately 0.06% of plasma albumin manages to pass through the filtration 
barrier, owing to the flexibility and ellipsoid shape of the albumin molecule enabling it to 
slide through the filtration slits7. The majority of the filtered albumin is then reabsorbed, 
predominantly by the proximal tubule, resulting in very low albumin excretion in the urine of 
healthy individuals. The resulting ultrafiltrate is forced into the Bowman’s space and then 
passes through to the proximal tubule at the urinary pole of the renal corpuscle. 
The Proximal Tubule 
The proximal tubule is responsible for reabsorption of proteins, amino acids, and glucose, 
and most of the reabsorption of water and salts from the ultrafiltrate produced in the renal 
corpuscle. Nitrogenous waste products, including urea and creatinine, are not reabsorbed at 
any point throughout the tubules, and remain in the filtrate. Cells of the proximal tubule are 
highly adapted for reabsorption, with a dense brush border of microvilli on the apical surface 
of tall tubular cells, which greatly increase the surface area available for reabsorption. The 
proximal tubule reabsorbs around 50 – 60% of the water and solutes filtered by the 
glomerulus8. The proximal tubule consists of a convoluted and a straight portion, and there 
is significant morphological variation throughout the tubule, and as such it can be divided 
into three segments, S1, S2, and S3. The S1 and S2 segments have greater rates of water and 
solute reabsorption, whilst the S3 segment establishes high solute concentration gradients8. 
Further along the proximal tubule, the cells become shorter in height and the brush border 






The Loop of Henle 
The loop of Henle consists of three distinct portions, the thin descending limb, the thin 
ascending limb, and the thick ascending limb, all of which are surrounded by an extensive 
vascular network, the vasa recta. The loop of Henle provides a ‘counter-current multiplier’ 
function, the purpose of which is to modify the water and solute content of the ultrafiltrate 
to produce a concentrated urine. The cells of the different portions of the loop have differing 
permeability to water and salts, thus creating an osmotic gradient in the renal medulla. The 
thin descending limb is freely permeable to water and salts, allowing water to passively 
diffuse by osmosis into the interstitial space, while sodium chloride (NaCl) and urea diffuse 
from the blood in the vasa recta into the lumen of the loop. The thin ascending limb is 
permeable to salts but impermeable to water, and the thick ascending limb is impermeable 
to water, and actively transports NaCl from the filtrate.  
The Distal Tubule 
Like the proximal tubule, the distal tubule is divided into a straight and a convoluted portion. 
The straight distal tubule is continuous with the thick ascending limb of the loop of Henle and 
also functions to actively pump NaCl out of the lumen of the tubule, whilst remaining 
impermeable to water. The distal tubule travels from the medulla back to the cortex and 
transitions from a straight tubule to the convoluted tubule. The convoluted distal tubule is 
responsible for removing any remaining sodium, and actively secretes hydrogen and 
potassium ions into the filtrate. 
Following glomerular filtration and tubular modification of water and solute content, the 
resulting product is a concentrated urine, containing nitrogenous waste products and excess 
water. Urine is transported from the distal tubule, via a collecting tubule, to the collecting 
duct.  
The Collecting Duct 
The collecting duct is the final portion of the nephron, and serves multiple collecting tubules 
in the surrounding area. The collecting duct then delivers the urine to the renal pelvis, which 
is continuous with the ureter, and transports urine into the bladder. 
1.1.2 Additional Functions of the Kidney 
The kidney is also involved in maintaining homeostasis across the whole body. The regulation 




bicarbonate from the filtrate, and secreting H+ and K+ into the filtrate. The kidney also 
participates in the renin-angiotensin-aldosterone system in order to regulate extracellular 
fluid volume and sodium and water balance, thus regulating blood pressure.  Renin is 
secreted by juxtaglomerular cells in the kidney in response to various factors, including 
hydrostatic pressure in the afferent arterioles of the glomeruli, angiotensin II levels, and 
sodium concentration in the macula densa. Renin is an enzyme which cleaves 
angiotensinogen, produced by the liver, forming angiotensin I. Angiotensin-converting-
enzyme (ACE) then converts angiotensin I to angiotensin II. There are two subtypes of 
receptor which angiotensin II acts upon, each with opposing roles. In addition to various 
other roles, activation of type I receptors leads to systemic and renal vasodilation, thus 
decreasing blood pressure, and activation of type II receptors leads to systemic and renal 
vasoconstriction, thus increasing blood pressure9.  
As such, the kidney is a vital organ involved in various important aspects of whole-body 
homeostasis. Dysfunction of the kidney is therefore a serious health problem which reduces 
the quality of life of an individual and can lead to death.  
 
1.2 Acute Kidney Injury and Chronic Kidney Disease: A Global Problem 
1.2.1 Acute Kidney Injury 
Kidney disease constitutes a serious health problem worldwide, with high costs for both the 
patient and the economy. Acute kidney injury (AKI) is defined as a rapid decline in kidney 
function over hours or days; resulting in a systemic accumulation of waste products such as 
creatinine and urea10. AKI is a common complication in hospitalised patients; affecting 
around 20% of adults and 30% of children worldwide11, with risk factors including older age, 
underlying chronic kidney disease (CKD), and pre-existing conditions such as cardiovascular 
disease and diabetes mellitus12. AKI can arise from a wide range of aetiologies, predominantly 
ischemia13,14, drug toxicity15-18, or sepsis19,20, and can range in severity from mild changes in 
kidney function to severe impairment of function requiring renal replacement therapy (RRT). 
AKI is associated with high morbidity and mortality: approximately 1 - 2% of AKI patients 
require RRT, and of those, 40 - 60% do not survive21. Previously, the term acute renal failure 
(ARF) was used to describe the acute loss of kidney function, however as the understanding 
of the syndrome increased, it became apparent that even mild changes in serum creatinine 
were associated with mortality22. As such, the term AKI was developed in order to reflect the 




Until relatively recently, there was a lack of standardisation for the characterisation and 
definition of AKI, with more than 35 different definitions used in AKI diagnosis23. The 
requirement for standardisation in staging AKI led to the development of the RIFLE criteria 
by the Acute Kidney Injury Network24. RIFLE is an acronym reflecting the increasing severity 
stages of kidney injury: Risk, Injury, Failure; and the potential outcomes: Loss and End-Stage 
Renal Disease (ESRD). This system was further refined to include patients with mild changes 
in serum creatinine of just 0.3mg/dL and above, and to exclude the ‘L’ and ‘E’ outcomes25, 
and thus a three-stage classification system was developed25,26 (Table 1.1). 
 
Stage Serum Creatinine Urine Output 
1 
1.5 – 1.9 times baseline 
< 0.5ml/kg/h for 6 – 12h OR 
≥ 0.3 mg/dL 
2 2.0 – 2.9 times baseline < 0.5ml/kg/h for ≥ 12h 
3 
3.0 times baseline  
OR < 0.3 ml/kg/h for ≥ 24h 
≥ 4.0 mg/dL OR 
OR anuria for ≥ 12h 
initiation of RRT  
 
The tubules are the predominant site of injury in AKI, and while there are some differences 
in the pathophysiology depending on the aetiology of AKI, common histopathological 
findings include a loss of the brush border on proximal tubules, detachment of tubular 
epithelial cells, sloughing of cells and cellular debris into the lumen of tubules, and the 
formation of casts within tubules13,27. The proximal tubule is the most sensitive part of the 
tubule to injury for two main reasons. 1) During ischemia, cells of the proximal tubule cannot 
efficiently use glycolysis for adenosine triphosphate (ATP) production, and as such are highly 
sensitive to ischemia; 2) the majority of tubular reabsorption takes place in the proximal 
tubule, so toxins filtered by the glomerulus will affect proximal tubular cells the most28. 
However, the kidney has a remarkable capacity for regeneration following an episode of AKI. 
Surviving tubular cells dedifferentiate to a progenitor-like state, migrate along the basement 
membrane of the denuded tubule, where they then proliferate and re-differentiate to 
replace lost tubular cells13,28,29. However, AKI is often associated with maladaptive repair, in 
which the resolution of kidney injury and functional recovery are incomplete, leading to 
persistent and progressive loss of kidney function. Maladaptive repair following AKI is more 
Table 1.1:  The stages of AKI. Table adapted from Kidney Disease: Improving Global 




common with increasing age, chronic insults to the kidney, and other co-morbidities, and is 
characterised by tubular loss, fibrosis, glomerulosclerosis, chronic inflammation, and 
vascular rarefaction30.  
1.2.2 Chronic Kidney Disease 
Chronic kidney disease is defined as an abnormality of kidney structure and/or function, 
which persists for more than three months31. CKD is an increasingly common problem 
worldwide, with an estimated prevalence of 11 - 13% of the global population32. The 
aetiology of CKD in adults is often multi-factorial, with risk factors including diabetes33, 
hypertension34,35, obesity34,36, older age37, and a previous episode of AKI38, in addition to 
various other factors including gender, ethnicity, and socio-economic status39. Conversely, 
CKD in children and young adults under around 25 years tends to arise from primary renal 
disease of genetic origin40,41.  
CKD is primarily classified based on the estimation of glomerular filtration rate (GFR)31 (Table 
1.2). There are no specific treatments for CKD. The progression of CKD to more advanced 
stages is currently only controlled by general lifestyle management, such as controlling blood 
pressure, having a good diet, and regular exercise31. When patients reach stage 5, they are 







1 > 90 
Normal kidney 
function 
Only classed as CKD in the presence of 
other evidence of kidney damage 





3a 45 – 59 
Moderately reduced kidney function 
3b 30 - 44 
4 15 - 29 Severely reduced kidney function 
5 < 15 Kidney failure (ESRD) 
 
 
Table 1.2: The stages of CKD. Table adapted from Kidney Disease: Improving Global 
Outcomes (KDIGO) CKD Work Group. Clinical Practice Guideline for the Evaluation and 




1.2.3 The relationship between AKI and CKD 
Previously, it was thought that AKI and CKD were entirely separate conditions38, and 
moreover, that AKI was a transient condition, whereby patients who survived AKI recovered 
fully and suffered no long-term consequences42. However, functional recovery is generally 
assessed by serum creatinine (SCr) levels, which is an insensitive biomarker43,44, and there is 
now evidence showing that in fact many patients never fully return to pre-injury kidney 
function levels45. Furthermore, a single episode of AKI may predispose patients to 
subsequent CKD38,46 47,48 or may even lead directly to ESRD49. The severity of AKI predicts 
progression to CKD, with patients who require dialysis being over 5,000 times more likely to 
progress to CKD than patients with less severe AKI46. In fact, it is now understood that AKI 
and CKD are closely interlinked conditions and each condition is a risk factor for the other: 
patients who have suffered AKI are at higher risk of developing CKD and ESRD than patients 
without AKI; patients with underlying CKD have a higher risk of suffering an episode of AKI, 
and such patients are less likely to recover from AKI and the underlying CKD may be 
exacerbated38 (Fig. 1.2). Despite improved understanding of the links between AKI and CKD, 









1.2.4 Current Treatment Options 
There are currently no specific treatments for AKI or CKD, and despite research efforts into 
different therapeutic interventions for reducing the severity of AKI50, none have yet been 
approved for use in the clinic. Treatments for AKI patients primarily remain at simply 
controlling blood pressure, avoiding nephrotoxins, and providing RRT26. RRT is required for 
patients with severe AKI, and for CKD patients whose kidney disease progresses to stage 5, 
placing them in end stage renal disease. While dialysis is effective at performing filtration and 
elimination of waste products, it does not perform other important functions of the kidney, 
such as hormone regulation and the production of vitamin D51. Additionally, dialysis is 
cumbersome for the patient, often requiring multiple hospital visits every week for 
haemodialysis, or daily dialysis at home for peritoneal dialysis52, and can be associated with 
various side-effects including fatigue, low blood pressure, sepsis, and peritonitis53. As such, 
dialysis is a relatively short-term solution, and while this is sufficient for sustaining AKI 
patients until kidney function improves, a kidney transplant is ultimately required for 
patients with ESRD. The number of patients registered in the UK as waiting for a kidney 
transplant has declined slightly in recent years54 (Fig. 1.3), however the number of donor 
kidneys available for transplant still does not come close to meeting the demand. In 2015/16, 
there were 5,275 patients registered in the UK as waiting for a kidney transplant, but only 
3,263 kidney transplants were performed in the same time period. The gap between the 
number of donor kidneys required and those available for transplant is even greater in the 
United States55. 
The problem with the lack of donor kidneys has been partially addressed by the introduction 
of expanded criteria donors (ECD), whereby high-risk donors that previously would have 
been deemed unsuitable for kidney donation are now accepted. ECDs are classed as donors 
over the age of 60, or those aged 50 – 59 with two of the following medical risk factors: a 
history of hypertension, a serum creatinine value greater than 1.5 mg/dL, or a 
cerebrovascular accident (stroke) as the cause of death56. It is recommended that ECD 
kidneys are preferentially transplanted to patients with a high risk of mortality on dialysis, 
and are unlikely to survive long enough to receive a standard kidney56. However, ECD kidneys 
are reported to have lower long-term graft survival than standard kidneys57-59, and despite 
the additional kidneys available for transplant, there are still not enough donor kidneys to 







There is therefore an urgent need for new therapies to treat kidney disease: to reduce the 
initial severity of AKI, to improve recovery following an episode of AKI, to reduce the risk of 
developing CKD following an episode of AKI, and to slow down the progression of CKD to 
ESRD. Regenerative medicine therapies (RMT) may provide a new therapeutic strategy for 
treating kidney diseases.  
 
1.3 Regenerative Medicine Therapies  
RMTs encompass a broad range of advanced therapy medicinal products, including cell 
therapy, gene therapy, and tissue engineering60. This thesis will focus on the use of cell-based 
therapies for ameliorating kidney disease.  
Stem cells are rare cells within tissues that have an unlimited capacity for self-renewal and 
can differentiate to form mature cells of the body61,62. There are many different types of stem 
cells, but can be broadly categorised into pluripotent stem cells (PSCs) and adult stem cells 
(ASCs). PSCs are immature cells capable of differentiation to form the three embryonic germ 
layers: endoderm, mesoderm, and ectoderm. They can be isolated from the inner cell mass 
of embryos (embryonic stem cells, ESCs)63-65, or can be generated by reprogramming 
terminally differentiated somatic cells back to a pluripotent state (induced pluripotent stem 
cells, iPSC) by the viral introduction of four transcription factors; Oct3/4, Sox2, c-Myc, and 
Figure 1.3: Kidney transplants in the UK. Data obtained from the NHS Blood and Transplant 




Klf4: the ‘Yamanaka factors’66,67. As iPSCs are derived from somatic cells, they circumvent 
many of the ethical issues surrounding the isolation of ESCs from embryos, and are not 
subject to the same legal regulations as ESCs.  
On the other hand, ASCs are multipotent or unipotent stem cells, and as such are more 
limited in the cell types that they can form. One of the most well-studied ASCs is the 
haematopoietic stem cell (HSC), which is found in the bone marrow and in cord blood. HSCs 
are responsible for forming all types of blood cells in the circulation68-70, and the potency of 
HSCs is such that it is possible to completely replenish the haematolymphoid system in a 
lethally-irradiated mouse with just a single HSC70. HSC transplants are now commonly used 
in the clinic for treating a range of haematological disorders, including blood malignancies 
such as leukaemia and lymphoma, and non-malignant disorders such as sickle cell anaemia, 
Fanconi anaemia, and auto-immune disorders71,72.  
In addition to HSCs, the bone marrow also contains mesenchymal stem/stromal cells (MSCs), 
which are multipotent cells that form components of the skeletal system: bone, cartilage, fat, 
and the supporting stroma73,74. MSCs are a highly heterogenous cell population, consisting of 
both true stem cells, with an unlimited capacity for self-renewal, in addition to multipotent 
stromal cells, capable of forming multiple cell types, but not unlimited self-renewal. As such, 
the International Society for Cellular Therapy suggested in 2005 that the term ‘mesenchymal 
stem cell’ should be restricted only to the subset of these cells which display true stem cell 
properties, whilst the term ‘multipotent mesenchymal stromal cell’ should be used for 
describing the unfractionated, heterogenous cell population75. The acronym ‘MSC’ is still 
used to describe both subsets of cells; in this thesis it is intended to describe mesenchymal 
stromal cells. There is no unique phenotypic marker by which to characterise MSCs. Rather, 
cells must meet the minimum criteria set out by the International Society for Cellular Therapy 
in order to be defined as MSCs: 1) they must adhere to plastic in culture; 2) they must express 
the markers CD73, CD90, and CD105 (≥ 95% positive); 3) they must not express the 
haematopoietic markers CD11b, CD14, CD19, CD34, CD45, CD79α, and HLA-DR (≤ 2% 
positive); 4) finally, they must be able to differentiate to form osteoblasts, chondrocytes, and 
adipocytes76. Since their discovery in the bone marrow in the early 1970s77, MSCs have also 
been identified in various other tissue types, including umbilical cord blood78, umbilical cord 
Wharton’s jelly79, adipose tissue80, and placenta81, in addition to most other organs in the 





In addition to forming mesodermal tissues, MSCs have been reported to potentially 
transdifferentiate to form tissues of the ectoderm (epithelial cells and neural cells) and 
endoderm (lung, muscle, and gut cells) lineages74 although this remains controversial. 
Regardless of whether or not MSCs are able to transdifferentiate, their potential application 
in regenerative medicine for a wide range of ailments predominantly arises from their 
immunomodulatory properties, rather than their ‘stemness’. The pathogenesis of many 
diseases, including those of the kidney, have a  strong immunological component, and MSCs 
potentially have a beneficial effect through their ability to modulate various components of 
the innate and adaptive immune systems, including T cells, B cells, regulatory T cells (Tregs), 
dendritic cells, natural killer (NK) cells, and inflammatory cytokines, to promote an anti-
inflammatory environment83. Additionally, MSCs express low levels of human leukocyte 
antigen (HLA) class I molecules, and do not express HLA class II molecules84. As such, 
allogeneic MSCs are not recognised as foreign cells when transplanted to a recipient: they 
are ‘immunoprivileged’, making them very attractive cell types for regenerative medicine. 
Consequently, MSCs are now being widely investigated in clinical trials for the treatment of 
graft-versus-host disease (GvHD), a common but life-threatening immunological 
complication of HSC transplantation, where immunocompetent donor cells attack host 
tissues. MSC therapy can be administered to patients with severe GvHD who do not respond 
to standard corticosteroid treatment85,86. The beneficial effect of MSC treatment for severe 
GvHD is striking: LeBlanc, et al., who first reported the use of MSCs for GvHD, stated that of 
the 25 patients they had encountered with grade IV acute GvHD, the only patient who was 
still alive was the child who received MSC infusions; the 24 patients who did not receive MSC 
therapy all died within 6 months of HSC transplantation87.  
However, despite vast quantities of preclinical research into the use of stem cells to treat 
many different diseases, and some promising results from clinical trials, very little progress 
has been achieved in translating such therapies to fully-approved products available to 
patients. Currently, there are only three stem cell therapies approved for use in Europe: 
haematopoetic stem cells for the treatment of blood cancers and other blood disorders, skin 
biopsies (containing epidermal stem cells) for the generation of skin grafts for burn patients, 
and limbal stem cells to restore the sight of patients with corneal damage88. Inadequate data 






1.4 Animal Models of Kidney Disease and Preclinical Studies of RMT Efficacy 
AKI and CKD in humans can arise from many different aetiologies; ranging from clinical 
complications in hospitalised patients such as ischemia or sepsis, to a predisposition to 
developing disease resulting from a person’s genetic make-up or lifestyle (i.e. obesity leading 
to type 2 diabetes). There are many different models of kidney disease in experimental 
animals, including both experimentally-induced diseases and spontaneously-developing 
disease in genetically modified animals93,94, reflecting the wide range of aetiologies in 
humans. Models of kidney disease can be used for studying the pathophysiology of disease, 
the cellular and molecular mechanisms of the repair processes, and the efficacy of 
interventional therapies. In particular, preclinical research into the efficacy of stem cell 
therapies in experimental rodent models of kidney disease has increased rapidly in recent 
years (Fig. 1.4), with the majority of studies reporting beneficial effects of cell treatment in 
ameliorating kidney injury in experimental models. 
 
 
An appropriate animal model must be selected in order to develop effective stem cell 
therapies for treating kidney diseases. There are many different animal models available, 
each producing certain characteristics of kidney injury that may model different aspects of 
the human disease. It is therefore imperative to test new therapies in the most appropriate 
Figure 1.4: Approximate number of publications reporting on the efficacy of stem cell 
therapies in animal models of kidney disease up to 2016. Scopus search on 16/03/17 using 
the search terms: (TITLE-ABS-KEY ("stem cell") AND TITLE-ABS-KEY ("kidney disease" OR 
"kidney injury" OR nephropathy OR AKI OR CKD) AND TITLE-ABS-KEY (treatment OR 
administration OR therapy OR  ameliorates OR improves OR efficacy) AND TITLE-ABS-KEY 




model for the human disease for which the therapy is intended, i.e. ischemic kidney injury, 
chemotherapy toxicity, diabetic nephropathy, ESRD, etc.  
The most common experimental rodent models used in RMT research are described below, 
with some brief details on the clinical relevance, method of inducing injury, and efficacy of 
cell therapies for each model. Mouse models of ischemia-reperfusion injury and adriamycin 
nephropathy are used in the experiments presented in this thesis, and as such more focus is 
placed on these models, with additional notes on their pathophysiology. 
1.4.1 Models of Acute Kidney Injury 
Ischemia-Reperfusion Injury  
Ischemia is the most common cause of AKI in humans95, and localised or global renal ischemia 
can occur following a range of causes, including cardiac surgery96,97, sepsis19,98, and kidney 
transplantation99,100. Owing to its clinical relevance, simplicity, and reproducibility, ischemia-
reperfusion injury (IRI) is a popular experimental model of AKI. Inducing IRI in experimental 
animals involves surgically clamping the renal artery in rats, or both the renal artery and vein 
in mice (ischemia), and the subsequent release of the clamp; restoring blood flow to the 
kidney (reperfusion). A more detailed description of the experimental model is provided in 
Chapter 5.  
The proximal tubules are particularly sensitive to ischemia due to the low baseline 
oxygenation levels of the outer medulla under normal circumstances30,101, and an inability to 
use glycolytic respiration in anoxic conditions28. Renal ischemia leads to a loss of tubular 
epithelial cell polarity, disruption of cytoskeletal integrity, loss of the proximal tubule brush 
border, and mislocation of cell adhesion molecules and membrane proteins soon after the 
onset of injury. This is followed by apoptosis and necrosis of tubular cells, and, due to 
inadequate cell adhesion, both viable and non-viable cells slough off from the basement 
membrane into the lumen of the tubule. Cellular debris builds up in the tubule lumen and 
complexes with proteins to form tubular casts, causing a physical obstruction and increased 
intratubular pressure13. The function of the injured, obstructed proximal tubule is therefore 
compromised, causing impaired solute reabsorption. Increased solute concentration in the 
distal tubule is detected by the macula densa, causing tubulo-glomerular feedback signals 
which result in a decrease in the afferent arteriole blood pressure and subsequent reduction 
in GFR13. In most cases, regeneration occurs to repair damaged tubules, as described 




The molecular pathophysiology of ischemic kidney injury in response to vascular endothelial 
cell and tubular epithelial cell damage is highly complicated, involving the interaction of 
various chemokines/cytokines and inflammatory cells. In cases of prolonged ischemia, 
anaerobic metabolism results in a decreased in cellular pH, depletion of ATP, and an 
accumulation of lactate. Subsequent reperfusion, whilst restoring cellular oxygen levels and 
physiological pH, causes an influx of reactive oxygen species (ROS) and nitric oxide, resulting 
in oxidative stress and damaging the endothelial cells of the renal microvasculature102,103. 
This in turn leads to a breakdown in the glycocalyx, disruption of the actin cytoskeleton, and 
loss of endothelial cell-cell contacts and barrier function, resulting in increased microvascular 
permeability and leakage of fluid into the interstitium (oedema)13. The damaged endothelial 
cells also increase their expression of cell adhesion molecules, resulting in endothelium-
leukocyte interactions, and leading to the activation and recruitment of further leukocytes, 
production of inflammatory cytokines, and the development of a pro-inflammatory state13.  
The pathophysiology of renal ischemic injury has a strong immunological component, 
comprising both the innate and adaptive arms of the immune system. The immune response 
is activated early after the induction of injury, following the release of pro-inflammatory 
damage-associated molecular patterns (DAMPs) from cells damaged by hypoxia, and the 
upregulation of hypoxia inducible factors (HIFs), cell adhesion molecules, pro-inflammatory 
cytokines, and upregulation of toll-like receptors (TLRs) on tubular epithelial cells104,105. These 
factors promote the rapid infiltration of macrophages, lymphocytes, dendritic cells, and 
neutrophils. Cells of the innate immune system predominate in the early phase of injury, 
whereas lymphocytes of the adaptive immune system are recruited several hours after 
injury, and are the most common immune cells throughout the later phase of injury13,105. 
Macrophages are key components of both injury and repair following renal IRI. Macrophages 
can be broadly categorised into two types: classically-activated M1 macrophages produce 
pro-inflammatory cytokines and are involved in defence against infection and tumours, 
whereas alternatively-activated M2-spectrum macrophages have an anti-inflammatory role 
and are involved in regulating tissue repair106. Pro-inflammatory M1 macrophages 
predominate in the initial phase of kidney injury, and depletion of macrophages prior to 
inducing renal ischemia protects the kidney from injury, demonstrating that the initial influx 
of macrophages into the kidney acts to promote damage. Conversely, macrophages are 
mainly polarised to an anti-inflammatory M2 phenotype during the later repair phase, and 
depletion of macrophages 3 – 5 days after ischemia (during the repair phase) exacerbates 




phenotype in response to the local microenvironment. Macrophages stimulated to an M1 
phenotype in vitro and administered to mice during the repair phase are able to switch to a 
M2 phenotype to help promote tissue repair107.  
Because of its popularity as an experimental model of AKI, the IRI model has been used in a 
vast number of studies assessing the efficacy of RMTs. Table 1.3 summarises just some of 
these studies, with more focus placed on reports published in recent years.  
Collectively, these studies demonstrate that various different cell types have the capacity to 
ameliorate structural and functional injury, as shown by reduced SCr, blood urea nitrogen 
(BUN), and histopathological tubular injury scores. Many studies show that cell therapy leads 
to significantly increased proliferation and reduced apoptosis of tubular cells108-121. This is 
achieved by modulating the immune response to injury, by downregulating the expression 
of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumour necrosis factor-
alpha (TNF-α)108,112-116,118,121,122 and upregulating anti-inflammatory cytokines such as IL-10 
and IL-4108,112,115,116,118,119,121,122. Immune cell infiltration to the post-ischemic kidney is 
attenuated, with a decrease in total macrophage infiltration108,110,114,118,122 but an increase in 
the proportion of anti-inflammatory M2-polarised macrophages122. Moreover, oxidative 
stress is reduced by increasing levels of antioxidant enzymes, such as glutathione reductase, 
glutathione peroxidase, and heme oxygenase-1108,111,115,121. Altogether, these effects act to 
limit the damage caused by inflammation and oxidative stress, thereby limiting tubular cell 
damage and preserving renal function.  
Most efficacy studies have been carried out with MSCs (of various sources, generally bone 
marrow-derived) and following intravenous administration. Other cell types and 
administration routes have also been investigated, however it is still unclear as to which is 




































































































































































































































rBM-MCs ameliorated functional and structural 
injury, with increased proliferation and 
decreased apoptosis of tubular cells. BM-MCs 
modulated expression of cytokines and 
antioxidant mediators.  
Cai et al., 
(2014) 
rBM-MSCs 









 ND ND ND ND ND ND 
RA administration was found to be superior to IV 
and CA, but the beneficial effects diminished 
with increasing cell doses, due to occlusion of 
glomerular capillaries by rBM-MSCs and 













  ND ND ND ND 
rBM-MSCs ameliorated functional and structural 
injury, promoted tubular cell proliferation, and 
restored tissue antioxidant enzyme levels 
independent of dose or route of administration.  
Table 1.3: Summary of studies assessing the efficacy of cell therapies in the IRI model. h, human;  m, mouse; r, rat; AD, adipose-derived; ASCs, adipose 
stem cells; BM, bone marrow-derived; CM, conditioned media; EPC, endothelial progenitor cell; ERC, endometrial regenerative cell; EV, extracellular 
vesicles; EX, exosomes; FKCs, fetal kidney cells; Gl, glomerular; iPSC, induced pluripotent stem cell; KC, kidney cell; MSC, mesenchymal stem cell; RPC, 
renal progenitor cell; SVF, stromal vascular fraction; UC, umbilical cord; UCB, umbilical cord blood;  WJ, Wharton's jelly; CA, carotid artery; IP, 











up to 5.0 
×106 per 





58, 40, or 
35 min 
 ND ND ND ND ND ND 
rBM-MSCs improved renal function recovery in 
the short-term, and preserved long-term renal 
function at 3 months, independent of cell dose. 
Autologous rBM-MSCs had greater efficacy than 
allogeneic cells at comparable doses. VEGF is an 
important mediator in renal protection of rBM-









     ND ND 
rBM-MSCs ameliorated functional and structural 
injury, and increased proliferation. rBM-MSCs 
polarised the immune response towards a Th2 
profile (decreased pro-inflammatory cytokines 




hBM-MSC 1.0 x106 IV; 0h 
mouse 
unilateral 
40 min / 
bilateral 
25 min  
 ND ND ND ND ND 
hBM-MSCs ameliorated injury and increased 
tubular cell proliferation. IV-administered hBM-
MSCs homed to injured kidneys (either via lungs 












30 min / 
bilateral 
28 min  
   ND ND  ND 
mBM-MSCs, but not CM, attenuated functional 
and structural renal injury, increased tubular cell 
proliferation, decreased tubular cell apoptosis, 
and decreased Mφ infiltration. Daily high-dose 









2.0 x106 RP; 0h 
rat 
unilateral 
45 min  
     ND ND 
Both hAD-MSCs and hAD-SVF cell therapies 
ameliorated functional and structural injury, 
with no differences between the two cell types. 
Cytokine modulation, increased proliferation, 
decreased apoptosis, and decreased 
microvascular rarefaction were observed 















 ND ND ND ND ND 
rAD-MSCs ameliorated functional and structural 
injury, with attenuated oxidative stress 






of cells + EX 




 ND   ND  
rAD-MSCs and rAD-MSC-EX both ameliorated 
functional and structural injury, but a 
combination therapy of both cells and EXs had 
greater efficacy than either therapy alone. 
Combination therapy led to greatest reduction in 













  ND   ND ND 
ASCs improved kidney histology by reducing 
inflammation and hypoxia, without migrating to 
kidneys. Late administration (week 6) of ASCs 














 ND    ND 
rAD-MSCs ameliorated functional and structural 
injury by decreasing inflammation, oxidative 












 ND   ND ND 
hWJ-EPCs ameliorated functional and structural 
injury, with increased proliferation and 
decreased apoptosis of tubular cells, decreased 















 ND ND    ND 
hUCB-MSCs could attenuate early functional and 
structural renal damage, and VEGF production 
had a role in efficacy. Injection route and dose 
did not affect efficacy. 
Li et al., 
(2013) 




      ND 
hUC-MSCs ameliorated functional and structural 
injury, with increased proliferation and 
decreased apoptosis of tubular cells. hUC-MSCs 
modulated cytokine expression, decreased Mφ 




















     ND 
FKCs ameliorated functional and structural 
injury, with increased proliferation and 
decreased apoptosis of tubular cells, modulation 
of cytokine expression, and upregulation of 
antioxidant enzyme expression. CM had no 

















   ND ND ND ND 
hGl-MSCs and hKCs ameliorated functional and 
structural injury, but hGl-MSCs had greater 
efficacy with increased tubular cell proliferation. 
EVs from hGl-MSCs had similar efficacy to the 
cells, but EVs from hKCs had no effect.  
iPSCs 









   ND  ND ND 
iPSC-RPCs ameliorated functional and structural 
injury, with increased proliferation and 
decreased apoptosis of tubular cells. iPSC-RPCs 

















 ND ND ND ND ND ND 
hiPSC-RPCs administered RP integrated into the 
kidney and generated tubular structures, but did 
not improve kidney injury, whereas cells 
administered SC did not integrate, but improved 
functional and structural injury. Only OSR1+SIX2+ 





Many different drugs are known to be toxic to the kidney123, and in one multi-national, multi-
centre study, drugs were implicated in 19% of all cases of AKI124. One of the most common 
nephrotoxicants is cisplatin (also known as cisplatinum or cis-diamminedichloroplatinum(II) 
(CDDP)). Cisplatin is a common chemotherapeutic drug used to treat a wide range of solid 
cancers, however the main clinical side-effect and dose-limiting factor of cisplatin in patients 
is nephrotoxicity125. Cisplatin nephrotoxicity is very common: around one-third of patients 
treated with a single dose of cisplatin develop AKI, and the risk of AKI increases with 
subsequent doses126. Cisplatin nephropathy is very simple and inexpensive to model in 
rodents, most commonly requiring a single intraperitoneal injection of 5 mg/kg in rats127, or 
up to 25 mg/kg in mice93,128. However, this single-dose model does not accurately reflect the 
clinical dosing regimen whereby multiple doses would be administered. A recent report 
described an alternative model of cisplatin nephrotoxicity, using multiple low doses of 
cisplatin to induce a kidney injury in mice which more closely replicates the injury in 
humans129. Due to its clinical relevance, cisplatin is a commonly used model of AKI for 
studying the efficacy of RMTs. A great number of studies have been published reporting 
beneficial effects of various cell types in rodent models of cisplatin nephropathy, including 
MSCs derived from bone marrow130-132, adipose tissue132,133, or amniotic fluid132, kidney-
derived cells134, and iPSC-derived renal progenitor cells135. 
Sepsis 
Sepsis, a systemic reaction to overwhelming infection, is a common complication in 
hospitalised patients, affecting almost 30% of patients in intensive care136. Sepsis can both 
contribute to, and result from, AKI, with one report stating that 28% of AKI patients had sepsis 
prior to developing AKI, and 40% of AKI patients became septic soon after their AKI 
diagnosis137. There are three main experimental models of sepsis: 1) infusion of 
lipopolysaccharide (LPS), which models the role of endotoxin in human sepsis; 2) infusion of 
a single pathogen, which allows reproducible infection for studying pathogen-specific 
infection; 3) caecal ligation and puncture (CLP), which models polymicrobial sepsis, and is 
more clinically relevant and the most widely used animal model of sepsis138. Very little 
research has been published on the effects of stem cell therapy for treating sepsis-associated 
AKI, however Luo and colleagues recently reported some promising results, showing that 






Rhabdomyolysis is a condition in which skeletal muscle rapidly breaks down, releasing 
electrolytes, myoglobin, and enzymes such as creatine kinase, lactate dehydrogenase, and 
aldolase into the bloodstream140. The most common causes of rhabdomyolysis in adults are 
trauma (e.g. crush injury) and alcohol/drug abuse, whilst in children the main causes are 
infection and congenital disorders141,142. AKI is a major complication of rhabdomyolysis, 
occurring in around 24% of patients. Kidney damage occurs as a result of renal 
vasoconstriction, toxicity of released myoglobin on kidney tubular cells, and myoglobin-
protein complexes leading to tubular obstruction140. Rhabdomyolysis is modelled in rodents 
by a deep intramuscular injection of 8 – 10 mg/kg 50% glycerol143, distributing the dose 
equally between both hind limbs. Various stem cell therapies have shown promise in rodent 
models of rhabdomyolysis, including MSCs144-146, kidney-derived cells147-149, and interestingly, 
liver-derived stem cells150. Notably, the CD133+ human kidney-derived cells utilised in many 
of the experiments described in this thesis were first tested for therapeutic efficacy in rodent 
models of rhabdomyolysis148,151. 
1.4.2 Models of Chronic Kidney Disease 
Adriamycin Nephropathy 
Adriamycin (ADR) (doxorubicin) is an anthracycline antibiotic capable of DNA intercalation, 
leading to DNA double strand breaks and subsequent apoptosis of cells152. As such, ADR has 
potent anti-tumour activity, and is commonly used clinically as a chemotherapeutic agent to 
treat various types of cancer152,153. The most potent side-effect of ADR in the clinic is 
cardiotoxicity154, however it is also nephrotoxic, and patients’ renal function must be closely 
monitored during chemotherapy to reduce the risk of AKI153. The mechanism by which ADR 
induces renal damage is poorly understood, but it is thought to be related to the generation 
of ROS following the reduction of ADR to semiquinone155-158. ADR is directly toxic to 
glomerular epithelial cells159, and clipping the renal artery during ADR administration can 
protect the kidney from ADR nephropathy160. ADR causes a breakdown of the glomerular 
filtration barrier by initiating podocyte dysfunction and loss, and therefore disrupting the 
integrity of the slit diaphragm161,162, and downregulating proteoglycan synthesis, leading to 
an 80% reduction in the thickness of the glycocalyx and causing a loss of charge- and size-
selectivity of the GFB163. As a result, large proteins are able to pass through the disrupted 
GFB into the tubules. The abnormal presence of proteins in tubules is intrinsically toxic to the 




to an upregulation of inflammatory mediators165. This therefore leads to interstitial 
inflammation and subsequent tubular cell dysfunction and atrophy165,166. When tubular 
protein load exceeds the reabsorption capacity of the tubules, protein is excreted into urine 
(proteinuria), and proteins complex with sloughed cellular debris, depositing proteinaceous 
casts within tubules.  
Experimentally, a single intravenous administration of ADR is sufficient to induce a 
progressive chronic kidney injury in rodents which closely resembles the human disease, 
focal segmental glomerulosclerosis (FSGS)167,168. ADR has a very narrow ‘therapeutic’ 
window, with doses just 0.5 mg above or below the optimum dose resulting in fatal toxicity 
or failure to develop injury, respectively169. As such, the dose of ADR must be carefully 
optimised for the species, strain, sex, and immune-status of the animal, in addition to the 
batch of ADR. ADR susceptibility has been shown to be determined by a single gene locus on 
chromosome 16, with recessive inheritance170. As a result, BALB/c mice are highly susceptible 
to ADR nephropathy, whereas C57BL/6 mice are highly resistant163,171. Furthermore, 
immunodeficient mice, such as severe combined immunodeficient (SCID) mice are more 
susceptible to ADR than their immunocompetent BALB/c counterparts, requiring half the 
dose to induce similar levels of injury: 5.3 mg/kg for male BALB/c SCID mice, compared with 
around 10 mg/kg for male BALB/c mice169,171,172. 
ADR nephropathy in rodents is primarily characterised by persistent overt proteinuria and 
glomerular sclerosis (Fig. 1.5). Injury progression is faster in mice171 than in rats167. In mice, 
the onset of glomerular sclerosis is evident from week 4, with expansion of the mesangium 
and collapse of the glomerular tuft, leading to extensive focal and global sclerosis by week 
six. Further histopathological features include an initial phase of increased glomerular size 
and hypercellularity, followed by a decrease in glomerular size and hypocellularity from week 
four; tubular atrophy, involving a decrease in tubular epithelial cell height and loss of the 
brush border; proteinaceous casts within dilated tubules; and interstitial expansion, 
inflammation, and fibrosis171,172. Ultrastructural changes detected by electron microscopy 
(EM) predominantly involve podocyte foot process effacement and fusion within two weeks, 
leading to the loss of foot processes and denudement of the glomerular basement by week 
six171,172. Typically, mice lose a lot of body weight within the first one to two weeks, losing up 
to 30% of the starting body weight171, but gradually gain weight from week two onwards. 
The Harris group in Sydney, Australia, have carried out extensive studies investigating the 




demonstrated that the progression of injury following ADR administration has an important 
immunological component, with prominent tubulointerstitial infiltration of CD4+ T cells, CD8+ 
T cells, and macrophages during injury171. Subsequently, the group have shown that while 
CD4+ T cells exert a protective effect in ADR nephropathy173, CD8+ T cells are involved in 
aggravating injury174. SCID mice, which lack T and B cells but have functioning macrophages 
and NK cells175, are more susceptible to ADR nephropathy172, suggesting a role of 
macrophages and/or NK cells in the development of renal injury. NK cells were shown to have 
little effect in the development of renal injury176, whereas macrophages played a key role in 
the pathogenesis of ADR nephropathy177,178. Moreover, inflammatory cytokines play a major 
role in the development of ADR nephropathy. Early work by the Harris group showed that 
ADR nephropathy led to significantly increased activation of the nuclear factor-kappa B (NF-
κB) family of transcription factors, which mediated infiltration of inflammatory cells into the 
cortex of ADR injured rats, and inhibition of NF-κB resulted in amelioration of renal injury179. 
The majority of studies assessing the efficacy of cell therapies using the adriamycin model 
have been carried out using MSCs in rat models, and report somewhat conflicting results. 
Guo et al., (2014) and Anan et al., (2016) both report beneficial effects of MSCs on kidney 
function and structure following ADR administration, as assessed by serum biochemistry and 
histology, respectively180,181. Conversely, Zoja et al., (2012), Sarhan et al., (2014), and 
Magnasco et al., (2008) all describe improvements in glomerulosclerosis, but not in 
functional biomarkers182-184. Very few publications report the efficacy of cell-based therapies 
in mouse models of adriamycin nephropathy, however a study published by Ronconi et al. in 
2009 is of importance to this thesis. Ronconi and colleagues isolated a population of 
endogenous renal progenitor cells and, using a mouse model of adriamycin nephropathy, 
demonstrated the ability of these cells to integrate into the injured kidney and regenerate 
damaged podocytes following intravenous administration, leading to improved kidney 









Unilateral Ureteric Obstruction 
Congenital urinary tract obstruction (UTO) is the leading known cause of CKD in 
children186,187, and can reduce nephron number and impair kidney growth and development 
depending on the severity, duration, and timing of obstruction. Unilateral ureteric 
obstruction (UUO) is a very commonly used experimental model, not only for studying the 
pathogenesis of UTOs in children, but also as a generic model of the development of renal 
fibrosis in CKD188,189. The progressive accumulation of interstitial fibrosis is a common final 
pathway in CKD of all etiologies188. The UUO model is highly predictable and reproducible in 
the development of renal fibrosis, in addition to being a very fast, high-throughput 
model188,189, making it ideal for studying the mechanisms of fibrosis development in addition 
to preventative therapies. The UUO model can either be irreversible or reversible. Both 
models require surgery and involve either clamping190 or ligation191 of the ureter, leading to 
hydronephrosis and renal fibrosis. In the reversible model, following a period of obstruction, 
the clamp is removed190 or the ligated ureter is re-anastamosed to the bladder191, allowing 
the kidney to decompress and undergo repair and remodelling. For RMT studies, the 
irreversible model is most frequently used in order to assess the effect of cell therapy on the 
development of renal fibrosis. Results have shown that MSCs ameliorate renal fibrosis 
following obstruction, both when administered at the time of obstruction192,193 and following 
seven days of obstruction194. 
Diabetic Nephropathy 
Diabetes mellitus is the leading known cause of ESRD195 and is a major problem for public 
health: the estimated worldwide prevalence of diabetes was 285 million in 2010, and is 
forecast to rise to 439 million by 2030196. CKD, diabetes, and cardiovascular disease are a 
triad of diseases that often occur together, due to complex interactions between the 
diseases and shared risk factors, leading to high mortality levels33. There are two types of 
diabetes: Type I (insulin-dependent) results from the autoimmune destruction of islet β-cells 
in the pancreas197, whereas type II (non-insulin dependent) is characterised by 
hyperglycaemia and insulin resistance and is predominantly caused by a combination of 
genetics and lifestyle factors, such as obesity, smoking, and alcohol consumption198. Diabetic 
nephropathy (DN) occurs, at least in part, due to persistent hyperglycaemia and 
hyperfiltration, and is characterised by proteinuria, thickening of the glomerular basement 
membrane, expansion of the mesangial matrix, and progressive glomerulosclerosis199,200. 




Type I diabetes is most commonly modelled either by administration of streptozotocin (STZ), 
an antibiotic that is toxic to the pancreatic β-cells201, or by the non-obese diabetic (NOD) 
mouse, which develops a spontaneous destruction of pancreatic β-cells at around five 
months of age201. Type II diabetes can be modelled simply with a high fat diet, which induces 
obesity and insulin resistance in C57BL/6 mice201. However, type II diabetes is most 
commonly modelled by obese genetic mutant mice, such as db/db, ob/ob, the Agouti 
mutation, and the New Zealand Obese mouse201, and new genetic mouse models of DN are 
continually developing in an attempt to more closely resemble the human disease202-204.  
MSCs have shown great promise in various models of DN, with decreased blood glucose 
levels reported in the majority of studies, and improved β-cell function and morphology 
reported in some studies, in addition to improved kidney function and histology205. Ezquer 
et al., (2008) showed that MSCs administered to STZ mice after the widespread destruction 
of pancreatic β-cells resulted in decreased blood glucose levels within one week of MSC 
administration, reaching normal levels after one month206.  Additionally, MSC therapy 
significantly increased the number of pancreatic islet cells and prevented the progression to 
nephropathy. A recent study described similar beneficial effects of BM-MSCs and 
conditioned media in both an STZ model of type I diabetes and a high-fat diet model of type 
II diabetes207, supporting a paracrine role of MSC therapy in both DN models. The 
amelioration of kidney injury was characterised by a decrease in the infiltration of bone 
marrow-derived cells and macrophages and downregulation of pro-inflammatory cytokine 
expression.  
Subtotal Nephrectomy 
Rather than attempting to recapitulate the causes of kidney disease in rodent models, the 
outcome of the disease can instead be modelled. Loss of renal mass (loss of nephrons) and 
progressive loss of renal function is an inevitable outcome in CKD208, regardless of the 
initiating cause. Moreover, low birth weight is associated with reduced nephron number, 
and is a risk factor for CKD in later life39,209; nephrectomy for the removal of renal tumours 
increases the risk of CKD210; and living kidney donation halves the donor’s renal mass, with 
currently unproven long-term consequences211. In the experimental model of subtotal 
nephrectomy (also known as partial or 5/6 nephrectomy, or the remnant kidney model), a 
proportion of the total renal mass (often five-sixths) is surgically removed by unilateral 
nephrectomy and removal of the poles of the remaining kidney, either by ligation or 




progression to renal failure93. Rats are most frequently used in this model, where removal of 
renal mass induces progressive CKD, featuring arterial hypertension, proteinuria, and 
glomerular sclerosis212. Mice can also be used, but susceptibility is strain-dependent: CD1 
mice are very susceptible to renal mass reduction, developing CKD within four weeks, and 
while C57BL/6 mice are highly resistant213,214, increasing their blood pressure with 
administration of angiotensin II heightens their susceptibility214. MSCs have been shown to 
improve functional and histopathological damage in models of subtotal nephrectomy215-219. 
An interesting study used two subtotal nephrectomy models (5/6 and 2/3) to simulate 
different stages of renal failure in order to assess the effect of timing on the efficacy of cell 
therapy219. MSC therapy improved kidney function and structure in both models, however 
the effect was greater in the 2/3 nephrectomy model, indicating that treatment is less 
effective when renal failure is more advanced. 
1.4.3 Benefits and Limitations of Animal Models 
The benefits of modelling human disease in animals are clear: studying experimental animals 
allows us to understand the pathology and progression of disease in a whole-body system, 
and the beneficial and adverse effects of therapeutic intervention in a strictly controlled 
environment with appropriate controls; tasks that are limited in in vitro models, and clearly 
impossible in humans.  
However, there are many limitations of animal models that must be considered. AKI and CKD 
are highly complex, multi-factorial diseases in humans, meaning that animal models of 
single-cause AKI/CKD do not faithfully recapitulate the human diseases220-222. Moreover, 
experimental models are most often carried out in young, otherwise healthy animals, and 
typically in inbred male animals221,222. This is clearly not representative of the patient 
population, who are first of all, genetically diverse and both male and female, and typically 
present with co-morbidities such as hypertension, obesity, and diabetes, and are of 
advanced age. An example of the gap between human disease and experimental models is 
the complex systemic disease, diabetes, which features complications such as cardiovascular 
disease, neuropathy, retinopathy, in addition to nephropathy223. While some of the early 
changes of diabetic nephropathy can be modelled in animals, such as glomerular 
hyperfiltration, albuminuria, and some histopathological changes, the development of renal 
failure is absent, and it is unknown whether this is due to an inherent resistance to 
nephropathy in the models used, or if the models are simply not analysed at a late enough 




However, the simplicity of animal models can be seen as a benefit in some cases. The onset 
of disease is known in animal models, allowing researchers to study the full course of disease 
progression from start to finish. Furthermore, by only modelling certain aspects of disease 
we can dissect out specific features of human disease and study them without confounding 
factors, for example, bilateral nephrectomy does not model any clinical disease, but allows 
the study of the effects of renal failure, without confounding effects of ischemia or toxic 
drugs224. This allows the most promising candidate therapies to be identified, and they 
should then be tested in more complex disease models, which should factor in age and sex 
heterogeneity, in addition to co-morbidities, such as modelling AKI in diabetic mice221,222.  
 
1.5 Traditional and Novel Measures of Assessing Kidney Function in vivo 
1.5.1 Traditional Measures of Kidney Function 
A common feature of all experimental models of kidney injury is the use of serum biomarkers 
SCr and BUN to evaluate kidney function. SCr is also the key parameter used clinically to 
diagnose and stage the level of kidney injury. However, it is widely known that SCr and BUN 
are insensitive and non-specific measures of kidney function43,225. SCr and BUN levels can be 
affected by both renal and non-renal factors that are unrelated to kidney function or injury, 
such as age, gender, muscle mass, protein intake, infection, and hydration status43. It has 
been shown in mice that creatinine excretion has a substantial secretory component, 
accounting for up to 50% of creatinine excretion and therefore making creatinine 
measurements a poor evaluation of GFR44. Moreover, subtle damage to the kidney can be 
masked by the renal functional reserve226,227. As such, efforts have recently gone into the 
search for urine and serum biomarkers that are sensitive and specific to kidney injury. 
Notably, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), 
and IL-18 have been identified as biomarkers of early AKI that identify patients before the 
rise in SCr43,228.  
These novel urine and serum biomarkers are slowly becoming more commonly used in 
preclinical renal research, however the serial collection of urine and/or blood from 
experimental animals still presents a major problem. Prolonged housing in a metabolic cage 
for urine collection is highly stressful for animals62,229, and the adverse effects are 
exacerbated in animals with poor health. Spot urine collection is less stressful, however 
animals with AKI often exhibit oliguria or anuria, adding further difficulties to the task of 




technically difficult in small animals, and only yields a small volume of serum for 
analysis230,231. The alternative is therefore terminal blood collection, which yields large 
volumes of serum, but precludes longitudinal monitoring of individual animals and, if data at 
multiple time points is required, necessitates large animal numbers per experiment.  
1.5.2 Novel Measures of Kidney Function 
Transcutaneous Measurement of FITC-sinistrin Clearance 
An alternative method of measuring kidney function in small animals is the transcutaneous 
assessment of fluorescein isothiocyanate (FITC)-sinistrin clearance232,233. The device 
comprises two light emitting diodes (LEDs), a photoreceptor, an internal memory, and is 
powered by a lithium battery which is connected to the device234. The device is affixed to the 
depilated skin of the animal with an adhesive patch, and the clearance of exogenously 
administered FITC-sinistrin is measured through the skin (see Chapter 2: Methods for a 
detailed description of the protocol). The LEDs emit light at 470nm to excite the FITC 
fluorophore, and the photoreceptor detects the excited light with a maximum sensitivity of 
525nm234. A reading is taken approximately every second for the duration of the 
measurement, allowing a kinetic assessment of FITC-sinistrin clearance. Sinistrin is an ideal 
dye for assessing renal function as it is a small molecule that is quickly and exclusively filtered 
by the glomerulus, with no secretory component232,235,236. Sinistrin is an analogue of the 
clinically used inulin, but has the advantage of being water soluble, and thus the preparation 
of sinistrin does not require dialysis235,236. The transcutaneous device has been validated 
against traditional inulin clearance methods of measuring GFR in rats237 and mice234, and was 
found to be more sensitive than plasma clearance measurements237. The transcutaneous 
measurement has several advantages as a method of measuring kidney function in animals: 
1. It is minimally invasive, and longitudinal measurements can be performed to monitor 
individual animals over time238 
2. The device is affixed whilst animals are anaesthetised, but the measurement period 
occurs in conscious animals, thereby limiting any effects of anaesthesia on GFR239,240 
3. It limits stress on animals234, since they tolerate the device very well, can eat and 
move freely during the measurement period, and are only separated from cage-
mates for a relatively short time during the measurement. Moreover, animals are 
anaesthetised during the most potentially stressful parts of the procedure (device 




4. It is repeatable, with an acceptable degree of variability in day-to-day 
measurements238 
5. It does not require repeated blood measurements, unlike the method of measuring 
clearance kinetics of plasma FITC-inulin241 
The transcutaneous measurement of kidney function has been applied in a range of 
preclinical renal studies. Cowley et al., (2013) demonstrated the benefit of this method over 
traditional creatinine measurements, showing that the transcutaneous measurement could 
detect a significant decrease in GFR in Dahl salt sensitive rats within 14 days on a high salt 
diet, despite there being no changes in creatinine clearance242. This method has also been 
used to characterise the long-term changes in kidney function in a rat model of Type 2 
diabetes243, and to assess the effect of therapeutic intervention on kidney function in animal 
models of non-diabetic CKD244, sepsis245, and cisplatin-induced AKI134. Importantly, 
Santeramo et al. demonstrated the value of the transcutaneous measurement in its ability 
to monitor individual animals longitudinally in response to cell therapy, by assessing kidney 
function at baseline, after cisplatin-induced AKI prior to therapeutic intervention, and 
subsequently after cell administration134. Furthermore, this method of assessing kidney 
function is now being explored for clinical use246,247. 
Multispectral Optoacoustic Tomography 
Another novel method of assessing kidney function is by photoacoustic imaging. IRDye 
800CW carboxylate (from now, referred to only as IRDye) is a near infrared (NIR) dye that is 
excreted predominantly by the kidneys248,249, and its clearance through the kidney can be 
directly imaged and quantified by photoacoustic imaging248. Photoacoustic imaging is a 
relatively new imaging technology which relies on the photoacoustic effect, that is, the 
production of sound waves from light250, in order to produce images from within the body. 
A short pulse of non-ionising laser energy is applied to the animal, and the tissues of the body 
absorb this energy and convert some of it into heat. The rise in temperature causes 
thermoelastic expansion, and subsequent relaxation, resulting in an acoustic pressure wave 
which is detected as an ultrasound wave. Different tissues of the body will have different 
absorption, thermal, and elastic properties, and so the resulting ultrasound waves will reach 
the detector at different times and amplitudes depending on the depth and characteristics 
of their tissue of origin. A photoacoustic image can then be generated by reconstructing the 
detected acoustic signals, using their magnitude and arrival times at the detector to 




(MSOT) is capable of imaging at multiple wavelengths, and signals can be spectrally unmixed 
to allow the identification of specific absorbers253. Furthermore, MSOT employs curved signal 
detectors which detect signals from multiple angles254,255, enabling 3D reconstruction of 
anatomical images. MSOT is most frequently used to monitor tumours in vivo256, however 
Taruttis et al., (2012) have demonstrated its potential in dynamic imaging of kidney and liver 
function, by directly imaging the kinetics of IRDye and indocyanine green (ICG) in the 
respective organs248. This method of monitoring kidney function has the disadvantage that 
the animal is anaesthetised during the measurement, and as such GFR will be 
decreased239,240, however an advantage is that the kidneys can be directly visualised during 
measurement. Photoacoustic imaging has a penetration depth of only around two to three 
centimetres251,252, which is suitable for small rodents, but limits clinical use to superficial 
tissues, such as imaging certain tumours257, vasculature258, and inflammation259. As such, this 
method of monitoring kidney function is unlikely to be applied to human use, but still 
presents as a valuable new method in preclinical research. 
 
1.6 Preclinical Imaging in Regenerative Medicine Research 
Imaging technologies are becoming more widely used in scientific research and have many 
applications in regenerative medicine research. The most commonly used imaging modalities 
in preclinical research are bioluminescence imaging (BLI), fluorescence imaging, magnetic 
resonance imaging (MRI), positron emission tomography (PET), single photon emission 
computed tomography (SPECT), ultrasound, and more recently, photoacoustic imaging89,260. 
Each modality has distinct advantages and disadvantages (Table 1.4), and no single modality 
is ideal for all applications. Some imaging technologies used in preclinical research are also 
available in the clinic, making them attractive for clinical translation of new imaging protocols 
and other techniques. However, modalities that are exclusively restricted to preclinical use 
are still of great value in translational research, as they can provide information that would 
not be possible or feasible to gather otherwise. 
Broadly speaking, imaging can provide three types of data that are important in regenerative 
medicine: anatomical structure, organ function, and/or cell tracking, depending on the 
modality chosen. Cell tracking is of particular interest in this thesis, as monitoring the 
biodistribution of cells is a key component of assessing the safety of a cell-based RMT. 




assessing renal function was already discussed above, and thus will not be covered again in 











 Excellent sensitivity 
 Good temporal resolution 
 Safe 
 Poor spatial resolution 
 Signal attenuation with 
greater imaging depths 
Fluorescence 
Imaging 
 Good temporal resolution 
 Safe 
 Poor sensitivity 
 Poor spatial resolution 
 Signal attenuation with 






 Excellent spatial resolution  
 Unlimited penetration depth 
 Safe 
 Poor temporal resolution - 
whole body imaging not 
feasible.  
Nuclear Imaging  
(PET & SPECT)  
 Excellent sensitivity 
 Good temporal resolution 
 Unlimited penetration depth 
 Can generate quantitative 
data from whole body scans. 
 Poor spatial resolution 
 No anatomical information 
 Exposure to ionising radiation 
- safety concerns 
Ultrasound 
Imaging 
 Can monitor renal perfusion 
with microbubble contrast 
agents 
 Safe 
 Limited to structural, rather 








 Excellent sensitivity 
 Good spatial and temporal 
resolution 
 Can generate quantitative 
data 
 Safe 
 Limited penetration depth
 Imaging lungs is not possible 
due to air spaces 
 
Cell tracking is conventionally performed by the histological detection of labelled cells ex 
vivo261. However, this requires the sacrifice of multiple animals at many time points in order 
to study biodistribution over time, which does not allow the longitudinal evaluation of 
individual animals, is time consuming for the researcher, and the very large numbers of 
animals required for such experiments is against the principles of the 3Rs (Replacement, 
Reduction, Refinement)262. Moreover, histological detection of cells is most commonly 
performed by labelling cells with fluorescent cell membrane dyes, such as PKH26 or CM-Dil, 
prior to in vivo administration147,148,185. A major flaw of cell membrane dyes is that they 
readily transfer to host tissues both in vitro and in vivo263, potentially resulting in false 
positive cell tracking. Conversely, preclinical imaging is minimally invasive, allowing 
individual animals’ responses to be monitored over time, and by using reporter genes for cell 
tracking, it can be very specific and reliable. The two imaging modalities used for cell tracking 
in this thesis are discussed in more detail below. 
Table 1.4: Summary of the advantages and disadvantages of the most commonly used 





BLI is an optical imaging modality commonly used for the in vivo tracking of cells in preclinical 
research264. BLI involves the detection of light which is generated following the oxidation of 
the substrate luciferin by the enzyme luciferase. For cell tracking experiments, the cells of 
interest are virally transduced to express luciferase prior to in vivo administration. The 
luciferase-expressing cells can then be detected in vivo following the administration of 
luciferin to the animals264-266. Mammalian tissues do not naturally emit light, resulting in very 
low background signals in BLI, giving very high signal-to-nose ratios and making BLI a very 
sensitive imaging modality265. However, the light emitted by luciferase is readily scattered 
and absorbed by overlying tissues, resulting in attenuation of the bioluminescent signal with 
greater depths. This leads to poor spatial resolution and penetration depth, and makes signal 
quantification somewhat unreliable264. BLI sensitivity decreases by approximately 10-fold for 
every centimetre of tissue266, however this is not too much of a problem when imaging mice, 
as they can simply be turned over and imaged from another aspect. Luciferase is only 
expressed by live cells, and the luciferase gene is passed to daughter cells following cell 
division266, making BLI useful for monitoring the survival and proliferation of transplanted 
cells. BLI has very good temporal resolution, with acquisition times ranging from one second 
to a couple of minutes, depending on the intensity of the signal. Moreover, most commercial 
systems allow up to five mice to be imaged at a time. This makes BLI a highly useful imaging 
modality for fast, high-throughput, whole-body imaging, suited to longitudinal stem cell 
tracking in vivo.  
BLI has been used to track the homing of systemically administered luciferase+ MSCs to the 
injured kidney following UUO193 and IRI109 surgery; to compare the biodistribution of cells 
following different administration routes267; and to validate the success of cell administration 
via a catheter threaded through the femoral artery to deliver cells specifically to the left 
kidney268. Furthermore, Gao and colleagues used BLI to monitor the longitudinal survival of 
MSC following administration to the renal parenchyma after bilateral IRI. The authors found 
that MSCs administered in a hydrogel had improved survival and longer retention in the 
kidney than MSCs administered in saline, and that this resulted in greater efficacy of MSCs, 
as shown by increased tubular cell proliferation and decreased apoptosis269.  
In addition to the kidney, BLI is used to track cell biodistribution and survival over time in a 
wide range of regenerative medicine applications, including myocardial infarction270-273, liver 




GvHD283. Furthermore, longitudinal tumour monitoring is a common application of BLI, with 
many reports in cancer models284-286, and with a specific focus of assessing the 
tumourigenicity of RMTs287,288.  
Magnetic Resonance Imaging 
MRI is a very common imaging technology in the clinic, and is becoming more widely used in 
preclinical research. MRI uses a strong magnetic field to align the spin moments of hydrogen 
protons within the patient or animal’s body relative to the magnetic field, and 
radiofrequency pulses to force these spins to higher energy levels. The spins relax when the 
radiofrequency pulse is removed, and release energy as they do so, which is then detected 
by radiofrequency coils, and can be reconstructed to produce images289,290. The longitudinal 
relaxation time is termed T1 relaxation, and the transverse relaxation time is termed T2 
relaxation290. In T1-weighted images, water appears dark and fat appears bright, whereas in 
T2-weighted images, water appears bright and fat appears dark. This therefore results in the 
characteristic greyscale images, as different tissues in the body exhibit specific T1 /T2 
relaxation times290. The main advantages of MRI are that it does not use ionising radiation 
and is therefore safe, and it has excellent spatial resolution with unlimited tissue penetration 
depth, allowing the generation of highly detailed images of organs260. However, MRI lacks 
sensitivity, and the temporal resolution is poor260, meaning that whole body scanning at high 
resolution is not feasible, especially as only one animal can be imaged at a time.  
Superparamagnetic iron oxide nanoparticles (SPIONs) are the agent most commonly used to 
track cells in vivo291-293. Reporter genes which generate MRI contrast such as ferritin, 
tyrosinase, or β-galactosidase, can also be used, however they have limited efficacy as cell 
tracking agents294,295. Reports have shown that following arterial administration, SPION-
labelled MSCs can be detected in the cortex of the kidney, but not the medulla, and Prussian 
blue staining of iron deposits on kidney sections identified SPIONs exclusively in the 
glomeruli, thus validating the in vivo imaging data296,297. MRI is also widely used to track 
labelled stem cells in other regenerative medicine applications, most commonly in models 








1.7 Summary and Thesis Aims 
To summarise, the kidney is a vitally important organ, involved in waste removal and 
homeostasis. AKI and CKD are serious diseases associated with very high morbidity and 
mortality. There are currently no specific treatments aimed to treat AKI or slow down the 
progression of CKD, and current treatments are simply aimed at good clinical care, blood 
pressure management, and the provision of RRT when required. Regenerative medicine 
therapy is a promising solution and various cell types have been shown to ameliorate injury 
in many models of kidney injury. However, current methods of assessing kidney function and 
tracking administered cells in vivo are not without controversy. Preclinical imaging methods 
offer a more reliable method of assessing kidney function and tracking cells, but are currently 
not widely used. 
The main aims of this thesis were to: 
1. Assess the use of two novel methods of assessing kidney function in mice with kidney 
injury, the transcutaneous measurement of FITC-sinistrin, and photoacoustic 
imaging of IRDye clearance kinetics 
2. Assess the efficacy of human kidney-derived cells in mouse models of acute and 
chronic kidney disease 
3. Use preclinical imaging methods to track the biodistribution of cells in vivo, both to 













All reagents and assays were purchased from Sigma Aldrich, UK, unless otherwise stated. 
2.1 Kidney Injury Models and in vivo Measures of Kidney Function 
BALB/c or BALB/c SCID mice were used for all kidney injury experiments. Animals were 
obtained from Charles River, UK, and were housed in individually ventilated cages (IVCs) 
under a 12h light/dark cycle, and were provided with standard food and water ad libitum. 
Animals were allowed one week after arrival to acclimate to the new surroundings before 
any experimental procedures began. All animal procedures were performed under a licence 
granted under the Animals (Scientific Procedures) Act 1986 and were approved by the 
University of Liverpool Animal Ethics Committee. 
Adriamycin Kidney Injury Model 
Female BALB/c SCID mice age 7-8 weeks were administered with 6.3mg/kg adriamycin 
(doxorubicin hydrochloride; Tocris Biosciences, UK, or TEVA, Israel) in 100µl (intravenous, IV). 
Uninjured control animals received 100μl 0.9% saline (IV). Body weight was monitored daily 
for two weeks, and twice weekly thereafter.  
Ischemia-Reperfusion Injury Models 
Male BALB/c mice age 8-10 weeks were anaesthetised with isoflurane and O2, given 1mg/kg 
buprenorphine (subcutaneous, SC), 70µl 1:10 Baytril antibiotic (SC), and 0.5ml warmed saline 
(SC). The surgical site was shaved and sterilised with iodine and ethanol, ophthalmic 
ointment was applied to prevent corneal drying, and the mouse was transferred to a heat 
pad on the surgical table, and a rectal probe was inserted to monitor core body temperature. 
The mouse was placed in the prone position with the limbs taped down, and a surgical drape 
was placed over the animal. Once a surgical plane of anaesthesia had been established and 
core body temperature was at 37°C, the kidneys were palpated through the skin and two 
dorsal incisions were made in the skin over the region of the kidneys. The skin was bluntly 
dissected from the muscle, and a smaller incision was made in the muscle layer. Depending 
on the model required, the kidneys may have been clamped or removed (nephrectomy, Nx).  
Two models of IRI were used in this thesis: 
1. Bilateral ischemia: both kidneys clamped. 





The nephrectomy was carried out by first displacing the adrenal gland from the kidney, using 
a sweeping motion with forceps. 4/0 silk suture was then tied around the renal artery, vein, 
and ureter with a double surgical knot. The kidney was removed by cutting distally to the 
knot. The stump was irrigated with sterile saline and returned to the abdominal cavity. The 
muscle layer was closed with a continuous suture using 7/0 absorbable suture material 
(Clinisorb), and the skin was closed with mattress sutures using 7/0 absorbable suture 
material (Clinisorb).  
Renal ischemia was induced by first gently holding the kidney with atraumatic blunt forceps, 
and dissecting fat and connective tissue away from the renal pedicel. Small holes were made 
in the connective tissue either side of the renal artery and vein using forceps, and a vascular 
clamp (Schwartz Micro Serrefine sharp angled clamp, FST, Germany) was applied to the renal 
artery and vein using Schwartz clip applying forceps (Roboz, South Pointe Surgical Supply, 
Florida, USA). The timer was immediately started. The kidney was replaced back under the 
skin for the duration of clamping.  
Successful ischemia was indicated by a uniform colour change from red to dark purple (Figure 
2.1). If the kidney was not uniformly dark purple, this indicated that the clamping was not 
successful and the mouse was removed from further analyses. After the appropriate 
clamping time, the clamp was removed. Full reperfusion was confirmed by an immediate 
lightening of the colour of the kidney after removal of the clamp, leading to a return to the 
normal red colour after a few minutes. The muscle and skin layers were closed as described 
above. The mouse was recovered in a heat box, and then transferred to a clean home cage. 
Renal ischemia-reperfusion surgery was carried out using sterile techniques to minimise the 
risk of infection. Post-operative checks, including monitoring weight and checking sutures 
and hydration status, were performed daily for the duration of the studies. 
Urine Collection 
Urine was collected over 24h in metabolism cages (Tecniplast, Italy) for the adriamycin 
model, or over 5h (3pm - 8pm) using hydrophobic sand (LabSand; Datesand Ltd, UK) for the 
IRI model. Metabolism cages were not used for the IRI model due to project licence 
restrictions. Collected urine was centrifuged to remove any contaminants, and aliquots were 






Transcutaneous Assessment of FITC-sinistrin Clearance 
Mice were anaesthetised with isoflurane and O2, and positioned prone on a heat mat. A 
region of the fur on the right side of the back was removed using an electric shaver and 
depilatory cream (Veet for sensitive skin), which was left on for a maximum of three minutes. 
The transcutaneous device (NIC-Kidney; Mannheim Pharma & Diagnostics, Germany; Figure 
2.2A)234,237 was connected to a lithium battery, and attached to the shaved skin using double-
sided black plaster (Mannheim Pharma & Diagnostics, Germany) which had been cut to size. 
The device was then secured in place with adhesive tape (Leukosilk, BSN Medical, Germany) 
wrapped around the abdomen of the mouse. After a period of one to three minutes to 
measure the background signals, 0.15mg/g body weight (BW) FITC-sinistrin (Fresenius-Kabi, 
Austria) was administered (IV). The mouse was recovered from the anaesthesia and 
transferred to a clean cage containing absorbent paper and some food pellets, and was 
monitored for 1h 30min (Figure 2.2B). The device was removed and the data read using MPD 
Lab software (Mannheim Pharma & Diagnostics, Germany). The half-life of the curve was 
analysed with a 3-compartment model using MPD Studio software (Mannheim Pharma & 
Diagnostics, Germany, Figure 2.2C)305,306.  
Multispectral Optoacoustic Tomography (MSOT) for assessing kidney function 
Mice were anaesthetised with isoflurane and O2, and placed on a nose cone on a heat mat. 
The abdomen was shaved using an electric shaver and a depilatory cream (Veet for sensitive 
skin), left on for a maximum of three minutes on the back, and two minutes on the stomach. 
A homemade catheter was prepared by using forceps to remove the tip from a 30G ½ inch 
needle, and inserting the cut end of the needle in to one end of 35cm fine bore catheter  
Sham-operated During ischemia 
Left kidney: ~2min after 
clamp removal 
A B C 
Figure 2.1: Ischemia Reperfusion Injury. Representative photographs showing the 
normal colour of kidneys (A), the colour change during ischemia (B), and the restoration 





tubing (inner diameter 0.28mm). A syringe containing sterile saline, attached to a 30G ½ inch 
needle, was then inserted into the other end of the tubing, and the tubing was flushed with 
saline before the free needle was inserted into the tail vein of the anaesthetised mouse. The 
mouse was transferred to the mouse holder, which was prepared according to standard 
MSOT protocols. The mouse was transferred to the MSOT scanner (inVision 256-TF, iThera 
Medical, Germany), and allowed to equilibrate to the temperature of the water for at least 
10 min prior to image acquisition. The centre of one kidney was identified and a 0.1mm slice 
was imaged in the MSOT using a multispectral protocol (wavelengths: 700, 730, 760, 775, 
785, 800, 850nm; frames per second: 10; averages: 20). 20nmol IRDye 800CW carboxylate 
(IRDye; LI-COR, Nebraska, USA) was administered in 200µl 0.9% saline via tail vein catheter 5 
min after imaging began over a period of 10s. Mice were imaged for a further 25 min, to a 
total of 30 min. Mice were transferred to a heat box after imaging until fully recovered from 
the anaesthesia. 
Figure 2.2: Transcutaneous assessment of FITC-sinistrin clearance. (A) Photograph of a 
transcutaneous device. (B) Photograph of a mouse during the measurement, showing that 
the mouse is conscious and alert, and tolerates the device well. (C) Representative FITC-
sinistrin clearance curve from a healthy mouse. Black data points represent raw data, blue 




The data was reconstructed and signals from IRDye were resolved using multispectral 
processing. Regions of interest (ROI) were drawn around the cortex and papilla/pelvis 
(referred to only as pelvis) regions of the kidney. The difference in time between the mean 
peak pixel intensity in the cortex and the pelvis (TMAX Delay) was calculated. Excretion half-
life was calculated by fitting the exponential decay for the mean cortex pixel intensities. 
Culling and Organ Collection 
Mice were culled via a schedule one method; either by a rising concentration of CO2 or by 
cervical dislocation. Blood was collected via cardiac puncture, and the needle was removed 
before expelling the blood from the syringe, to avoid haemolysis. Blood was collected into 
Eppendorf tubes, and allowed to clot at room temperature for several hours, before being 
repeatedly centrifuged at increasing speeds to collect serum. Aliquots of serum were made 
and stored at -20°C until analysis. Kidneys or other organs of interest were dissected from 
the mouse and fixed in 4% formaldehyde at 4°C for 24h. Kidneys were cut along the coronal 
or axial planes immediately after collection. 
Paraffin-embedding and Sectioning 
Fixed kidneys were washed in phosphate buffered saline (PBS) twice, and then transferred 
to 70% ethanol. Kidneys were processed in increasing concentrations of ethanol, then xylene, 
and finally molten paraffin wax (Tissue Processor TP1020, Leica, Germany), and then 
embedded in paraffin (Tissue Embedding Centre 1150, Leica, Germany). 5µm sections were 
cut using an automatic microtome (Microm HM 355S, Thermo Scientific, UK) on to glass slides 
(Superfrost Plus, Thermo Scientific, UK), and stored in an oven set at 36 - 40°C overnight to 
adhere the tissue to the slide. Slides were stored at room temperature until histological 
staining and analysis. 
Freezing and Cryostat Sectioning 
Fixed kidneys or other organs were washed in PBS twice, and soaked in 30% sucrose 
overnight, or until the tissue had sunk to the bottom of the tube. Tissues were then 
embedded in optimal cutting temperature (OCT) matrix (Cryomatrix, Thermo Scientific) and 
immersed in a bath of isopropanol cooled to a very low temperature with dry ice. Frozen 
tissues were stored at -20°C until cryosectioning, or -80°C for long term storage. 7µm sections 
were cut with a cryostat (HM 505, Microm, UK) on to glass slides (Superfrost Plus, Thermo 





2.2 Analysis of Kidney Injury 
All serum and urine samples were thawed and centrifuged at 70-80,000 revolutions per 
minute (rpm) for 5 minutes prior to analysis. 
Urinary Creatinine 
Urinary creatinine (UCr) was measured using an in-house assay based on the Jaffe method307. 
25µl standard or sample added to wells of a 96-well plate (Corning Costar 9018, Fisher 
Scientific, UK) in duplicate. 125µl reagent A added to all wells and plate was incubated at 
room temperature for 2 minutes. The reaction was stopped with 5µl reagent B. The plate 
was incubated on a plate shaker set at 500rpm for 10 minutes, and the plate was read at 
490nm. The standard curve was plotted and the equation for the line of best fit was used to 
calculate the creatinine concentration in the unknown samples.  
Creatinine standards: 1mg/ml creatinine stock. 400µg/ml top standard was prepared with a 
2 in 3 dilution of the stock solution, and this was serially diluted to produce standards at the 
following concentrations: 400, 200, 100, 50, 25, 12.5, 6.25µg/ml. 
Samples: 5µl urine was added in duplicate to all wells, and 20µl dH2O added to all urine 
samples, to produce a 1:5 dilution. 
Reagent A: 50ml 0.5M NaOH, 25ml 0.1M sodium phosphate dibasic, 29.5ml 0.56M Borax, 
25ml sodium dodecyl sulphate (SDS), 45ml, picric acid, 5ml dimethyl sulphoxide (DMSO). 
Reagent B: 5ml acetic acid, 1ml concentrated sulphuric acid, 44ml distilled water 
Urinary Albumin 
Urinary albumin was quantified with the mouse albumin enzyme-linked immunosorbent 
assay (ELISA) quantitation kit (Bethyl Laboratories, Texas, USA) according to manufacturer’s 
instructions. A 1:1,000 dilution was required for baseline and control samples in the 
adriamycin model (female mice), and up to 1:1,000,000 dilution for samples from injured 
mice. A 1:10,000 dilution was required for all samples for the IRI model (male mice). The 
absorbance of the samples was read in a plate reader (FLUOstar Omega, BMG Labtech, 
Germany) at 450 nm immediately after the addition of the stop solution. The data was 
analysed using a four-parameter logistic fit (software from www.myassays.com). Albumin 
data was normalised to urine volume produced over 24h (mg/24h) or creatinine 





Urinary Kidney Injury Molecule-1 
Urinary KIM-1 was quantified using Mouse TIM-1/KIM-1/HAVCR DuoSet and the DuoSet 
Ancillary Reagent Kit 2 (R&D Systems, UK), according to manufacturer’s instructions. Samples 
were diluted 1:200 prior to analysis. The absorbance of the samples was read in a plate 
reader at 450 nm and 540 nm immediately after the addition of the stop solution. The reading 
at 540 nm was subtracted from that at 450 nm. The data was analysed by plotting a standard 
curve and the equation for the line of best fit was used to calculate the KIM-1 concentration 
in the unknown samples. 
Serum Creatinine 
SCr was quantified using the DetectX® Serum Creatinine Detection Kit (ArborAssays, 
Michigan, USA) according to manufacturer’s instructions. Samples were assayed undiluted. 
The absorbance of the samples was read in a plate reader at 490 nm at 1 min and 30 min 
after the addition of the substrate. The reading at 1 min was subtracted from that at 30 min. 
The data was analysed by plotting a standard curve and the equation for the line of best fit 
was used to calculate the SCr concentration in the unknown samples.  
Blood Urea Nitrogen 
BUN was quantified using the QuantiChrom™ Urea Assay Kit (BioAssay Systems, California, 
USA) according to manufacturer’s instructions. Samples were diluted 1:5 prior to analysis. 
The absorbance of the samples was read in a plate reader at 520 nm 20 min after the addition 
of the substrate. The data was analysed by plotting a standard curve and the equation for 
the line of best fit was used to calculate the BUN concentration in the unknown samples. 
Histological Staining and Scoring 
Picro-Sirius Red (PSR) Staining: Slides were de-waxed and hydrated in two changes of xylene 
(5 min each) and graded alcohols (100% through to 50% ethanol, then distilled water; 2 min 
each). Slides were stained in picro-sirius red solution (0.5g Sirius red F3B in 500ml saturated 
aqueous solution of picric acid) for one hour. Slides were washed in two changes of acidified 
water (5ml acetic acid in 1L distilled water), dehydrated in graded alcohols (50% through to 
100% ethanol; 2 min each), cleared in two changes of xylene (5 min each) and mounted with 
a resinous medium (DPX Mountant).  
Periodic Acid-Schiff (PAS) Staining (PAS staining kit 395B-1KT): Slides were de-waxed and 




ethanol, then distilled water; 2 min each). Slides were immersed in 0.01% periodic acid 
solution for 5 min and rinsed in several changed of distilled water. Slides were stained in 
Schiff’s reagent for 15 min, and washed with running tap water for 5 min. Slides were 
counterstained with Gill’s Haematoxylin No. 3 solution for 90s, and rinsed in running tap 
water until the water ran clear. Slides were finally dehydrated in graded alcohols (50% 
through to 100% ethanol; 2 min each), cleared in two changes of xylene (5 min each) and 
mounted with a resinous medium (DPX Mountant). 
Masson’s Trichrome Staining: Slides were de-waxed and hydrated in two changes of xylene 
(5 min each) and graded alcohols (100% through to 50% ethanol, then distilled water; 2 min 
each). Slides were stained in Weigert’s haematoxylin working solution (equal parts solution 
A (1g haematoxylin in 100ml 95% ethanol) and solution B (4ml 29% ferric chloride, 1ml 
concentrated hydrochloric acid, 95ml distilled water)) for 10 min, rinsed in warm running tap 
water for 10 min, and then rinsed in distilled water. Slides were stained in Biebrich scarlet-
acid fuschin solution (90ml 1% biebrich scarlet, 10ml 1% acid fuschin, 1ml glacial acetic acid) 
for 10 min, and then washed in distilled water. Slides were differentiated in 
phosphomolybdic-phosphotungstic acid solution (25ml 5% phosphomolybdic acid, 25ml 5% 
phosphotungstic acid) for 10-15 min, or until collagen was not red. Slides were directly 
transferred to aniline blue solution (2.5g aniline blue, 2ml acetic acid, 100ml distilled water) 
for 5-10 min, briefly rinsed in water, then immersed in 1% acetic acid solution for 2-5 min. 
Slides were washed in distilled water, then dehydrated quickly in 95%, then 100% ethanol. 
Slides were cleared in two changes of xylene (5 min each) and mounted with a resinous 
medium (DPX Mountant). 
PSR-stained kidney sections from the adriamycin model were blindly scored for the 
percentage of glomerular damage by a qualified paediatric nephrologist, Professor Adrian 
Woolf, University of Manchester. All glomeruli were assessed, and were categorised as 
abnormal if the PSR staining extended beyond the confines of the mesangium, into the 
glomerular tufts. Additional features of injury included the adhesion of glomerular tufts to 
the Bowman’s capsule, and the obliteration of capillary loops.  
Fibrillar collagen within PSR-stained kidney sections was detected using polarised 
microscopy, and image analysis software (Fiji) was used to quantify the percentage of 
fibrosis.  
PAS-stained kidney sections from the IRI model were blindly scored for tubular injury by a 




of Liverpool. 10 fields of view (FOV) within the OSOM and distal cortex at x200 magnification 
were scored 0-5 based on the degree of necrosis and cast formation: 0 = none, 1 = <10%, 2 = 
11-25%, 3 = 26-45%, 4 = 46-75%, 5 = >76% (Figure 2.3). The overall score is the sum of the 
scores for the 10 FOVs. This method was adapted from Wang et al. (2005)308.  
Immunofluorescence on Frozen Tissue Sections 
Immunostaining was performed within a humidified chamber. 7µm frozen tissue sections 
were removed from the freezer and allowed to thaw at room temperature for 10-15 minutes. 
The sections were washed three times with PBS, for 2-3 min each wash. Sections were 
permeabilised with 0.25% Triton-X 100 in PBS for 10 min at room temperature, and then 
washed three times in PBS. Each section on a slide was encircled with a hydrophobic pen, 
(PAP pen, Abcam) and then blocked with 2% bovine serum albumin (BSA) in PBS for 1h at 
room temperature. Primary antibodies (KIM-1: Goat polyclonal IgG, R&D Systems (AF1817-
SP); Ki67: Rabbit polyclonal IgG, Abcam (ab16667)) were diluted 1:100 in 2% BSA in PBS, and 
sections were incubated with the primary antibody, or 2% BSA in PBS for the negative control, 
overnight at 4°C. The next day, sections were washed thoroughly three times with PBS, for 5 
min each wash, and then incubated with the secondary antibodies (Alexa Fluorophores, 
Invitrogen) and 4',6-diamidino-2-phenylindole (DAPI), diluted to a working concentration of 
100 µg/ml in 2% BSA in PBS, for 1h at room temperature. The secondary antibodies were 
applied to the negative control, to test the specificity of the secondary antibodies. Sections 
were washed three times with PBS, and once with distilled water, for 5 min each wash, 
mounted with antifade mounting media (Gelmount, Biomedia), and sealed with clear nail 
polish. Immunostained slides were stored at 4°C. Fluorescence images were acquired using 
a Leica DM2500 microscope with a Leica DFC350 FX camera (Leica, Germany). 
Note that an irrelevant isotype antibody would have been the optimal control to ensure the 
specificity of the antibody to the antigen of interest.  
 
2.3 Cell Therapy: Administration and Tracking 
Cell Preparation and Administration 
Mouse kidney stem cells (mKSCs)309, mouse MSCs (mMSCs; D1 ORL UVA [D1](ATCC® CRL-
12424™), ATCC, UK), human umbilical cord-derived MSCs (hUC-MSCs; provided by NHS Blood 
and Transplant) and human bone marrow-derived MSCs (hBM-MSCs; Lonza Walkersville Inc., 




Figure 2.3: Tubular injury scoring. Representative images of tubular injury scoring by a veterinary pathologist: (A) 0 = none, (B) 1 = <10%, (C) 2 = 11-25%, 




Translational Medicine (ITM), University of Liverpool (UoL). Human kidney-derived cells 
(hKCs)134 were isolated from a human infant kidney donated from Alder Hey Children’s 
Hospital, Liverpool, UK, and were cultured and prepared for in vivo administration by Dr Ilaria 
Santeramo, ITM, UoL. All cells were cultured at 37°C under a humidified atmosphere with 5% 
CO2 as described perviously134,309. Average cell diameter was estimated by measuring the 
volume of a cell pellet in a packed cell volume (PCV) tube according to the manufacturer’s 
instructions (Techno Plastic Products, Switzerland). 
Prior to in vivo administration, mKSCs, mMSCs, hKSCs, and hBM-MSCs (only those used in 
Chapter 6) were transduced with a lentiviral vector encoding firefly luciferase and ZsGreen 
under control of the constitutive promoter EF1a, by Dr Arthur Taylor as previously 
described310,311. The mKSCs were infected with a multiplicity of infection (MOI) of 10, whereas 
all other cells where infected with an MOI of 5. In all cases, at least 90% of the cell population 
expressed the vector after transduction. SPIONs291,293 for mMSC labelling were synthesised 
by Dr Michael Barrow, Department of Chemistry, UoL, and were incubated with cells at a 
labelling concentration of 25 µg/ml for 24h prior to in vivo administration. For in vivo 
administration, cells were trypsinised, pelleted, carefully resuspended in ice cold PBS and 
kept on ice until injection.  Immediately prior to administration, cells were gently re-
suspended using a pipette, and warmed slightly to room temperature before administration 
to the animal, using a 29G ½ inch insulin needle.  
Ultrasound-Guided Intracardiac Injection 
Mice were provided with 1mg/kg buprenorphine for pain relief prior to intracardiac injection. 
Mice were anaesthetised using isoflurane and O2, and positioned supine on the heated 
ultrasound platform, with the limbs taped (Leukosilk, BSN Medical, Germany) in the extended 
position (Figure 2.4A). The chest was shaved using an electric shaver and a depilatory cream 
(Veet for sensitive skin), left on for a maximum of two minutes. The skin over the chest was 
held taut by a strip of tape placed over the abdomen, and swabs were placed either side of 
the mouse (Figure 2.4A, B, C). Ultrasound gel (ultrasoundgel.co.uk, UK) was placed liberally 
on the chest, making sure to avoid introducing bubbles. The heart was located by ultrasound 
(S-Sharp, Taiwan), with the transducer at a slight angle (approx. 30° counter-clockwise) 
(Figure 2.4B, C, F). The needle was then introduced in to the plane of imaging and tapped on 
the skin of the mouse several times, to confirm the needle stayed within the imaging plane, 
even when moved (Figure 2.4D, E). The needle was then gently inserted in to the heart, and 




solution was slowly injected. The needle was then withdrawn from the heart in a smooth 
motion. The ultrasound gel was cleaned off the mouse and the mouse was recovered in a 
heat box. Mice were closely monitored for signs of adverse effects following the intracardiac 
injection. A successful injection could be observed by a change in contrast within the heart 
as the cell solution was administered (Figure 2.4H), and by bioluminescence imaging of 
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D E 
Figure 2.4: Ultrasound-guided intracardiac administration of cells. (A) Photograph of 
mouse set-up for ultrasound-guided intracardiac injection. (B - C) Photographs of the 
ultrasound transducer in place for heart imaging. (D - E) Photographs of position of needle 
for intracardiac injection. (F - H) Snapshot images of left cardiac ventricle, outlined with a 
dashed white line, before injection (C), during the injection, with the tip of the needle 
(arrow) in the left ventricle (D), and after injection of the cell solution (E), where the 






Mice were anaesthetised using isoflurane and O2, and imaged in the IVIS Spectrum (Perkin 
Elmer, UK) 15 min after the administration of 150mg/kg BW luciferin (SC). Image acquisition 
was performed using automatic exposure settings, where the system automatically adjusted 
the exposure time, up to a pre-set maximum, in order to obtain a minimum of 3000 
bioluminescence counts. Mice were returned to the home cage after imaging. Images were 
normalised to express average radiance (photons/second/cm2/steradian (p/s/cm2/sr)), and 
the scale was set according to the level of signal detected. Generally, the standard scale was 
set to 1.0 x105 – 1.0 x106 p/s/cm2/sr, and was adjusted only if necessary, to display weaker 
or stronger signals. The scale was never set below 5.0 x103 p/s/cm2/sr, in order to avoid 
visualising unspecific background noise. Signals were quantified by ROIs around the whole 
mouse, or a specific region of the mouse. Organs were imaged ex vivo after being dissected 
from the mouse soon after luciferin administration. Organs were placed on parafilm for ex 
vivo imaging. It was necessary to cut the kidneys open (coronally) in order to detect signals 
from within the kidney. All other organs (brain, heart, lungs, liver, and spleen) could be 




Figure 2.5: Unsuccessful IC injections. Mis-injection in to the right ventricle, leading to 
cells present in the lungs (A), and mis-injection in to the chest cavity (B). Partial mis-





Magnetic Resonance Imaging 
Mice were anaesthetised using isoflurane and O2. Mice were placed on a nose cone on the 
imaging bed appropriate for the anatomical region (abdominal or brain) being imaged. 
Ophthalmic ointment was applied to avoid corneal drying. A rectal probe was lubricated and 
inserted into the rectum, and a respiration pillow was secured on the mouse’s back, for 
monitoring temperature and respiration respectively. A water-heated pad was secured in 
place over the animal to keep the body temperature constant. All MR data was acquired with 
a Bruker 9.4 T Avance III HD instrument (Bruker, UK). The mouse was inserted into an 86mm 
resonator and a 4-channel receive-only surface coil array was used for brain imaging, 
whereas a 4-channel receive-only cardiac array was used for abdominal imaging. All data 
acquisition and processing was carried out using Paravision 6.0.1 (Bruker). Imaging 
sequences are summarised in Table 2.1. FLASH T2* sequences were designed to optimally 
detect signals from SPION-labelled cells. T2* relaxation times were quantified from the T2* 
map by drawing ROIs around the cortex of the kidney or the liver, in order to quantify the 
relative presence of SPIONs at various time points in the study. B0 field maps were obtained 
prior to T2* mapping to optimize the field homogeneity. Ex vivo imaging was performed on 
organs fixed in 4% formaldehyde, and then immersed in Fomblin solution for imaging. All MR 
imaging and data analysis was performed with the help of Dr Arthur Taylor. 
Fluorescence Microscopy for Tracking ZsGreen+ Cells 
7µm frozen tissue sections were removed from the freezer and allowed to thaw at room 
temperature for 10-15 minutes. DAPI diluted in distilled water to a working concentration of 
100 µg/ml was applied to tissue sections and incubated at room temperature for 5 min. Slides 
were washed twice with PBS, and once with distilled water, mounted with antifade mounting 
media (Gelmount, Biomedia), and sealed with clear nail polish. DAPI-stained slides were 
stored at 4°C. Fluorescence images were acquired using a Leica DM2500 microscope with a 
Leica DFC350 FX camera (Leica, Germany).  
The presence of ZsGreen+ cells in the kidney was assessed by quantifying the percentage of 
glomeruli that contained ZsGreen+ cells. All glomeruli in one kidney section per animal were 







Table 2.1: Data acquisition details for MR imaging. 
 





B0 Map T2* Map 
FLASH T2* 
(Organs) 
Slices 20 20 1 20 70 
Averages (NEX) 3 3 3 2 24 
Repeat Time (TR) 262.6ms 262.6ms 10ms 900ms 1300 
Echo Time (TE) 5.5ms 4.2ms 3.6ms N/A 6.3 
Flip Angle (FA) 20.0° 20.0° 15.0° 50.0° 20 
Matrix Size (MTX) 
386 x 386 
pixels 
256 x 256 
pixels 
64 x 64 x 64 
pixels 
256 x 256 
pixels 
386 x 386 
pixels 
Field of View 
(FOV 
35 x 35mm 20 x 20mm 
45 x 45 x 
45mm 
35 x 35mm 15 x 15mm 
Slice Thickness 
(SI) 
0.5/0.6mm 0.5/0.6mm 45mm 0.5/0.6mm 0.2/0.2mm 
Echo Images N/A N/A N/A 8 N/A 




Acquisition Time 5m 35s 4m 4s 2m 3s 5m 7s 3h 20m 43s 
 
Isolectin Staining of Blood Vessels 
Blood vessels in the brain were identified by isolectin IB4 staining on frozen tissue sections 
from the brains of perfusion-fixed mice. Immunostaining was performed within a humidified 
chamber. 7µm frozen tissue sections were removed from the freezer and allowed to thaw at 
room temperature for 10-15 minutes. The sections were washed three times with PBS, for 2-
3 min each wash. Sections were permeabilised with 0.3% Triton-X 100 in PBS for 10 min at 
room temperature, and then washed three times in PBS. Each section on a slide was encircled 
with a hydrophobic pen, (Abcam) and then blocked with blocking solution (2% BSA, 2% 
normal goat serum (NGS) and 0.05% Triton X-100 in 0.1 M PBS) for 1h at room temperature. 
Isolectin IB4 (L2140, Sigma Aldrich, UK) was diluted 1:50 in CaCl2-containing buffer and 
blocking solution, and sections were incubated with the isolectin for 72h at 4°C. Sections 
were washed thoroughly three times with PBS, for 5 min each wash, and then incubated with 
streptavidin (Alexa Fluorophore-Streptavidin, 016-580-084-JIR, Stratech) and DAPI, diluted 
1:200 in CaCl2-containing buffer and blocking solution, overnight at 4°C. Sections were 
washed three times with PBS, and once with distilled water, for 5 min each wash, mounted 
with antifade mounting media (Gelmount, Biomedia), and sealed with clear nail polish. 




DM2500 microscope with a Leica DFC350 FX camera (Leica, Germany). IB4 staining was 
performed by MRes student, Lydia Beeken, ITM, UoL.  
Prussian Blue Staining of Iron for Tracking SPIONs 
SPIONs were detected in frozen tissue sections with the Prussian Blue Iron Detection Kit 
(Sigma, UK) according to manufacturer’s instructions. Prussian blue-stained tissue sections 
were imaged under light microscopy. Prussian blue staining was performed by MRes student, 
Cai Astley, ITM, UoL.  
Bone Marrow Extraction and FACS analysis 
Mice were culled by cervical dislocation and their femurs and tibias were collected in PBS 
containing penicillin/streptomycin. In a sterile fume hood, muscle tissues were removed, and 
bone marrow was flushed out with PBS. Bone marrow was centrifuged (400g, 5 mins) and 
then resuspended in fresh PBS. Bone marrow suspensions were then analysed by FACS for 
ZsGreen expression. Bone marrow extraction and FACS analysis were performed by Dr Jack 
Sharkey, ITM, UoL. 
Histological Analysis of Tumours 
Tumours that developed as a result of cell administration were embedded in paraffin, and 
5μm tissue sections were stained with Haematoxylin & Eosin (H&E). Slides were de-waxed 
and hydrated in two changes of xylene (5 min each) and graded alcohols (100% through to 
50% ethanol, then distilled water; 2 min each). Slides were then immersed in haematoxylin 
for 5 min, rinsed in distilled water, and placed in acid-alcohol solution for 10 s before being 
immersed in eosin for 2 min. Slides were finally rinsed in distilled water, dehydrated in graded 
alcohols (50% through to 100% ethanol; 2 min each), cleared in two changes of xylene (5 min 
each) and mounted with a resinous medium (DPX Mountant). H&E-stained tissue sections 
were evaluated and characterised by a qualified veterinary pathologist (Dr Lorenzo Ressel, 
Institute of Veterinary Science, UoL). 
 
2.4 Statistical Analyses 
All statistical analyses were performed using Minitab 17 statistical software. A two-sample t-
test was used to compare two unpaired groups, a paired t-test was used to compare two 
paired groups, and a one-way ANOVA (analysis of variance) was used to compare multiple 




comparison was performed in order to determine which groups were statistically significantly 
different. The Tukey pairwise comparison assigned each group at least one letter, and groups 
that did not share a letter were significantly different from one another. A p-value below 0.05 
was considered statistically significant. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).  
It must be noted that power calculations were not performed to determine optimal group 
sizes. This was because of practical considerations of performing complicated experiments, 









Characterising the adriamycin mouse model of chronic kidney disease, 
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Maximising the use of preclinical murine models of progressive kidney disease as test beds 
for therapies ideally requires kidney function to be measured repeatedly in a safe, minimally 
invasive manner. To date, most studies of murine nephropathy depend on unreliable markers 
of renal physiological function, exemplified by measuring blood levels of creatinine and urea, 
and on various end points necessitating sacrifice of experimental animals to assess 
histological damage, thus counteracting the principles of Replacement, Refinement and 
Reduction. Here, we applied two novel minimally invasive techniques to measure kidney 
function in SCID mice with adriamycin-induced nephropathy. We employed i) a 
transcutaneous device that measures the half-life of intravenously administered FITC-
sinistrin, a molecule cleared by glomerular filtration; and ii) multispectral optoacoustic 
tomography, a photoacoustic imaging device that directly visualises the clearance of the near 
infrared dye, IRDye 800CW carboxylate. Measurements with either technique showed a 
significant impairment of renal function in experimental animals versus controls, with 
significant correlations with the proportion of scarred glomeruli five weeks after induction of 
injury. These technologies provide clinically relevant functional data and should be widely 
adopted for testing the efficacies of novel therapies. Moreover, their use will also lead to a 
reduction in experimental animal numbers. 
3.2 Introduction 
Chronic kidney disease (CKD) represents a huge socioeconomic burden, with treatment 
options for severe disease being limited to dialysis and transplantation. By developing 
regenerative medicine therapies (RMTs) for CKD in preclinical models, novel and alternative 
clinical approaches may be established to halt progression to end stage renal disease (ESRD). 
In order to maximise the use of preclinical murine models of progressive kidney disease as 
experimentation platforms for novel therapies, including drugs and stem cells151,185,312,313, 
kidney function, in concert with structural morphology, needs to be monitored repeatedly in 
a safe, minimally invasive manner. The glomerular filtration rate (GFR) is considered the gold 
standard measure of the main physiological function of the kidney, i.e. to efficiently clear 
small molecular waste products from the blood stream. However, its measurement generally 
requires repeated blood sampling, and for some methods, precisely timed urine collections. 
While these techniques are feasible in patients, it is much more cumbersome and challenging 
to apply them to small experimental animals.  To date, therefore, most mouse studies have 




These are unreliable measures of GFR because levels only rise when over 50% of renal 
function is lost; moreover, factors such as food intake can affect blood levels independently 
of GFR.  Furthermore, most studies of murine nephropathy have relied heavily on end point 
analysis for the assessment of histological damage, which necessitates killing experimental 
animals. While this provides useful data, the sole reliance on necropsy material is not 
compatible with optimal application of the principles of Replacement, Refinement and 
Reduction (the 3Rs). 
Here, we have evaluated the ability of two minimally invasive in vivo technologies to monitor 
kidney function in an adriamycin (doxorubicin)-induced nephropathy mouse model. The 
anthracycline antibiotic adriamycin (ADR) primarily targets both glomerular endothelium and 
podocytes in rodents and is a model of focal segmental glomerulosclerosis (FSGS), which 
accounts for 2.3% of all cases of ESRD314. The incidence of primary FSGS has increased by up 
to 13 fold in the last 30 years315. Along with diabetic nephropathy, it is a common cause of 
severe proteinuria. Administration of a single dose of ADR in both BALB/c and BALB/c severe 
combined immunodeficient (SCID) mice leads to two phases of disease163,169,172,185. In the first, 
glomeruli are grossly histologically intact (i.e. they show no scarring) but their ability to act 
as a macromolecular barrier is severely compromised. This is manifest as ‘proteinuria’. Its 
magnitude can be assessed by measuring the amount of albumin, which appears in the urine 
over unit time; the simpler measure, the urine albumin/creatinine ratio, can also be 
employed. In the second phase of disease, glomeruli become scarred or ‘sclerotic’ and this 
leads to the loss of total filtration surface. This occurs long after ADR has been cleared and it 
exemplifies the ‘progression of CKD’ often observed in clinical practice. This has two clinical 
outcomes: both the degree of proteinuria may fall and, at the same time, the GFR also falls. 
Given that an unchecked fall of GFR will ultimately lead to ESRD, minimally invasive measures 
which correlate with gross structural glomerular damage would be highly informative.  
Importantly, we chose SCID mice in the current study with a longer-term view of using 
immunocompromised mice with drug-induced nephropathy as test beds for assessing the 
safety and efficacy of different types of human stem cells. The two minimally invasive 
technologies comprised firstly, a transcutaneous electronic device for measuring the 
clearance from the blood of (FITC)-sinistrin, a molecule of approximately 4000 Da cleared by 
glomerular filtration234,237. This device can be applied in conscious animals, which is a key 
advantage, given the well-described confounding effects of general anaesthesia on GFR239,240. 
The second technology was multispectral optoacoustic tomography (MSOT). This imaging 




carboxylate (from now on referred to simply as IRDye), through the kidney parenchyma into 
the renal pelvis. Specifically, a recent report suggested that MSOT could effectively monitor 
renal clearance of IRDye in mice248. MSOT illuminates tissue with light pulses at multiple 
wavelengths and detects acoustic waves generated by the thermoelastic expansion which 
follows light absorption316,317. The technique is not harmful and offers very good temporal 
and spatial resolution in live animals; however, it requires the animals to be studied under 
general anaesthesia.  
Results obtained with these techniques were compared with standard biochemical and 
histological indicators of kidney damage. This included 24-hour-albuminuria or urinary 
albumin-to-creatinine ratio, serum creatinine (SCr), blood urea nitrogen (BUN), and Picro-
Sirius red (PSR) and Masson’s Trichrome staining in order to detect structural histological 
damage. Subsequently, we applied an extensive range of statistical tests to determine 
whether the transcutaneous device and MSOT are appropriate tools for monitoring kidney 
function. Furthermore, we assessed whether both technologies could be used to predict 
histological damage during progression to CKD in the ADR model. 
 
3.3 Materials and Methods  
Animals 
Female BALB/c severe combined immunodeficient (SCID) mice (Charles River, Margate, UK) 
were housed in individually ventilated cages at a 12 hour light/dark cycle, with ad libitum 
access to food and water. At age seven to eight weeks, ADR-induced nephropathy was 
induced in six mice by injecting once intravenously (iv) adriamycin (ADR, doxorubicin 
hydrochloride, Tocris, Bristol, UK) at 6.3mg/kg body weight (BW) in 0.9% saline (Braun, 
Melsungen, Germany), while five control mice received saline. The optimal dose had been 
previously determined in a dose-finding study, and is similar to previously reported 
adriamycin dose given to BALB/c SCID mice172,185,318. Mortality in the ADR-administered group 
during the five-week study period was zero. Experimental animal protocols were performed 
under a licence granted under the Animals (Scientific Procedures) Act 1986 and approved by 
the University of Liverpool Animal Ethics Committee. BALB/c SCID mice were used in order 






Albuminuria, serum creatinine and BUN 
To collect urine, mice were housed individually in metabolic cages (Tecniplast, Buguggiate, 
Italy) once a week for 24 hours (h). Despite being gradually acclimated to the metabolic 
cages, 24h urine collection is stressful for mice, leading to weight loss of up to 1.5g during 
the time spent in the cages. Because the mice on average weigh less than 20g, it was 
necessary to omit urine collection at week five, since the long term anaesthesia for MSOT 
imaging is another stressful procedure for the mice. Total urine volume was measured and 
albumin levels were quantified using a Mouse Albumin ELISA Quantification Kit (Bethyl 
Laboratories, Montgomery, TX, USA) according to manufacturer’s instructions. Urinary 
creatinine (UCr) was quantified using a plate based colourimetric assay. Blood was collected 
via cardiac puncture after sacrifice, and separated into serum. Serum creatinine (SCr) and 
blood urea nitrogen (BUN) were quantified according to manufacturer’s instructions (Detect 
X Serum Creatinine Detection Kit, Arbor Assays, Ann Arbor, MI, USA; QuantiChrom Urea 
Assay Kit, BioAssay Systems, Hayward, CA, USA, respectively).  
Histopathology 
Kidneys were dissected at week 5, cut along the sagittal plane, and processed for histology 
using standard methods. Sections (4μm) were stained with Picro-Sirius Red (PSR, Sigma-
Aldrich, Dorset, UK) or Masson’s Trichrome following standard protocols. All glomeruli (on 
average 116 glomeruli) in one PSR-stained kidney section per animal were blindly scored for 
glomerular histological damage and the percentage of abnormal glomeruli calculated. 
Glomeruli were categorised as abnormal if the PSR staining extended beyond the confines of 
the mesangium into the glomerular tufts. Using one panorama kidney section per animal, 
fibrillar collagen was detected using polarised microscopy, while PSR-staining in the cortex 
was captured by bright field microscopy. Images were stitched together319 and image analysis 
software (Fiji) was used for quantification.  
Transcutaneous FITC-sinistrin decay 
FITC-sinistrin half-life was measured weekly in all animals234. In short, the transcutaneous 
device was fixed to the depilated skin on the back of mice using a double-sided adhesive 
patch (Lohmann, Neuwied, Germany). Transcutaneous measurement started with 
background reading one to three min before 0.3mg/g BW FITC-Sinistrin (diluted in 0.9% 
saline; Braun, Melsungen, Germany) was administered iv. Animals were allowed to fully 




(min). Using a 1-compartment model, the half-life of FITC-Sinistrin was calculated from the 
transcutaneously measured kinetics234 (Figure S3.3). 
Measuring the clearance of IRDye 800CW carboxylate using MSOT 
Five weeks after adriamycin or saline administration, anaesthetised (isoflurane) mice had 
hair removed from the abdominal region and were imaged in the inVision 256-TF MSOT 
imaging system (iThera Medical, Munich, Germany) using a multispectral protocol for 30 min 
(rate of 10 frames per second using wavelengths: 700, 730, 760, 775, 785, 800 and 850 nm, 
and averaging 20 consecutive frames to minimise influences of motion). Five min into the 
imaging mice received 200µl (20nmol) IRDye 800CW carboxylate (LI-COR, USA) in 0.9% saline 
through a tail vein cannula over a period of 10 seconds (s). Data was reconstructed and 
multispectral processing performed to resolve signals for the IRDye, including gradient 
scaling for each animal at a time prior to the injection of the IRDye. Regions of interest (ROIs) 
drawn around renal cortex and the renal papilla-pelvis region (in short: pelvis) of the right 
kidney of each mouse were used to determine the time between the mean peak pixel 
intensity (TMAX) in the cortex and the pelvis (TMAX delay). Exponential decay was fitted for 
mean cortex pixel intensities to determine the characteristic excretion half-life.  
To depict the temporal dynamics of IRDye clearance in colour code, a Matlab routine was 
developed to process a stack of images and calculate a composite image on a pixel-by-pixel 
basis of TMAX, defined as the time (or frame number in the stack) at which the highest intensity 
was recorded at that pixel. A pseudocolor was applied to display this time (or frame number) 
per pixel as different colours on the spectrum colour scale. Image stacks were typically 
composed of 15 images.  With a temporal resolution from in vivo imaging of approximately 
16 s this equated to approximately 4 min of imaging data after injection that were used for 
temporal analysis. A CMAX image as a maximum intensity projection was computed of the 
same image stack. ImageJ was used to amplitude modulate the pseudocoloured TMAX image 
using the CMAX in order to dim areas with little contrast and therefore to reduce background 
noise in the TMAX caused by an absence of substantial temporal change in a certain pixel. 
Statistical analyses 
Linear mixed-effects (LME) models were fitted to characterise changes of albuminuria and of 
FITC-sinistrin half-life over time. The advantage of using a linear mixed-effects model is that 
the correlation between measurements across time points within mice is taken into account 




between the treatment and control group (e.g., differences in linear or quadratic changes 
over time) were subsequently tested using these models.  
Multiple linear regression models were applied to test whether glomerular histological 
damage was associated with transcutaneous measurements of albuminuria (maximum 
observed values and week 4 values), FITC-sinistrin half-life (week 4 values), TMAX delay and 
excretion half-life of IRDye (the latter measured at 5 weeks). 
Independent t-tests were applied to compare measures of kidney function at 4 weeks and of 
post-mortem histology measurements at 5 weeks between the control and the treatment 
group. The assumptions of normality and homogeneity of variances were checked.  
Plasma Protein Binding of IRDye 
A dye-protein stock solution was prepared by incubating of 2ml IRDye (10µmol) with 8ml 
Sprague Dawley rat plasma Li Heparin (Innovative Research, Novi, MI, USA) in phosphate 
buffered saline (PBS) at 37°C, while 2ml PBS was incubated with 8ml rat plasma as control. 
Plasma protein-binding measurements were performed by equilibrium dialysis of PBS against 
dye-protein stock solution (or control stock solution) using a two-chamber dialysis set-up 
(Equilibrium Dialyzer, Havard Apparatus, Holliston, MA, USA)320,321. After 24h the absorption 
of IRDye in PBS and plasma were determined in three independent measurements by 
absorption spectroscopy in a microplate reader (Tecan Infinite M200) and the concentrations 
of IRDye was calculated on the basis of the corresponding molar absorption coefficients 
(Figure S3.4, Table S3.3).  
Plasma protein binding (PPB) of IRDye in percent was determined by averaging three 
independent measurements and following the equation of Beer-Lambert law: 
[A(plasma) - A(PBS)] / [A(plasma) + A(PBS)] * 100 









3.4 Results  
3.4.1 The half-life of transcutaneously measured FITC-sinistrin becomes significantly 
increased over the course of ADR-induced nephropathy 
Kidney injury was induced by intravenous (iv) ADR administration once in 6 SCID female mice 
while 5 control SCID females received saline injection. The weights of ADR-administered 
versus control mice reached their lowest point one week after nephrotoxin administration.  
Over the next four weeks, weights in the ADR group returned towards time-matched control 
values but did not attain them (Figure 3.1A, S3.1A). To determine damage to the glomerular 
macromolecular barrier, we measured total 24-hour urinary excretion and the 
albumin:creatinine ratio on a weekly basis (Figure 3.1B, C, S3.1B, C). Using either measure, 
albuminuria was significantly elevated in the ADR group at weeks 2 to 4, with attenuation at 
week 4 (Figure 3.1B, C, Table S3.1A, S3.3). Similar effects have been previously reported in 
ADR-induced SCID mice172,185,318. A linear mixed-effects (LME) model showed statistically 
significant linear and quadratic changes of albuminuria over time within the ADR group 
(p<0.001 for both the linear and second degree terms, Table 3.1).  
To assess changes in glomerular filtration over time with the transcutaneous device, we 
undertook serial measurements of FITC-sinistrin half-life over 4 weeks. Representative 
examples of clearance curves from control and ADR animals are shown in Figure 3.2A-D. The 
FITC-sinistrin half-life in the ADR group was increased with statistical significance from week 
2 onwards (Figure 3.2E, Table S3.1A, S3.3). Given that GFR is inversely correlated to the FITC-
sinistrin half-life237,322, these results suggest that GFR is slightly impaired 2 weeks after ADR 
administration and deteriorates further between weeks 3 and 4, reflecting the progressive 
nature of the nephropathy171. An LME model revealed statistically significant linear changes 
in the FITC-sinistrin half-life within the ADR group over time, with an average increment of 
2.45 (= (0.02 + 0.33) x 7) minutes per week (p<0.001). These changes were statistically 
different when compared with controls, in which no significant changes in half-life were 
detected (p=0.76, Table 3.1). The levels of BUN and SCr as indicators of kidney function 
revealed no significant differences between the experimental control groups at week 5 






Figure 3.1: Assessment of body weight change and urinary albumin 
excretion. (A) Mean change in body weight of mice up to five weeks after 
adriamycin administration. Animals of the ADR group had a mean body 
weight loss of approximately 20% by week 1, while control animals had a 
mean body weight gain of 5%. (B) Mean albuminuria over 24 hours, 
measured weekly. ADR-administered animals had a mean maximum of 
albuminuria of approximately 90mg/24h at 3 weeks, while in control 
animals urinary albumin stayed constant throughout the study at around 
0.03mg/24h. (C) Mean albumin:creatinine ratio (alb:cr) measured weekly, 
showing similar temporal dynamics to 24h albuminuria. Data points 
(circles = control, n=5; squares = ADR-administered, n=6) and bars show 
mean ± standard error. Asterisks indicate significance of mixed-design 




Figure 3.2: Transcutaneous assessment of FITC-sinistrin clearance over time. (A-D) Typical FITC-sinistrin kinetic curves (arbitrary units) in a control mouse 
at week zero (A), and four (B); and in an ADR-administered mouse prior to (C) and at four weeks post-adriamycin administration (D). (E) The mean half-
life of FITC-sinistrin for the ADR-administered and control groups is shown weekly for four weeks. Data points (circles = control, n=5; squares = ADR-
administered, n=6) and bars show mean ± standard error. Asterisks indicate significance of mixed design ANOVA models: p≤0.05 (*), p≤0.01 (**), see also 





Urinary Albumin   FITC-sinistrin half-life 












Group -12.94 8.11 0.12   Intercept 9.96 0.91 <0.001 
Group x Time 8.34 1.3 <0.001   Time 0.02 0.07 0.76 
Group x Time2 -0.24 0.04 <0.001   Time x Group 0.33 0.07 <0.001 
Error terms Mean SD     Error terms Mean SD   
Random 
Error* 
0 6.86     
Random 
Error* 
0 0.71   
Residual* 0 4.64     Residual* 0 3.74   
 
3.4.2 The passage of IRDye through the kidney measured using MSOT is delayed in ADR mice 
To investigate the potential of MSOT for evaluating renal function in ADR mice, IRDye 
clearance was monitored in real-time at week 5, before killing for necropsy studies. Movies 
and snap-shot images taken prior to, and 15 s, 45 s, 1 min 30 s and 3 min after administration 
of IRDye showed that its passage through the kidney appeared to be delayed in ADR versus 
control mice (Figure 3.3A, supplementary movie 3.1, 3.2). More specifically, temporal colour 
maps of the clearance kinetics confirmed that in nephropathic mice, the dye took longer to 
transit from the kidney cortex to the papilla/pelvis region than in controls (Figure 3.3B). 
Visualisation of the TMAX allows discrimination between the ADR and the control group, 
highlighted by the peak signal intensity in the cortex of the control animals appearing at ~30 
s and visualised in yellow. By contrast, the yellow tone indicating 30 s peak signal intensity is 
absent in the ADR treated mice; instead, green colour tones visualise peak signal intensities 
that appear with a delay at around 1 min. Furthermore, the papilla/pelvis region of control 
animals show peak concentrations from 1.5 – 3 minutes (green, blue, violet, red), whereas 
the ADR treated mice show peak concentrations in this region only after 3 minutes (violet, 
red, Figure 3.3B). We determined the pharmacokinetics of IRDye clearance by calculating the 
TMAX delay between the renal cortex and pelvis (Figure  
Table 3.1: Statistical mixed-effects models that describe albuminuria and FITC-Sinistrin 
half-life over time. The model terms are listed with the corresponding coefficients 
estimates (Coef. estimate), standard error (SE) and p-value. The factor ‘Group’ is defined 
as 1 if the mouse belongs to the ADR group, and as 0 otherwise. The error terms of the 





Figure 3.3: MSOT imaging of IRDye clearance kinetics. (A) MSOT images of a typical control (top) and ADR-administered (bottom) mouse before and 
after the administration of IRDye. Region of interests (ROIs) depicted in yellow (cortex) and red (papilla/pelvis region). Times indicated above apply to 
both control and ADR-treated animal. (B) Temporal colour maps of control and ADR-administered mice reveal a delay in IRDye clearance kinetics in the 
treated mice. (C) Characteristic plot of mean pixel intensity (MSOT arbitrary units) from ROIs drawn around the renal cortex (black) and papilla/pelvis 
region (grey). (D-E) Graphs showing distribution of TMAX delay (D) and the excretion half-life in the cortex (E) in ADR-administered and control animals. 
Data points (D-E) represent individual animals (circles = control, n=5; squares = ADR-administered, n=6) and lines represent mean ± standard error. 




3.3C, D, Table S3.1B), and the clearance half-life in the cortex, using exponential decay fitting 
(Figure 3.3C, E, Table S3.1B). TMAX delay was significantly increased in the ADR-administered 
group versus controls (p=0.015), and there was a non-significant increase in clearance half-
life between these two groups (Figure 3.3D, E; Table S3.2). However, equilibrium dialysis 
revealed that over 40% of IRDye bound to plasma proteins (Table S3.4), suggesting that the 
exponential decay might be shorter than expected in ADR mice due to leakage of plasma 
proteins through the glomerular filtration barrier, thus leading to a potential 
underestimation of the true clearance half-life in the cortex.  
3.4.3 Minimally invasively measured clearance kinetics of sinistrin and IRDye show a strong 
correlation with glomerular histological damage   
To visualise and measure structural damage, we made use of Picro-Sirius Red (PSR) staining 
which binds specifically to fibrillar collagen type I and III under polarising microscopy. 
Analysing PSR staining on parasagittal kidney sections from mice necropsied at week 5, we 
determined that ADR kidneys contained a subset (12-29%, across the whole experimental 
group) of glomeruli with lesions (Figure 3.4B, C; Tables S3.1B, S3.2). In these glomeruli, there 
was a loss of capillary loops and extension of PSR staining into the glomerular tuft beyond 
the normal tree-like mesangial pattern. In control kidneys, such glomerular lesions were 
rarely detected (Figure 3.4A). Quantification of total PSR staining (i.e. not confined to 
glomeruli) under bright field microscopy, and of fibrillar collagen under polarising 
microscopy, failed to show significant differences in ADR versus control kidneys (Figure 3.4D, 
E, S3.2A, B; Tables S3.1B, S3.2). However, we noted the occurrence of proteinaceous casts 
together with flattened tubular epithelia in both PSR- and Masson’s Trichrome-stained ADR 
kidneys viewed under bright field microscopy (Figure S3.2B, D), but not in control kidneys 
(Figure S3.2A, C). These observations show that in this model, at this particular time point, 
glomerular damage is the predominant lesion, while tubulo-interstitial changes are much less 
prominent.  
Next, we evaluated whether the two novel minimally invasive dye clearance methods we 
have used here to detect kidney filtration function, are suitable for long-term regenerative 
medicine therapy studies through their statistical association with detected glomerular 
damage. Importantly, since we had observed a wide range in the proportions of scarred 
glomeruli (as assessed by the above criteria) in the ADR kidneys, we questioned whether 
specific glomerular damage in individual mice was associated with specific measures of 




Figure 3.4: Histological evaluation and quantification of glomerulosclerosis and fibrosis. 
Typical examples of normal (A) and abnormal (B) glomeruli imaged under bright field 
microscopy in 4μm Picro-Sirius Red-stained paraffin sections at week five. On one kidney 
section per animal the percentage of abnormal glomeruli was determined (C). One whole 
kidney section per animal was photographed under bright field and polarised microscopy 
and the images were stitched together to produce one whole kidney image. On each 
whole-kidney image the percentage of PSR staining under bright field light (D) and the 
percentage of fibrillar collagen under polarised light (E) were quantified using image 
analysis software. Scale bars (A-B) represent 50 μm. Data points (C-E) represent individual 
animals (circles = control, n=5; squares = ADR-administered, n=6) and lines represent mean 





glomerular histological lesions and (i) albuminuria, (ii) FITC-sinistrin half-life and (iii) IRDye 
excretion kinetics in individual animals (Figure 3.5). In ADR mice, there was no significant 
association between glomerular histological damage (week 5) and the amount of  
albuminuria measured at the maximum (weeks 2-3) or at the final point of urine collection in 
week 4 (Table 3.2). Therefore, albuminuria is not a reliable measure of glomerular histological 
damage in this model. By contrast, assessment of the relationship between FITC-sinistrin 
half-life and the proportion of histologically damaged glomeruli revealed a significant positive 
correlation between FITC-sinistrin half-life values at week 4 and glomerular damage at week 
5 (coefficient=0.94, p=0.001; see Table 3.2).  
When we assessed the relationship at 5 weeks between glomerular histological damage and 
IRDye clearance half-life, we found a significant association in the ADR group 
(coefficient=0.12, p=0.02; Table 3.2). Furthermore, the TMAX delay was significantly associated 
with glomerular histological damage in the ADR group (coefficient=0.16, p=0.002; Table 3.2). 
The coefficient suggests that an increment of 60 seconds in TMAX delay is associated with an 
increment of glomerular histological damage of about 10%.  
3.5 Discussion 
Here, we report for the first time the use of transcutaneous measurement of FITC-sinistrin 
decay and MSOT detection of IRDye clearance as measures of glomerular filtration function 
in SCID mice with ADR-induced nephropathy. Our albuminuria measurements strongly 
suggest that ADR-induced nephropathy featured a loss of glomerular macromolecular barrier 
integrity in SCID mice from week 2, peaking at week 3, similarly to recently published 
results172,185,318. In ADR mice, the FITC-sinistrin half-life was significantly prolonged from week 
2. The fact that the half-life continued to rise thereafter in the ADR group is a strong indicator 
of a progressive loss in the ability of the kidneys to excrete small molecules from the 
circulation, i.e. a progressive decline in GFR. Previous studies have demonstrated the 
accuracy and reliability of the transcutaneous measurement of FITC-sinistrin half-life as a 
measure of GFR in various strains of rats and mice232,234,237,238,242,322,323. Of note, although 
remaining elevated, the degree of albuminuria fell between weeks 3 and 4. This again might 
be explained by a loss in total filtration surface associated with glomerular damage as 






Figure 3.5: Correlation graphs between % abnormal glomeruli and minimally invasive methods of measuring kidney function. Correlation graphs 
showing the correlation of both control and ADR group data between the percentage of abnormal glomeruli and maximum observed albuminuria (A), 
FITC-Sinistrin half-life at week 4 (B), IRDye excretion half-life in the cortex at week 5 (C) and IRDye TMAX delay (D) at week 5. Data points represent individual 






Biomarker Coefficient SE P-value 
AlbuminuriaMAX 0.04 0.05 0.45 
Albuminuria4w 0.2 0.15 0.21 
FITC-sinistrin half-life4w 0.94 0.18 0.001 
IRDye excretion half-life 0.12 0.04 0.02 
IRDye TMAX delay 0.16 0.03 0.002 
 
Using MSOT imaging, we showed here that IRDye is cleared in a dynamic fashion as it first 
appears in the kidney cortex and then transits to the renal pelvis, confirming a previous 
report248. The simplest interpretation of the TMAX delay of IRDye clearance we measured in 
the ADR versus control group, is that the glomerular clearance of this small molecule is 
impaired. The observation that some IRDye binds to plasma proteins, and that the ADR model 
features proteinuria, may have led to an underestimation of the true ‘TMAX delay’. In addition, 
it is possible that the passage of IRDye along the lumen of kidney tubules may be 
compromised in the ADR model but this will require further study.  
Our BUN and SCr measurements revealed that these are not useful indicators of ADR-induced 
nephropathy at a time point when sinistrin clearance deviated most from normal. Both BUN 
and SCr measurements have been questioned as biomarkers for the early detection of human 
and rodent kidney disease at the histological level since they frequently identify abnormal 
kidney function only in the later stages of the diseases324,325. Previously, an increase in SCr in 
ADR-induced nephropathy has only been observed in male rodents, while in female rodents, 
SCr levels remained unchanged when compared to control animals, even though 
pathohistology clearly indicated the full spectrum of renal damage156,172,313,326-328. 
Crucially, our observations that BUN and SCr fail to detect significant differences in kidney 
function at a time point when histological changes are clearly quantifiable, emphasises the 
need to develop novel molecular biomarkers that are better able to monitor renal health and 
Table 3.2: Table summarising the associations in the ADR group between abnormal 
glomeruli (5w) and the four biomarkers: albuminuria at the maximum observed and at 
four weeks, FITC-Sinistrin half-life, IRDye clearance half-life, IRDye TMAX delay. The results 
included in this table were derived from the statistical models described in 
Supplementary Table S3.5 by using contrast analysis. Each coefficient estimate indicates 





assess the efficacy of therapeutic interventions, including regenerative medicine 
therapies324,329,330.  
We conclude that transcutaneous measurements of FITC-sinistrin half-life provide a 
minimally invasive method to repeatedly assess GFR in conscious mice, thus allowing for 
longitudinal evaluation of kidney function. Furthermore, our analysis suggests that MSOT 
imaging has the potential to be employed for the repeated and minimally invasive 
measurement of kidney function in mice by assessing renal clearance of injected small near 
infrared dyes. The use of near infrared dyes with negligible plasma protein binding properties 
will further improve MSOT imaging performance for the measurement of renal clearance 
kinetics.  Optoacoustic imaging can also be employed to track administered stem cells 
labelled with gold nanorods, expressing tyrosinase or near infrared fluorophores in whole 
animals331-338. Therefore, this imaging technology will be of high importance for preclinical 
studies in regenerative approaches to nephropathies as it will allow the detection of labelled 
cells in parallel with functional measurements of renal clearance kinetics. 
In order to assess whether functional kidney data correlated with glomerular scarring, we 
performed histological analysis of sections by staining with PSR and Masson’s Trichrome. 
While SCID animals with ADR-induced nephropathy showed a strong elevation in the number 
of abnormal glomeruli at 5 weeks, at this time point we only observed occasional 
pathohistological changes in the tubulo-interstitial zone of ADR mice.  Cortical glomerular 
and tubulo-interstitial damage have been reported previously in mice with ADR-induced 
nephropathy156,171,172,339,340. 
Importantly, we aimed to statistically analyse whether any associations could be detected 
between glomerular histological damage and albuminuria, FITC-sinistrin half-life or IRDye 
clearance, respectively, in mice with ADR-induced nephropathy on the SCID background. Our 
evaluations provide evidence that FITC-sinistrin half-life and TMAX of IRDye clearance were 
strongly correlated with glomerular scarring in SCID mice with ADR-induced nephropathy. 
We therefore conclude that FITC-sinistrin half-life and IRDye clearance (TMAX) measurements 
may be good predictors of glomerular histological damage. In contrast, neither peak 
albuminuria nor albuminuria at 4 weeks after ADR-induced nephropathy were significantly 
correlated with glomerular scarring, suggesting that urinary albumin measurements fail to 





In a recent report, rats with ADR-induced nephropathy were analysed with magnetic 
resonance imaging to monitor changes in kidney function and histopathology during disease 
progression. This study is another example, similar to the one we report here, to demonstrate 
the feasibility of a longitudinal, minimally-invasive imaging technology as an approach to 
assessment of changes in the kidney over time341. 
In conclusion, our results indicate that the minimally invasive technologies for detecting FITC-
sinistrin half-life and IRDye clearance kinetics could be widely adopted for in vivo monitoring 
of models of RMT in progressive kidney disease. Each technology potentially allows recurrent 
testing in individual animals, maximising the information obtained as nephropathy and/or 
regenerative effects progress. The observations that sinistrin clearance and IRDye kinetics 
significantly correlate with the proportions of damaged glomeruli in individual animals, 
indicates that these minimally invasive measurements could markedly reduce animal 
numbers in preclinical models of nephropathy.  
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Supplementary Figure S3.1: Additional body weight, urinary albumin, BUN and SCr 
data. (A) Mean body weight measured weekly for 5 weeks. (B-C) Mean 24h urinary 
albumin levels (B) and urinary albumin:creatinine ratio (C) in control animals only, 
measured weekly up to week 4. (D, E) Blood urea nitrogen (BUN, D) and serum creatinine 
(E) in ADR-administered and control mice measured in serum collected via cardiac 
puncture immediately after sacrifice at week 5. Serum biomarkers in µmol/L for 
reference. BUN: ADR, mean = 2316.54, SE = 357.87; CTRL, mean = 2069.13, SE = 67.41. 
SCr: ADR, 117.44, SE = 6.94; CTRL, 119.47; SE = 5.25. Data points represent the group 
mean (A-C) or individual animals (D, E) (circles = control, n=5; squares = ADR-







Supplementary Figure S3.2: Additional PSR and Masson’s Trichrome images of renal 
injury. Typical examples of normal (A, C) and slightly scarred (B, D) regions of the renal 
cortex imaged under polarised microscopy in Picro-Sirus Red-stained (A, B) or under 
bright field microscopy in Masson’s Trichrome-stained (C, D) paraffin sections at week 5. 
Scale bars represent 50μm. Tubular casts (*) and scarred glomerulus (arrow) can be 








Supplementary Figure S3.3: Sample graph depicting FITC-sinistrin emission data points 
plotted against time after bolus injection to illustrate the way the 1-compartment fit is 
determined. The blue line shows the 3-exponential function, while the red line (1-
exponential function) corresponds to the orange line in Figures 2A-D of the manuscript. 
Specifically, the 1-compartment fit was applied from 50% to 15% of the peak height (red 
curve) and t1/2 was calculated as described in Schreiber et al., 2012 (PMID: 22696603). 
The reference peak height was recognized as the peak of the 3-exponential function that 
was preliminary fitted to the whole measured curve.  
Supplementary Figure S3.4: Absorption and emission spectrum scan of IRDye. 
Normalised absorption (black) and emission (blue) spectrum scan of 10μmol IRDye in 






  Urinary Albumin (mg/24h) 
Urinary Albumin : Creatinine ratio 
(mg/mg) 


































A1 0.02 16.10 59.49 34.11 23.23 0.20 123.61 176.84 153.16 176.00 8.14 X 15.05 14.25 19.80 
A2 0.01 4.30 45.53 32.30 9.06 0.14 35.34 176.21 226.65 46.02 10.60 10.10 14.90 10.76 11.00 
A3 0.04 11.08 85.16 66.98 32.19 0.16 97.98 271.34 192.71 114.56 12.19 14.11 14.10 17.47 27.19 
A4 0.01 0.74 37.21 139.00 16.19 0.13 3.40 180.82 372.47 90.78 10.64 14.67 17.67 13.18 16.91 
A5 0.04 0.87 28.34 54.40 44.71 0.19 3.91 82.12 260.72 132.80 12.43 X 11.34 X 15.75 
A6 0.01 1.16 46.57 149.05 35.89 0.14 6.78 140.94 629.59 92.70 8.10 13.32 15.11 32.11 16.82 
Mean 0.02 5.71 50.38 79.31 26.88 0.16 45.17 171.38 305.88 108.81 10.35 13.05 14.69 17.55 17.91 
SE 0.01 2.63 8.14 21.18 5.39 0.01 21.57 25.18 71.57 17.94 0.77 0.83 0.83 3.46 2.19 
CTRL 
C1 0.02 0.03 0.03 0.01 0.06 0.16 0.14 0.09 0.18 0.22 5.78 15.18 6.40 8.77 7.18 
C2 0.02 0.05 0.03 0.01 0.05 0.13 0.50 0.11 0.28 0.15 8.05 8.87 10.76 9.29 6.15 
C3 0.03 0.02 0.03 0.01 0.03 0.26 0.13 0.10 0.08 0.14 9.75 9.94 9.09 10.87 11.85 
C4 0.01 0.07 0.02 0.03 0.07 0.10 0.34 0.11 0.08 0.45 10.54 6.66 9.75 15.33 14.25 
C5 0.02 0.04 0.02 0.02 0.04 0.15 0.19 0.10 0.06 0.20 6.62 7.78 11.00 8.70 13.47 
Mean 0.02 0.04 0.03 0.02 0.05 0.16 0.25 0.12 0.14 0.23 8.15 9.69 9.40 10.59 10.58 
SE 0.01 0.01 0.01 0.01 0.01 0.03 0.06 0.01 0.04 0.06 0.90 1.48 0.83 1.25 1.65 
 
 
Supplementary Table S3.1A: Table summarising the individual values of all longitudinal parameters measured in adriamycin (ADR)-administered and 
control (CTRL) mice from weeks zero to four. The mean and standard error (SE) for ADR-administered and control groups are shown. x = data unsuitable 













































































































Week 5 Week 5 Week 5 Week 5 Week 5 
ADR 
A1 143.99 220.20 22.22 2.33 1.06 1.39 23.60 
A2 29.02 154.80 12.50 2.28 3.24 1.03 18.42 
A3 116.01 189.60 29.14 3.95 1.48 1.61 45.95 
A4 96.01 172.20 26.02 1.02 0.09 1.25 21.42 
A5 112.02 141.60 23.81 1.70 1.73 1.39 24.65 
A6 80.02 167.40 19.57 2.34 2.32 1.29 23.18 
Mean 96.18 174.30 22.21 2.27 1.65 1.33 26.21 
SE 16.02 11.32 2.35 0.40 0.44 0.08 4.05 
CTRL 
C1 31.99 159.00 5.13 1.58 1.53 1.32 22.56 
C2 32.00 148.80 0.00 1.74 1.63 1.43 21.99 
C3 47.99 65.40 0.00 2.79 2.62 1.16 25.07 
C4 15.98 119.40 0.00 1.77 2.05 1.51 25.43 
C5 64.01 151.80 1.30 1.08 1.03 1.33 21.99 
Mean 38.40 128.88 1.29 1.79 1.77 1.35 23.41 
SE 8.16 17.25 0.99 0.28 0.27 0.06 0.76 
Supplementary Table S3.1B: Table summarising the individual values of end-point 
measures in adriamycin (ADR)-administered and control (CTRL) mice 5 weeks after the 
administration of adriamycin. The mean and standard error (SE) for ADR-administered 

















TMAX Delay (s) Yes 
Two-sample t-test 
assuming unequal 
variance T = 3.21 0.015 7 
IRDye excretion 








Wilcoxon rank sum 
test with continuity 
correction W = 30 0.008   
% PSR staining Yes 
Two-sample t-test 
assuming unequal 
















Wilcoxon rank sum 
test with continuity 
correction W = 14 0.927   
 
 
  Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 
Weight Change  p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 
24h Albumin p = 0.999 p = 0.194 p = 0.001 p = 0.004 p = 0.001  
Alb:Cr p = 0.999 p = 0.223 p = 0.001 p = 0.001 p = 0.001  
FITC-sinistrin 
half-life 
p = 0.510 p = 0.326 p= 0.029 p = 0.041 p = 0.005  
 
 
Supplementary Table S3.2: Table summarising the statistical analyses used to assess if 
there was a statistically significant difference between the adriamycin (ADR)-
administered and control groups for parameters measured at week 5 only. Normality 
tests were applied to check the assumption that the data come from a normal 
distribution; when the normality hypothesis was rejected a non-parametric test was 
applied. No adjustment for multiple comparisons was made.  
Supplementary Table S3.3: Table summarising the results of mixed-design ANOVA 
models carried out to assess the significance of comparisons between adriamycin-





  Control group (no IRDye) Sample group Sample - Control 
Plasma 0.1673 0.1663 0.1691 0.2046 0.202 0.2051 
0.0364 
Mean 0.1675 0.2039 
PLBS 0.0428 0.042 0.0416 0.0595 0.058 0.054 
0.0151 
Mean 0.0421 0.0572 























Supplementary Table S3.4: IRDye protein plasma binding (PPB) determined by 
measuring the UV absorption (A) at 774nm of IRDye or phosphate buffered saline (PBS) 





(i) glomerular histological damage (5w) - 
maximum observed albuminuria 
(ii) glomerular histological damage (5w) - 
albuminuria (4w) 
Factor Coef. SE P-value Factor Coef. SE P-value 
Intercept 1.29 2.08 0.55 Intercept 1.29 1.95 0.53 
Group 17.65 4.97 0.008 Group 15.57 4.76 0.01 
AlbuminuriaMAX x Group 0.04 0.05 0.45 Albuminuria4w x Group 0.2 0.15 0.21 
Error terms Mean SD  Error terms Mean SD  
Residual* 0.00 4.64  Residual* 0 4.35  
(iii) glomerular histological damage (5w) - FITC-
sinistrin half-life (4w) 
    
Factor Coef. SE P-value 
    
Intercept 5.15 3.23 0.15 
    
FITC4w half-life -0.36 0.3 0.28 
    
FITC4w half-life x Group 1.3 0.18 0.001 
    
Error terms Mean SD  
    
Residual* 0.00 3.00  
    
(iv) glomerular histological damage (5w) - 
IRDye800CW excretion half-life (5w) 
(v) glomerular histological damage (5w) - 
IRDye800CW TMAX delay (5w) 
Factor Coef. SE P-value Factor Coef. SE P-value 
Intercept 0.92 7.01 0.9 Intercept 6.27 3.29 0.09 
Extretion half-life 0.005 0.05 0.93 TMAX delay -0.11 0.08 0.23 
Excretion half-life x Group 0.116 0.02 0.001 TMAX delay x Group 0.27 0.06 0.003 
Error terms Mean SD  Error terms Mean SD  
Residual* 0.00 4.74  Residual* 0.00 4.03  
 
Supplementary Table S3.5: Mathematical representation (multiple regression models) 
of the association between abnormal glomeruli at week 5 and (i) maximum albuminuria, 
(ii) albuminuria at week 4, (iii) FITC-Sinistrin half-life at week 4, (iv) IRDye excretion half-
life in the cortex at week 5, and (v) IRDye TMAX at week 5. The factor Group is defined 
as 1 if the mouse belonged to the adriamycin (ADR) group, and as 0 otherwise. Goodness-
of-fit was assessed for each model using the R2 values: Model (i) R2 = 0.84, (ii) R2 = 0.86, 
(iii) R2 = 0.93, (iv) R2 = 0.84, (v) R2 = 0.88. *Follows a normal distribution with mean zero 






Supplementary Movie 3.1: Movie showing the clearance of IRDye (20nmol) through the 
kidney of an adriamycin (ADR)-administered mouse at week 5. IRDye was administered 
to the mouse through a tail vein cannula at 4.8 min and can be first seen in the renal 
cortex before it clears through the cortex and collects in the renal pelvis. Videos are 
displayed at 3 frames per second (1 frame is equal to approximately 15 seconds).  
https://www.dropbox.com/s/ilg6u93jb24r4rm/A1.3%20IR%20Injection.avi?dl=0  
 
Supplementary Movie 3.2: Movie showing the clearance of IRDye (20nmol) through the 
kidney of a control mouse at week 5. IRDye was administered to the mouse through a 
tail vein cannula at 4.4 minutes and can be first seen in the renal cortex before it clears 
through the cortex and collects in the renal pelvis. Videos are displayed at 3 frames per 










Assessing the efficacy of human kidney-derived cells for ameliorating 





Stem/progenitor cells isolated from the adult kidney have been proposed as a potential 
source of therapeutic cells for treating kidney disease342,343. Various methods of isolating 
stem/progenitor cells from the kidney have been explored, including by the identification of 
label-retaining cells, collecting side-population cells, through cell culture, and by the 
expression of specific cell surface markers342. In particular, the cell surface marker CD133 was 
first discovered on haematopoietic progenitor cells and, although its function remains 
unclear344, cells expressing CD133 have been isolated from the adult kidney and proposed as 
a multipotent stem cell population151. A number of reports have described the efficacy of 
CD133+ adult human kidney-derived cells for ameliorating kidney injury in various 
experimental models of kidney disease, such as adriamycin185, rhabdomyolysis147-149,345, and 
cisplatin134 (Table 4.1). The necessity for the expression of CD133 for renal regeneration was 
emphasised in several of these studies, where it was reported that CD133+ cells were able to 
ameliorate functional and structural damage, but CD133- cells had no effect, resulting in 
functional and structural injury levels that were comparable to control injured animals 
receiving saline only147,148,185. A report from our laboratory, however, has challenged this, 
indicating that while hKC therapy was beneficial for improving kidney function, the 
expression of CD133 had no effect on the therapeutic outcome134.  
In the majority of preclinical studies, the efficacy of stem/progenitor cells for ameliorating 
kidney injury is assessed primarily in models of AKI, such as rhabdomyolysis, cisplatin, and 
IRI. These models are ideally suited for testing the efficacy of RMTs for improving kidney 
function following an isolated insult which temporarily impairs kidney function, such as 
ischemia or drug exposure, and there is a great clinical need for such therapies for AKI21,343,346. 
However, these models do not represent the growing number of patients with CKD31,347, for 
whom models of AKI do not accurately recapitulate the nature of their disease. Patients with 
CKD often do not present to clinicians in the early stages of disease, due to the large renal 
functional reserve capacity of the kidneys226,348, meaning that symptoms of kidney 
impairment are not evident until the disease is more advanced. As such, CKD patients would 
not be able to benefit from the fast intervention, or even pre-emptive treatment, that RMTs 
for AKI may lead to. Experimental models of CKD are therefore vital to assess the feasibility 
of cell therapy for chronic disease, and to investigate the effect of the timing of RMT 
administration on therapeutic outcome. Notably, Ronconi et al. (2009) have assessed the 
therapeutic potential of hKCs in a mouse model of adriamycin nephropathy185, a well-




(2009) compared the efficacy of CD133+ and CD133- hKCs, and found that when cells were 
administered on days one and four after the induction of injury, CD133+, but not CD133- 
hKCs, were able to ameliorate albuminuria measured at day seven. While this study 
investigated the potential for therapeutic intervention in a chronic disease model, a 
drawback of the experimental design was that the cell therapy was administered very soon 
after induction of injury. The timing of cell administration in this study therefore did not 
reflect the clinical scenario, whereby patients would not present symptoms until they had 
well-established CKD; potentially months or years after the onset of kidney injury. We 
propose that in order to develop efficacious treatments for CKD, it is essential to assess the 
effect of timing of administration on the therapeutic outcome of a cell therapy. Chronic 
progressive kidney disease models, such as adriamycin nephropathy, are ideally suited to 
such investigations. 
In many of the reports on the efficacy of CD133+ hKCs, it was suggested that the cells homed 
to the injured kidney following IV administration, where they subsequently engrafted into 
the damaged tissue, and differentiated to form specialised renal cells, thereby exerting a 
therapeutic effect on the kidney147,148,185. However, these conclusions were largely based on 
histological tracking of cells labelled with PKH26, a lipophilic cell membrane dye. PKH26 has 
been reported to transfer from labelled cells to host tissues both in vitro and in vivo263, and 
thus raises the possibility of false-positive cell tracking. Indeed, a recent study by Santeramo 
et al. (2017) demonstrated the unreliability of PKH26 as a cell tracking agent, by labelling 
green fluorescent protein (GFP)-expressing CD133+ hKCs with PKH26, and tracking both 
labels by fluorescence microscopy. The authors showed that the PKH26 signals were often 
not associated with GFP+ cells, suggesting that the PKH26 label had dissociated from the 
administered human cells. Moreover, they showed that following IV-administration of 
GFP+/PKH26+ hKCs to rats with cisplatin-induced AKI, PKH26 signals could occasionally be 
detected in the kidneys, while GFP+ cells were only found in the lungs, and never in the 
kidneys134.  
While the tracking of GFP+ cells is more reliable than PKH26-labelling, it still has a major 
disadvantage since it requires the sacrifice of many animals at multiple time points to detect 
the cells histologically, and to gain an understanding of the changes in biodistribution over 
time. As such, very large animal numbers are required for such experiments, which is against 
the principles of the 3Rs (Reduction, Refinement, Replacement)262, and the response of 




Table 4.1: Summary of published studies assessing the efficacy of hKCs in animal models of kidney injury. ADR, adriamycin; Alb:Cr, urinary albumin to 
creatinine ratio; α-SMA, α-smooth muscle actin; BUN, blood urea nitrogen; CP cisplatin; hKCs, human kidney-derived cells; HLA-I, human leukocyte antigen 
class I; IF, immunofluorescence; KIM-1, kidney injury molecule-1; MCP-1, monocyte chemotactic protein-1; qRT-PCR, quantitative reverse transcriptase 
polymerase chain reaction; RB, rhabdomyolysis; SCr, serum creatinine; TA, transcutaneous assessment (of FITC-sinistrin clearance); TGF-β, transforming 
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Alternatively, BLI, an optical imaging modality, can be used to visualise the biodistribution of 
luciferase+ cells in vivo. BLI is a fast and high-throughput imaging technology, and is highly 
sensitive for detecting luciferase-expressing cells in vivo, resulting from the low background 
signals produced by non-bioluminescent mammalian tissues265,266. Moreover, BLI is a 
minimally invasive method of tracking cells, and thus individual animals can be monitored 
longitudinally, precluding the need to sacrifice large numbers of animals. In addition, this 
strengthens the scientific data by avoiding the ‘between-mice’ variation associated with 
analysing different groups of mice at each time point, and thus reducing the overall variability 
within the study.   
One of the main aims of this thesis was to assess the efficacy of cell therapies for ameliorating 
kidney injury in mouse models. This chapter is therefore focused on assessing the efficacy of 
hKCs in a mouse model of adriamycin nephropathy. The aims of these studies were: 
1. To compare the efficacy of CD133+ and CD133- hKCs in a mouse model of adriamycin 
nephropathy 
2. To compare the beneficial effects of administering hKCs in the acute stage (days 1 
and 4) or in the chronic stage (day 15) of adriamycin nephropathy 
3. To determine the longitudinal biodistribution of IV-administered hKCs in vivo by BLI 
 
4.2 Experimental Design 
Following on from the results obtained in Chapter 3, some refinements were made to the 
experimental protocols of the adriamycin model for the current studies. Because urinary 
albumin and FITC-sinistrin half-life were not found to be significantly elevated until week two 
(Fig. 3.1B, 3.2D, respectively), measurements following adriamycin administration were not 
performed until week two in the current study.  This strategy also improved the animals’ 
welfare by reducing stress during the first week of the study, where animals typically lose a 
high percentage of their body weight (Fig. 3.1A). Moreover, SCr and BUN were not found to 
be significantly elevated in injured animals (Fig. S3.1D, E) and so were not measured in the 
current studies.  
For the acute study (Fig. 4.1A), female BALB/c SCID mice age 5-6 weeks were administered 
7.5 x105 ZsGreen+/luciferase+ hKCs (either CD133+ or CD133-) in 100μl PBS (IV) on days 1 and 






age 7-8 weeks, but younger mice were used in this study in order to recapitulate the study 
by Ronconi et al. (2009). Control mice received 100μl saline (IV). Treatment groups were as 
follows: ADR + CD133+ hKCs (n = 6), ADR + CD133- hKCs (n = 6), ADR + saline (n = 6), healthy 
control (saline for all injections; n = 4). Urine was collected over 24h in metabolism cages at 
baseline, and on day 10. BLI was performed on days 1, 3, 4, 7, and 11. Mice were culled on 
day 11 with a rising concentration of CO2, organs were imaged ex vivo for bioluminescence, 
and kidneys were collected and processed for paraffin embedding. 
For the chronic study (Fig. 4.1B), adriamycin nephropathy was induced in 20 mice, and kidney 
function was assessed via urinary albumin at day 12 and FITC-sinistrin half-life at day 14. Mice 
were grouped based on the level of injury measured (or excluded from further study if 
deemed uninjured, n = 4), and subsequently assigned to receive hKCs or saline, such that the 
mean injury levels were similar for each group. 7.5 x105 ZsGreen+/luciferase+ hKCs (unsorted) 
were administered in 100μl PBS (IV) on day 15 after induction of adriamycin nephropathy. 
Control mice received 100μl saline (IV). Treatment groups were as follows: ADR + hKCs (n = 
8), ADR + saline (n = 8). Urine was collected for 24h in metabolism cages at baseline, and on 
days 12, 18, 25, 32, and 42. FITC-sinistrin half-life was assessed via transcutaneous 
measurement at baseline, and on days 14, 21, 27, 35, and 42. BLI was performed immediately 
after cell/saline administration, and on days 1, 4, 7, 14, 21, and 28 following cell 
Figure 4.1: Experimental Design Schematics. Schematics showing the experimental 




administration. Mice were culled on day 42 with a rising concentration of CO2, organs were 
imaged ex vivo for bioluminescence, and kidneys were collected and processed for paraffin 
embedding. 
For both studies, details of urinary albumin measurements, kidney processing, sectioning, 
staining, and analysis were as described in the general methods. 
 
4.3 Results 
4.3.1 Acute Study 
4.3.1.1 Morbidity and Mortality 
Two mice in the ADR + CD133- hKC group did not survive this study. One mouse died soon 
after the first cell injection, and one mouse was culled on day 9 after losing 36% body weight. 
All mice that received ADR lost weight during the study, but mice that received hKCs lost less 
weight than the mice that received only saline (Fig. 4.2). There was no difference in weight 
loss between mice that received CD133+ or CD133- hKCs. Healthy control mice maintained a 
relatively constant weight during the study and overall did not lose any weight. However, all 
mice lost weight between days 10 – 11, as a result of the highly stressful 24h urine collection 
in metabolism cages. 
4.3.1.2 In vivo Cell Tracking 
In order to evaluate the biodistribution of luciferase+ hKCs, bioluminescence imaging was 
performed at multiple time points after administration of the cells. Mice from every 
treatment group were imaged at each time point, but signals were never detected from mice 
that received only saline (Fig. 4.3A). The signal intensity from mice that received CD133+ and 
CD133- cells were comparable. Immediately following IV administration of cells on days 1 
and 4, cells were found to be located mostly in the chest region of the animal, with a small 
amount of signal at the site of injection in the tail. Subsequent imaging two to three days 
later, on days 3 and 7, revealed that the majority of cells had died within a few days after 
administration. By day 11, only the cells at the site of injection could be detected, with no 
detectable signal remaining in vivo in the chest or elsewhere. Ex vivo imaging of organs on 





4.3.1.3 Kidney Function 
Kidney function was assessed on day 10 by urinary albumin measurement. Urinary albumin 
increased for all mice that received ADR, but mice that received hKCs showed a marked 
reduction in urinary albumin levels (CD133+, mean: 0.81 mg/24h, standard error (SE): 0.38; 
CD133-, mean: 1.05 mg/24h, SE: 0.52) compared to mice that received only saline (mean: 
3.90 mg/24h, SE: 2.29) (Fig. 4.4, Supplementary Table S4.1). This reduction was not 
statistically significant (one-way ANOVA, p = 0.090). Healthy control mice maintained 
baseline levels of urinary albumin at day 10 (baseline, mean: 0.04 mg/24h, SE: 0.01; day 10, 
mean: 0.03 mg/24h, SE: 0.01). 
4.3.1.4 Histology 
PSR-stained paraffin kidney sections were assessed by a qualified pathologist, but 
histological changes were not evident at this time point by light microscopy (data not shown).  
Figure 4.2: Mean body weight change of mice in the acute study. ADR mice that received 
either CD133+ (orange triangle; n = 6) or CD133- (green diamond; n = 6) hKC therapy did 
not lose as much weight during the first week of the study as ADR mice that received only 
saline (red square; n = 6). Healthy control mice (blue circle; n = 4) maintained a steady 
body weight throughout the study and did not lose any weight overall. All animals lost 
some weight between days 10-11, as a result of 24h urine collection in MCs, which is 
highly stressful for mice. Days in bold indicate days of cell/saline administration, data 




Figure 4.3: Bioluminescence imaging of ZsGreen+/Luciferase+ hKC biodistribution in vivo and ex vivo. Representative in vivo (A) and ex vivo (B) 
bioluminescence images of ADR mice that received CD133+ hKCs (top), CD133- hKCs (middle), or saline (bottom). (A) in vivo images: dorsal (left) and ventral 
(right) images of animals are shown for each time point. Time points in bold indicate dates where imaging occurred after cell/saline administration. (B) ex 
vivo images: kidneys (cut coronally; K, dashed circle), liver (Li), heart (H), spleen (S), lungs (Lu). Ex vivo imaging of organs confirmed that following IV 
administration cells were restricted to the lungs only, as suggested by the in vivo signal. Images show average radiance; in vivo scale (A) = 1.0 x105 – 1.0 






4.3.2 Chronic Study 
4.3.2.1 Morbidity and Mortality 
All mice survived this study, and all mice lost weight within the first week, reaching a nadir 
between days 7-10, however there was no difference in weight loss between cell- and saline-
treated mice (Fig. 4.5).  
4.3.2.2 Initial Assessment of Kidney Injury and Grouping 
Kidney injury levels were assessed at week two prior to assigning mice a treatment group. 
Urinary albumin revealed the most prominent change (Fig. 4.6A; paired t-test, p < 0.001) 
between baseline levels (mean: 0.28 mg/24h, median: 0.07 mg/24h, SE: 0.20) and day 12 
(mean: 29.47 mg/24h, SE: 5.12). However, there was a high level of variation across the 
group, from 2.51 mg/24h to 74.97 mg/24h, which split it naturally into three categories: very 
low, low, and high levels of albumin (Fig. 4.6A, Table 4.2). Kidney injury levels assessed by 
transcutaneous measurements revealed a subtle but statistically significant (paired t-test, p 
= 0.026) increase in FITC-sinistrin half-life (Fig. 4.6B; baseline, mean: 7.95 min, SE: 0.22; day 
14, mean: 8.84 min, SE: 0.37). Of note, the FITC-sinistrin half-life data did not show any 
natural grouping towards injury levels, so urinary albumin levels were used to assign mice in 
Figure 4.4: Mean urinary albumin of mice in the acute study. ADR mice that received 
either CD133+ (n = 6) or CD133- (n = 6) hKC therapy had much lower urinary albumin 
levels at day 10 than ADR mice that received only saline (n = 6), although this reduction 
was not statistically significant (one-way ANOVA, p = 0.090). Healthy control mice (n = 4) 
maintained baseline levels of urinary albumin at day 10. Data represents the group 




to three injury level groups: ‘very low-responders’, with urinary albumin below 5 mg/24h (n 
= 4); ‘low-responders’, with urinary albumin between 5 and 21 mg/24h (n = 7); and ‘high-
responders’, with urinary albumin above 38 mg/24h (n = 9) (Table 4.2). Very low-responders 
were deemed insufficiently injured and so were excluded from further study.  
 
Low- and high-responding mice were then divided within these groups as evenly as possible 
to achieve similar injury levels, before they received an administration of cell therapy or 
saline control (cell-treatment group, mean albumin: 36.41 mg/24h, mean change in FITC-
sinistrin half-life from baseline to day 14: 1.14 min; saline-treatment group, mean albumin: 
35.59 mg/24h, mean change in FITC-sinistrin half-life from baseline to day 14: 1.08 min; Table 
4.3). 
Of note, there were some discrepancies in the health of the animal as measured by the three 
different parameters: peak percentage body weight loss, change in FITC-sinistrin half-life 
between baseline and day 14, and urinary albumin at day 12. Generally, larger changes in 
FITC-sinistrin half-life (highlighted in orange, Table 4.2) which indicated more severe kidney 
damage, tended to be associated with higher urinary albumin levels. However, some mice 
exhibited conflicting data. For example, animal 3.2 had the third largest increase in FITC-
Figure 4.5: Mean body weight change of mice in the chronic study. All mice lost weight 
as expected in the first week, but returned towards the starting weight by week 2, and 
continued to gain weight for the remainder of the study. High-responding mice that 
received hKCs (dark orange triangle; n = 4) maintained a higher percentage of weight loss 
than high-responding mice that received saline (dark blue diamond; n = 5), whereas low-
responding mice that received hKCs (light blue circle; n = 4) put on the most weight of all 
groups, (light orange square; n = 3). Data points represent the group mean, and error bars 




sinistrin half-life (1.99 min), but had relatively low urinary albumin levels (16.83 mg/24h). 
Conversely, animal 1.4 had a lower FITC-sinistrin half-life at day 14 than at baseline (change 
= -1.45 min), suggesting improved renal clearance, but had the second highest urinary 
albumin levels (67.97 mg/24h), suggesting substantial renal injury. Body weight loss, which 
is a good indicator of the general health status of the animal, tended to increase as urinary 
albumin increased, however mouse 4.1 in particular lost the most weight of all animals (-
33.76%), but had low kidney injury levels as suggested by FITC-sinistrin half-life change (0.22 
min) and urinary albumin (13.11 mg/24h).  
 
 
4.3.2.3 Longitudinal Assessment of Kidney Function 
Following cell or saline administration at week 2, kidney function was assessed weekly for 
four weeks by urinary albumin measurement and transcutaneous assessment of FITC-
sinistrin half-life. Neither urinary albumin (Fig. 4.7A) nor FITC-sinistrin half-life (Fig. 4.7B) 




Figure 4.6: Pre-treatment assessment of kidney injury. Kidney injury levels were 
assessed at week two by urinary albumin (A) and FITC-sinistrin half-life (B). (A) Urinary 
albumin measurements were significantly elevated over baseline levels (p < 0.001) and 
appeared to naturally split into three injury levels: very low (encircled in green), low (blue) 
and high (red) injury. (B) Transcutaneous assessment of FITC-sinistrin half-life also 
revealed a statistically significant increase over baseline levels (p = 0.026), but the data 
did not naturally group into injury levels. Urinary albumin was used to categorise mice in 
to groups based on the degree of kidney injury. Data points represent individual animals, 
and bars represent mean (wide line) and standard error (short lines). Two-sample t-test, 





High-responding mice that received cells, and low-responding mice that received either hKCs 
or saline had increased urinary albumin levels between week two (before intervention) and 
week three (one week after intervention), whereas high-responding mice that received 
saline maintained urinary albumin levels between weeks two and three (Fig. 4.7A, 
Supplementary Table S4.2). From week four onwards, all groups showed a gradual decrease 





Weight Lost (%) 
Change in FITC-
sinistrin half-life 
(baseline - day 
14) 
Urinary Albumin 
(day 12) (mg/24h) 
Injury Level 
Grouping 
1.3 -18.86 -2.49 2.51 Very low/no 
injury - excluded 
from further 
analyses 
4.5 -3.31 -0.45 2.97 
3.4 -14.65 0.93 3.50 
4.4 -22.6 0.03 4.39 
4.3 -28.65 -0.05 11.52 
Low injury: 'low-
responders' 
3.5 -18.52 0.86 12.85 
4.1 -33.76 0.22 13.11 
3.2 -20.11 1.99 16.83 
4.2 -13.71 -0.57 18.50 
2.1 -21.39 1.59 20.49 
3.3 -17.54 0.23 20.49 
1.1 -28.41 1.07 38.12 
High injury: 'high-
responders' 
2.5 -30.53 4.94 38.51 
2.4 -22.86 1.93 41.98 
3.1 -23.9 3.56 43.64 
1.2 -25.27 1.40 44.56 
1.5 -14.63 1.62 46.57 
2.2 -30.05 1.76 65.90 
1.4 -20.61 -1.45 67.97 
2.3 -21.18 0.64 74.97 
Table 4.2 : Pre-treatment evaluation of kidney function (sorted by increasing urinary 
albumin values). Animals were grouped in to injury level groups based on where the 
urinary albumin data naturally split in to three groups at day 12 or 14. Animals with a very 
low elevation in urinary albumin (below 5 mg/24h) were deemed to have insufficient 
renal injury and were excluded from further study. Animals with urinary albumin values 
below 21 mg/24h were considered to have ‘low’ injury, and animals with greater than 38 











(day 12) (mg/24h) 
Change in FITC-
sinistrin half-life 








(day 12) (mg/24h) 
Change in FITC-
sinistrin half-life 
(baseline - day 14) 
(min) 
Low 
4.3 11.52 -0.05  
Low 
3.5 12.85 0.86 
3.2 16.83 1.99  4.1 13.11 0.22 
4.2 18.50 -0.57  2.1 20.49 1.59 
3.3 20.49 0.23  Mean 15.48 0.89 
Mean 16.84 0.40  
High 
1.1 38.12 1.07 
High 
2.5 38.51 4.94  2.4 41.98 1.93 
1.2 44.56 1.40  3.1 43.64 3.56 
2.2 65.90 1.76  1.5 46.57 1.62 
2.3 74.97 0.64  1.4 67.97 -1.45 
Mean 55.99 2.19  Mean 47.66 1.35 
Overall Mean 36.41 1.14  Overall Mean 35.59 1.08 
Table 4.3: Assignment of animals to a cell therapy or control treatment group. Animals were randomly assigned a cell therapy or saline treatment, 





In the high-responding group, mice that received hKC therapy had higher urinary albumin 
levels at week three than mice that received saline (cell-treated, mean: 70.17 mg/24h, SE: 
10.09; saline-treated, mean: 46.24 mg/24h, SE: 7.71), however this difference was not 
statistically significant. A one-way ANOVA revealed that at least one group was significantly 
different from another group (p < 0.001), however a post-hoc Tukey pairwise comparison 
Figure 4.7: Longitudinal assessment of kidney function. Urinary albumin (A) and FITC-
sinistrin half-life (B) were measured at baseline, and week two, immediately before 
experimental intervention, and then weekly thereafter until week six. There was no 
significant beneficial effect of hKC therapy (orange) compared with saline (blue) on either 
urinary albumin levels or FITC-sinistrin half-life in either the low-responding (light colours) 
or the high-responding (dark colours) groups. Data points represent the group mean, and 




test showed that none of these significant comparisons were of saline-treated vs cell-treated 
mice at the same time point, and were therefore not physiologically relevant (Supplementary 
Table S4.3A). A specific analysis of the week three time-point confirmed that the difference 
was not significant (two-sample t-test; p = 0.292). Conversely, in the low-responding group, 
mice that received hKC therapy had slightly lower urinary albumin levels at week three than 
mice that received saline (cell-treated, mean: 23.13 mg/24h, SE: 4.29; saline-treated, mean: 
32.36 mg/24h, SE: 5.83). As above, many treatment/time point comparisons were 
significantly different (one-way ANOVA, p < 0.001), however none were physiologically 
relevant (Supplementary Table S4.3B). A specific analysis of the week three time-point 
confirmed that the difference was not significant (two-sample t-test; p = 0.118). 
FITC-sinistrin Clearance 
For all treatment groups, there was a trend of increased FITC-sinistrin half-life over time (Fig. 
4.7B), indicating a progressive loss of kidney function. In the high-responding group, there 
was no difference in FITC-sinistrin half-life between mice that received hKC therapy and 
those that received saline at any time point (one-way ANOVA, p = 0.021; Tukey pairwise 
comparison, no physiologically relevant comparisons, Supplementary Table S4.3C). In the 
low-responding group, both treatment groups had very similar mean FITC-sinistrin half-lives 
at all time points except week 5, where mice that received hKC therapy had a lower FITC-
sinistrin half-life (mean: 9.57 min, SE: 0.48) than mice that received saline (mean: 12.15 min, 
SE: 1.17), however this difference was not statistically significant (one-way ANOVA, p < 0.001; 
Tukey pairwise comparison, no physiologically relevant comparisons, Supplementary Table 
S4.3D; two-sample t-test at week five, p = 0.185). 
4.3.2.6 In vivo Cell Tracking 
Bioluminescence imaging was performed immediately after cell administration (0h), on days 
1, 4, and 7, and then weekly thereafter in order to monitor the biodistribution of hKCs and 
detect any homing to the kidneys or abnormal behaviour such as tumour formation. 
Immediately after IV cell administration (0h) the signal was restricted to the lungs (Fig 4.8A). 
By day 1, the signal had decreased such that it could not be visualised using the same scale 
required at 0h (1.0 x105 – 1.0 x106 p/s/cm2/sr, green frame). Reducing the scale to 5.0 x104 – 
5.0 x105 p/s/cm2/sr (orange frame) allowed weaker signal to be detected, and revealed that 
some cells were still located in the lungs. By day 4, a very low scale of 5.0 x103 – 5.0 x104 
p/s/cm2/sr (blue frame) was required to visualise very weak signals in the lungs. From day 7 




detected anywhere in the body. Ex vivo imaging of organs at the end of the study confirmed 
that there were no bioluminescent hKCs remaining in any of the organs of any mice (Fig. 
4.8B).  
4.3.2.7 Histology 
PSR-stained paraffin sections of kidney tissue were analysed by a blinded nephrologist for 
evidence of glomerulosclerosis. It was found that there were no significant differences in 
glomerulosclerosis scores between hKC-treated and control mice (high-responders: cell-
treated, mean: 20.40% injured glomeruli, SE: 2.24; saline-treated, mean: 11.49%; SE: 3.56, 
two-sample t-test, p = 0.079; low-responders: cell-treated, mean: 7.20%, SE: 1.26; saline-
treated, mean: 7.17%, SE: 2.62; two-sample t-test, p = 0.993; Figure 4.9, Table 4.4). 
4.4 Discussion 
The aim of the studies in this chapter was to assess the efficacy of hKCs in the adriamycin 
mouse model of CKD. The first experiment was designed to closely recapitulate the study by 
Ronconi et al. (2009), in order to confirm the efficacy of CD133+ hKCs in the acute phase of 
the adriamycin model.  In the second study, the potential for hKCs to ameliorate kidney injury 
when administered at a later stage of the disease was assessed. 
These two experiments resulted in several important and novel findings: 
(i) both CD133+ and CD133- hKCs demonstrated a trend towards ameliorating kidney 
function when administered in the acute phase of adriamycin nephropathy, although 
this was not statistically significant. 
(ii) IV-administered cells failed to reach the kidneys and survive. 
(iii) hKCs did not ameliorate kidney injury when administered in the chronic phase of 
adriamycin nephropathy. 
These results showed that when hKCs were administered in the acute stage (days 1 and 4) 
of adriamycin-induced chronic progressive glomerular disease, before the onset of 
albuminuria, cell-treated mice exhibited reduced urinary albumin levels at day 10 compared 
with saline-treated mice. While this change was not statistically significant, largely due to the 
high degree of variability in renal damage induced by adriamycin, it is important to point to 
the biological significance of the drastic reduction in urinary albumin excretion compared 
with saline-treated mice. Because histological evidence of damage by light microscopy was 
not evident at this early time point in the animals treated with adriamycin, any effects the 





Figure 4.8: Bioluminescence imaging of ZsGreen+/Luciferase+ hKC biodistribution in vivo and 
ex vivo. Representative in vivo (dorsal) (A) and ex vivo (B) bioluminescence images of mice that 
received hKCs. (A) in vivo imaging suggested that cells were trapped in the lungs following IV 
administration, where they subsequently died. Bioluminescence signal on day 1 was much 
lower on at 0h, requiring a lower scale to display the signals. By day 4, a far lower scale was 
required to display very weak signals, and from day 7 – 28 no signal could be detected in vivo. 
(B) ex vivo images: clockwise from top right kidneys (cut coronally), spleen, liver, lungs, heart, 
brain. Ex vivo imaging of organs confirmed that there were no bioluminescent cells present in 
any organs four weeks after IV administration of hKCs. Images show average radiance; in vivo 
scale (day 0) = 1.0 x105 – 1.0 x106 p/s/cm2/sr (green frame); in vivo scale (day 1) = 5.0 x104 – 
5.0 x105 p/s/cm2/sr (orange frame); in vivo scale (days 4 - 28) and ex vivo scale (B) = 5.0 x103 – 





However, histological changes at early time points have previously been detected by electron 
microscopy (EM)171, and further investigations could allude to early structural changes 
following cell therapy. Nonetheless, these results support previously published reports134,147-
149,151,185,345, which indicated that hKCs have the potential to ameliorate acute kidney injury. 
The majority of these studies tested the efficacy of hKCs in the rhabdomyolysis model of AKI, 
and used SCr and BUN as the primary methods of assessing efficacy (Table 4.1). As shown in 
Chapter 3, SCr and BUN are not significantly changed in adriamycin nephropathy, and so 
were not assessed here or by Ronconi et al. (2009). Alternatively, urinary albumin, also 
assessed by Ronconi et al. (2009), provided an early biomarker of kidney injury which 
detected differences in kidney function between cell- and saline-treated mice. 
The efficacy of CD133+ and CD133- hKCs administered on days one and four during the acute 
phase was assessed and it was found that there were no significant differences in 
amelioration of kidney injury based on the expression of the stem cell marker, CD133. This 
finding is surprising since it is in direct opposition to a number of other published studies, 
which report that CD133 is not only essential for ameliorating functional and structural 
injury, but is also necessary for cells to home to the injured kidneys147,148,185. However, this 
observation supports the findings of Santeramo et al. (2017), who reported that the 
Figure 4.9: Histological evaluation of glomerulosclerosis. High-responding mice that 
received hKCs (dark orange triangles; mean: 20.4%) had a higher percentage of abnormal 
glomeruli than those that received saline (dark blue diamonds; mean: 11.49%), however 
this difference was not statistically significant (p = 0.079). There was no significant 
difference between low-responding mice that received hKCs (light orange circles; mean: 
7.20%) and those that received saline (light blue squares; mean: 7.17%; p = 0.993). Data 
points represent individual animals, and bars represent mean (wide line) and standard 




expression of CD133 had no effect on the therapeutic outcome of hKCs in a rat model of 
cisplatin-induced AKI134.  
It is important to note that the cells used in the current studies and in those described by 
Santeramo et al. (2017) were the same population of cells derived from one human kidney, 
and thus may exhibit unique characteristics that differ from the hKCs used in other studies, 
which were isolated from different kidneys. Additionally, the cells administered here and by 
Santeramo et al. (2017) were isolated from a healthy infant kidney deemed unsuitable for 
transplant, whereas the cells isolated for use in other studies were often described as being 
from the healthy portion of kidney tissue from patients with ‘localised renal tumours’, or 
patients undergoing nephrectomy for undisclosed reasons (Table 4.1). It is possible that the 
presence of renal carcinoma cells may have had an impact on the ‘healthy’ tissue 
surrounding the tumour, affecting the phenotype of the cells subsequently isolated from this 
tissue. These differences in cell origin may therefore explain the discrepancies observed in 
efficacy between the studies.  
Adriamycin induces a chronic progressive renal damage in mice, resulting in a glomerular 
injury which closely resembles the human disease FSGS. This model is well-suited to studying 
the effect of timing of cell administration, as the progressive nature of the disease allows 
efficacy to be assessed when cells are administered at different stages of injury. A 
disadvantage to this model, however, is the large degree of variability associated with the 
level of injury induced in animals. It is known that adriamycin has a narrow therapeutic range, 
and small differences in the dose administered may cause large variances in response, 
ranging from no renal injury, to toxicity and subsequent death169. However, despite careful 
adriamycin dose preparation, it was found that some animals developed very high urinary 
albumin excretion, while others excreted relatively low levels of albumin. It was initially 
thought that this variability was due to technical difficulties in performing IV drug 
administration, as strong experience is required to avoid mis-injections. However, 
subsequent experiments with vastly improved IV administration technique did not reduce 
variability (data not shown). In addition, changing the source of adriamycin from a research-
grade powder (Tocris) to a clinical-grade ready-to-use solution (Teva), did not impact the 

























Saline 2.1 16 129 segmental damage 12.40 
7.17 Saline 3.5 6 126 ?normal/a few casts 4.76 
Saline 4.1 4 92 ?normal/a few casts 4.35 
hKCs 3.2 11 106 segmental damage 10.38 
7.20 
hKCs 3.3 3 70 almost normal/a few casts 4.29 
hKCs 4.2 8 106 mild segmental damage 7.55 
hKCs 4.3 6 91 few casts in medulla 6.59 
High 
Saline 1.1 4 135 normal 2.96 
11.49 
Saline 1.4 17 128 major damage 13.28 
Saline 1.5 21 91 lots of casts in medulla 23.08 
Saline 2.4 6 118 minimal damage 5.08 
Saline 3.1 15 115 segmental damage 13.04 
hKCs 1.2 26 138 segmental damage 18.84 
20.40 
hKCs 2.2 13 87 few casts in medulla 14.94 
hKCs 2.3 16 71 quite damaged 22.54 
hKCs 2.5 24 95 very damaged 25.26 
Table 4.4: Histological evaluation of glomerulosclerosis. PSR-stained kidney sections were analysed by a clinical nephrologist and glomerulosclerosis was 
scored as the percentage of abnormal glomeruli in one kidney section per animal. The nephrologist’s comments and glomerulosclerosis scores highlight 




In the chronic cell therapy study where the efficacy of late administration of hKCs was 
analysed, the injury levels of mice were assessed prior to administration of the cell therapy 
by urinary albumin levels at day 12, and change in FITC-sinistrin half-life between baseline 
and day 14. The two injury parameters did not always correlate with one another, making it 
difficult to definitively class certain mice into injury levels, however urinary albumin 
measurements showed a natural grouping of mice, and as such was selected as the 
parameter by which mice would be categorised. Subsequently, mice were grouped into high- 
and low-responders, or excluded if they failed to develop kidney injury. Of the four mice that 
were excluded from the chronic study, the lack of renal damage could be explained for one 
mouse (mouse 4.5), due to a large mis-injection of approximately 50% of the dose of 
adriamycin. This mouse did not exhibit any significant weight loss, and urinary albumin 
excretion was very low, indicating that the kidneys suffered very minimal damage. However, 
the other three mice that failed to develop significant injury had received 100% of the 
adriamycin dose, and lost a similar percentage of body weight to all other mice, and so the 
minimal kidney damage indicated by urinary albumin levels is unexplained. As all known 
variables were controlled, it is possible that the variation in susceptibility to adriamycin is 
simply due to natural biological variability between individuals. Indeed, susceptibility to 
adriamycin has already been shown to have a genetic basis; the BALB/c strain is known to be 
highly susceptible to renal injury, while C57BL/6 mice are resistant169.  
Assessing the degree of functional damage prior to cell administration was highly beneficial 
as the true efficacy of a cell therapy is otherwise very difficult to assess when it is not known 
whether a cell-treated mouse would have developed mild, moderate, or severe injury 
without the therapy. This was only possible in the chronic study due to the late stage of cell 
administration.  
As the results of the acute study indicated that expression of CD133 was not necessary for 
therapeutic efficacy, unsorted hKCs were used in the chronic study. In contrast to the acute 
study, administration of hKCs to mice in the chronic stage of the disease (day 15), after overt 
albuminuria was established, had no effect on urinary albumin excretion, FITC-sinistrin half-
life, or structural histological damage compared with saline treatment. Regardless of 
whether mice had mild or severe injury (low- or high-responders to the initial injury), the 
half-life of FITC-sinistrin increased progressively over the six-week study period in both cell- 
and saline-treated groups, indicating a progressive loss of renal function in all animals, with 
no beneficial effect of hKC therapy. This data suggests that while hKCs may be a viable cell 




in one of the earlier stages of CKD, and late administration may have little to no therapeutic 
value. Indeed, administration of MSCs in a rat model of subtotal nephrectomy (5/6 
nephrectomy) resulted in very little improvement in kidney damage compared with saline-
treated rats. Over the course of a five-month study, the progression of proteinuria was 
attenuated in MSC-treated rats, but SCr, BUN, and histology failed to show any improvement 
over saline-treated rats215. A recent study by Caldas et al. (2016) assessed the therapeutic 
effect of MSCs in the subtotal nephrectomy model of chronic kidney disease219. By surgically 
removing different amounts of renal tissue (2/3 nephrectomy and 5/6 nephrectomy), the 
authors were able to model two different stages of CKD for assessing the importance of 
timing of therapeutic intervention. It was shown that MSC therapy significantly improved 
kidney function, as assessed by SCr, proteinuria, and creatinine clearance, equally in both 
models, however improvement was more pronounced in the 2/3 nephrectomy model, 
suggesting that intervention in the earlier stages of CKD is beneficial. Moreover, the number 
of doses of a cell therapy may be a key factor in obtaining a therapeutic effect in a chronic 
model. A single dose was used in the chronic study reported here, however Semedo et al. 
(2009) showed that while a single dose of MSCs was ineffective in a rat model of subtotal 
nephrectomy, dosing every two weeks for eight weeks resulted in improvement of kidney 
function216. 
The possibility for a cell therapy to exacerbate renal damage must also be considered. The 
hKC-treated mice in the high-responding group had almost twice as many abnormal 
glomeruli compared with saline-treated mice, indicating that the hKCs may have had a 
negative effect on the kidney. However, before therapeutic intervention, the mice assigned 
to hKC treatment already had slightly higher injury levels than the mice assigned to saline 
treatment, which may account for the higher percentage of glomerulosclerosis at week six. 
Nonetheless, further investigation is required to fully understand any negative effects of late 
administration of cell therapy on kidney function, and to determine the latest time point at 
which a cell therapy may still provide beneficial effects. 
In the two studies described here, hKCs had been labelled with luciferase-expressing 
lentivirus, allowing for longitudinal in vivo cell tracking by BLI. The data from these studies 
showed that regardless of when hKCs were administered to mice (day one/four or day 15), 
the luciferase+ cells became trapped in the lungs following IV administration, where they 
subsequently died and, in the chronic study, became undetectable within seven days. This 
supports the findings of multiple other studies, which showed that large cells such as hKCs 




administration111,134,267,349-351.  Indeed, ex vivo imaging of organs six days after the last hKC 
infusion in the acute study confirmed that both CD133+ and CD133- cells were exclusively 
located in the lungs, and could not be detected in the kidneys or any other organs imaged. 
Furthermore, in the chronic study, ex vivo organ imaging four weeks after hKC administration 
failed to detect any luciferase+ hKCs in any organs. Similarly to the efficacy results, the data 
presented here is more consistent with the data reported by Santeramo et al. (2017), than 
those reported by Ronconi et al. (2009), Sagrinati et al. (2006), and Angelotti et al. (2012), 
who relied primarily on histological detection of cell membrane dyes and human leukocyte 
antigen class I (HLA-I) detection. Key to this, is the use of reliable cell-tracking agents, such 
as reporter genes for detection by in vivo imaging, or ex vivo fluorescence microscopy, to 
avoid false-positive cell detection.  
Despite the cells remaining in the lungs and dying soon after cell administration, a beneficial 
effect on kidney function was still observed when cells were administered in the acute phase 
of the disease. This phenomenon has been reported in multiple other 
studies105,110,111,134,139,145,352,353, and supports the theory that the mechanism of action of the 
cell therapy is by endocrine/paracrine secretion of therapeutic factors, as opposed to 
physical integration and regeneration of damaged tissue. Geng et al. (2014) investigated the 
cytokine expression levels in the serum of mice with AKI, and showed that administration of 
MSCs led to decreased levels of the pro-inflammatory cytokines tumour necrosis factor alpha 
(TNF-α) and interleukin 6 (IL-6), and increased levels of the anti-inflammatory cytokine IL-10. 
Moreover, they showed that MSCs recruited macrophages to the site of injury, and could 
promote the polarisation of macrophages to the anti-inflammatory M2 phenotype, overall 
suggesting that MSCs may ameliorate kidney injury by modulating the immune response to 
reduce inflammation145. However, the cytokine expression levels following hKC 
administration have not yet been reported, and further investigation is required to 
determine whether a similar mechanism is also responsible for the amelioration by hKCs.  
In conclusion, the data presented in this chapter provided evidence that cells derived from 
the human kidney may have therapeutic value for treating CKD, however the expression of 
the stem cell marker CD133 was not necessary for amelioration. Additionally, longitudinal in 
vivo cell tracking data confirmed that IV administration of cells resulted in lung entrapment, 
and cells did not home to the kidneys. The therapeutic effect, despite cells not homing to the 
kidneys, supports the theory that the mechanism of action of the cell therapy is by 
paracrine/endocrine secretion of therapeutic factors. Moreover, it may be necessary to 




therapeutic value. Further investigation is required to determine the latest time point at 
which a cell therapy may still provide beneficial effects on kidney function. 
 
4.5 Supplementary Tables 
 
Treatment Animal ID 
Urinary Albumin 
(mg/24h) 
Day 0  Day 10 
ADR + 
CD133+ hKCs 
A1.1 0.09 2.66 
A1.2 0.19 0.16 
A1.3 0.02 0.25 
A2.1 0.06 0.42 
A2.2 0.03 0.80 
A2.3 0.13 0.55 
Mean 0.09 0.81 
SE 0.03 0.38 
ADR + 
CD133- hKCs 
A5.1 0.05 ND 
A5.2 0.03 0.13 
A5.3 0.02 0.21 
A6.1 0.02 2.71 
A6.2 0.01 1.80 
A6.3 0.02 0.39 
Mean 0.03 1.05 
Mean 0.00 0.52 
ADR + Saline 
A3.1 0.02 0.73 
A3.2 0.03 1.33 
A3.3 0.21 0.80 
A7.1 0.03 12.78 
A7.2 0.01 3.86 
A7.3 0.02 ND 
Mean 0.05 3.90 
SE 0.03 2.29 
Healthy 
Control 
C4.1 0.06 0.02 
C4.2 0.03 0.05 
C8.1 0.02 0.02 
C8.2 0.04 0.01 
Mean 0.04 0.03 
SE 0.01 0.01 
Supplementary Table S4.1: Acute study: individual urinary albumin values. This table 






Week 0 Week 2 Week 3 Week 4 Week 5 Week 6 Week 0 Week 2 Week 3 Week 4 Week 5 Week 6
Day 0 Day 12 Day 18 Day 25 Day 32 Day 40 Day 0 Day 14 Day 21 Day 28 Day 35 Day 42
2.1 0.04 20.49 43.86 33.51 25.72 23.03 7.98 9.57 8.56 10.12 12.81 10.01
3.5 0.06 12.85 28.29 13.34 3.63 2.37 6.60 7.45 8.88 8.76 9.88 6.09
4.1 0.10 13.11 24.94 19.67 12.69 2.84 8.54 8.76 7.37 8.20 13.77 8.28
Mean 0.07 15.48 32.36 22.17 14.01 9.41 7.70 8.59 8.27 9.03 12.15 8.13
SE 0.02 2.50 5.83 5.96 6.41 6.81 0.58 0.62 0.46 0.57 1.17 1.13
3.2 0.02 16.83 19.12 24.58 7.84 7.37 6.28 8.27 7.79 7.97 ND 6.53
3.3 0.02 20.49 17.38 8.21 4.64 3.70 8.27 8.50 8.32 ND 10.69 7.21
4.2 0.04 18.50 35.90 15.56 15.17 5.19 7.38 6.82 8.47 7.65 9.04 7.61
4.3 0.10 11.52 20.11 6.92 3.88 5.80 8.07 8.02 8.51 8.63 8.97 8.19
Mean 0.05 16.84 23.13 13.82 7.88 5.52 7.50 7.90 8.27 8.09 9.57 7.38
SE 0.02 1.92 4.29 4.06 2.58 0.76 0.45 0.38 0.16 0.25 0.48 0.35
1.1 0.21 38.12 45.21 22.38 6.01 7.18 8.78 9.85 11.35 10.57 9.84 9.32
1.4 0.21 67.97 49.64 40.86 50.10 24.71 9.90 8.45 10.24 9.25 10.36 7.35
1.5 4.00 46.57 31.32 35.45 22.18 18.21 7.98 9.60 10.18 11.25 11.53 15.09
2.4 0.05 41.98 31.60 18.10 8.29 8.41 7.13 9.06 8.82 9.68 12.21 10.21
3.1 0.13 43.64 73.44 34.56 13.41 10.50 7.73 11.29 8.57 11.71 14.27 9.15
Mean 0.92 47.66 46.24 30.27 20.00 13.80 8.30 9.65 9.83 10.49 11.64 10.22
SE 0.77 5.26 7.71 4.29 8.02 3.33 0.48 0.48 0.51 0.46 0.78 1.30
1.2 0.04 44.56 70.55 21.48 13.02 13.22 8.47 9.87 10.37 9.07 ND ND
2.2 0.07 65.90 61.07 42.99 27.89 13.38 7.86 9.62 8.55 9.90 12.95 11.70
2.3 0.12 74.97 97.99 47.99 28.26 14.18 8.99 9.63 10.32 11.78 10.42 10.53
2.5 0.02 38.51 51.06 42.05 40.22 10.97 8.64 13.58 9.42 10.24 13.93 9.92
Mean 0.06 55.99 70.17 38.63 27.35 12.94 8.49 10.68 9.67 10.25 12.44 10.72











Supplementary Table S4.2: Chronic study: individual urinary albumin and FITC-sinistrin half-life values. This table highlights the high degree of variability 




n Mean n Mean
ADR + Sa l ine 5 0.92 E ADR + Sa l ine 5 8.30 B
ADR + hKCs 4 0.06 E ADR + hKCs 4 8.49 A B
ADR + Sa l ine 5 47.66 A B ADR + Sa l ine 5 9.65 A B
ADR + hKCs 4 55.99 A B ADR + hKCs 4 10.68 A B
ADR + Sa l ine 5 46.24 A B C ADR + Sa l ine 5 9.83 A B
ADR + hKCs 4 70.17 A ADR + hKCs 4 9.67 A B
ADR + Sa l ine 5 30.27 B C D ADR + Sa l ine 5 10.49 A B
ADR + hKCs 4 38.63 B C D ADR + hKCs 4 10.25 A B
ADR + Sa l ine 5 20.00 C D E ADR + Sa l ine 5 11.64 A
ADR + hKCs 4 27.35 B C D E ADR + hKCs 4 12.44 A
ADR + Sa l ine 5 13.80 D E ADR + Sa l ine 5 10.22 A B
ADR + hKCs 4 12.94 D E ADR + hKCs 4 10.72 A B
n Mean n Mean
ADR + Sa l ine 5 0.07 C ADR + Sa l ine 5 7.70 B
ADR + hKCs 4 0.05 C ADR + hKCs 4 7.50 B
ADR + Sa l ine 5 15.48 A B C ADR + Sa l ine 5 8.59 B
ADR + hKCs 4 16.84 A B C ADR + hKCs 4 7.90 B
ADR + Sa l ine 5 32.36 A ADR + Sa l ine 5 8.27 B
ADR + hKCs 4 23.13 A B ADR + hKCs 4 8.27 B
ADR + Sa l ine 5 22.17 A B ADR + Sa l ine 5 9.03 B
ADR + hKCs 4 13.82 A B C ADR + hKCs 4 8.09 B
ADR + Sa l ine 5 14.01 A B C ADR + Sa l ine 5 12.15 A
ADR + hKCs 4 7.88 B C ADR + hKCs 4 9.57 A B
ADR + Sa l ine 5 9.41 B C ADR + Sa l ine 5 8.13 B
ADR + hKCs 4 5.52 B C ADR + hKCs 4 7.38 B












































Supplementary Table S4.3: Tukey Pairwise Comparisons. Four separate post-hoc statistical analyses following statistically significant results from 
separate one-way ANOVAs comparing the urinary albumin (A – B), or the FITC-sinistrin half-life (C – D) data from high-responders (A, C), and low-








Assessing the efficacy of human kidney-derived and mesenchymal 





The previously held belief that AKI is a transient condition, and that those who survive AKI 
suffer no long-term consequences42, has now been replaced with a more comprehensive 
understanding of the complexity of AKI, its relationship with CKD, and the long-term 
consequences of an episode of AKI38,45-49. It is now understood that AKI makes an individual 
more susceptible to subsequent AKI and/or CKD38,46-48, and that the severity of initial AKI 
predicts the likelihood of progressing to CKD46. Consequently, there is a need to develop 
specific therapies that limit the initial severity of AKI and promote recovery, thus reducing 
the patient’s risk of progressing to CKD.  
Cell-based therapies may provide such a treatment option, and vast numbers of publications 
point to the efficacy of cell therapies in the IRI model of AKI (Table 1.3). Many different cell 
types have been shown to be efficacious in the IRI model, including MSCs derived from the 
bone marrow108-112,352,354,355, adipose tissue113-116,356, and the umbilical cord and its 
products105,117,118, in addition to cells isolated from the kidney itself120,121 and kidney cells 
generated from iPSCs119,357. Collectively, these cell therapies appear to have similar modes of 
action, acting to suppress inflammation and oxidative stress to reduce tubular cell damage 
and preserve renal function (Table 1.3). However, it is still unclear which cell type may 
provide the most effective therapy. The majority of studies have been carried out using 
MSCs, however it is unknown whether the source of the MSCs has any effect on ameliorative 
potential. Furthermore, it is not known whether cells derived from the kidney itself may 
provide an advantage over non-kidney cells, such as MSCs. Notably, human kidney derived 
cells have been shown to share some cell surface characteristics with MSCs, and had an 
ameliorative effect in cisplatin-induced AKI134. 
Renal IRI is a desirable experimental model of AKI. Ischemia is the predominant cause of AKI 
in the intensive care setting95 and an inevitable consequence of kidney transplantation99, 
making experimental IRI a clinically relevant model. Moreover, once optimised, the model is 
reproducible and amenable to modifications to alter the severity of injury and time course of 
disease, making it a versatile model. The IRI model is, however, highly sensitive to changes in 
experimental conditions, and as such it is vitally important to spend time optimising the ideal 
conditions of renal IRI prior to embarking upon experimental work.  
There are multiple variations of the IRI model reported in the literature (Table 5.1). First of 
all, the kidneys can be accessed either via a ventral or a dorsal approach. A ventral approach 





Approach Advantages Disadvantages 
Ventral Easier access to the kidneys. 
Longer recovery time, increased risk of systemic 
inflammation/infection, increased mortality 
Dorsal 
Less traumatic, allows faster recovery times, and 
improved survival. 
More difficult to access kidneys. 
Model Advantages Disadvantages 
Bilateral 
Approximates hypoperfusion in humans (both 
kidneys affected). 
Variable results due to differences in effective 
clamp pressure and/or renal responses to 
ischemia. Renal injury is also less severe and there 
is higher mortality. 
Unilateral 
No nephrectomy 
Allows for longer clamp times and subsequent 
development of interstitial fibrosis. Internal control 
kidney for histological evaluation. 




Substantially reduced variability compared with 
bilateral ischemia, and allows renal function to be 
assessed. Provides control renal tissue prior to 
ischemia. 
Shorter clamp times than with no/delayed Nx leads 
to less severe injury 
Delayed contralateral 
nephrectomy 
Allows for longer clamp times and subsequent 
development of interstitial fibrosis. Kidney function 
can be monitored from the day after Nx. 
Requires two surgeries. Kidney function cannot be 
measured until after the Nx. 




mortality, poorer recovery, and increased risk of infection358,359. A dorsal approach requires 
smaller incisions and is associated with faster recovery times359, but the kidneys must be 
manipulated more in order to access the renal vasculature, increasing the risk of damaging 
the kidneys. Secondly, either one or both kidneys can be injured. The bilateral model involves 
clamping both kidneys358,360 and more closely resembles certain human conditions in which 
systemic hypoperfusion is present, such as cardiac surgery96. Experimentally, however, the 
bilateral model is associated with higher variability, due to small differences in the conditions 
imposed on each kidney, such as effective clamp pressure from different clamps and the 
amount of tissue and fat also clamped with the renal vasculature359. Alternatively, the 
unilateral model involves clamping only one kidney, and this may be performed with359,361 or 
without362 a contralateral nephrectomy (Nx). Models of unilateral ischemia have been 
suggested to be associated with lower variability than the bilateral model359. In the unilateral 
ischemia without Nx model, the presence of a healthy contralateral kidney provides an 
internal control kidney, which may be of value in certain studies, and also allows for longer 
clamp times to induce severe renal ischemia without subsequent renal failure and 
death359,362, and as such can be used to model the progression of AKI to CKD362. However, the 
presence of the healthy contralateral kidney compensates for the reduced function of the 
injured kidney, and precludes functional analyses of renal biomarkers in the urine or blood. 
The inclusion of a Nx to the unilateral model allows renal function in the damaged kidney to 
be measured unequivocally359,361. The Nx can either be performed simultaneously at the time 
of ischemia, or can be delayed and performed sometime after reperfusion, e.g. one week. A 
simultaneous Nx allows kidney function to be evaluated immediately after surgery, but 
requires shorter clamp times to avoid renal failure and death. A delayed Nx requires a second 
surgery, but allows for longer ischemia times due to the presence of an uninjured 
contralateral kidney, and therefore enhances the development of post-injury fibrosis, with 
the advantage of being able to evaluate kidney function following the Nx359. 
As expected, longer clamp times are associated with higher degrees of renal injury362. 
Temperature is also one of the most important factors determining renal injury, with 
increasing core body temperature during ischemia leading to increased renal injury362,363. 
Moreover, it is necessary to actively control body temperature during ischemia, as surgery 
performed without a heat mat leads to relative hypothermia and reduced renal injury360,363, 
whereas surgery performed with a heat mat that does not feature feedback-loop 
temperature control may lead to effective hyperthermia and excessive renal injury363. The 




anaesthetics such as isoflurane, sevoflurane, and halothane providing protection from renal 
IRI compared with injectable anaesthetics such as pentobarbital and ketamine364. 
Furthermore, the age, sex, and strain of the animal can affect renal injury. Older365 and 
male366 animals are more sensitive to renal IRI, and some strains, such as NIH Swiss mice, are 
highly resistant367.  
Kidney function is usually assessed by SCr and BUN measurements in published literature, 
but these methods are insensitive and not entirely specific to kidney injury43,225,368. The 
transcutaneous measurement of FITC-sinistrin clearance is a novel method of measuring 
kidney function in experimental animals232,234,237 and its use has been demonstrated in 
various animal models of kidney injury, including unilateral nephrectomy234,237, polycystic 
kidney disease234,237, salt-sensitive hypertension242, diabetic CKD243, non-diabetic CKD244, 
sepsis245, cisplatin-induced AKI134, and adriamycin-induced glomerular injury (Chapters 3 and 
4). However, the use of the transcutaneous measurement of kidney function has not been 
described in a model of ischemic AKI, and its suitability and feasibility are unknown.  
The aims of the experiments described in this chapter were: 
1. To establish and optimise a model of renal IRI in our laboratory. Initial pilot studies 
were carried out to assess whether the unilateral model would provide a significant 
advantage over the bilateral model in terms of reducing variability. Subsequent 
experiments were carried out to optimise the clamp time and other experimental 
variables, and to characterise the injury induced. 
2. To assess whether the transcutaneous measurement of FITC-sinistrin clearance 
would be an appropriate measure of kidney function in the IRI model 
3. To assess the efficacy of different cell types in the IRI model, in order to determine 
the cell type with the greatest regenerative or repair capacity. 
 
5.2 Experimental Design 
Establishing and optimising the IRI model 
Initially, we needed to decide which model (bilateral ischemia or unilateral ischemia with 
contralateral Nx) was preferable, and to determine an approximate clamp time that would 
induce moderate-severe renal injury with acceptable levels of mortality. Therefore, pilot 




40 min (or sham-operated) on one mouse per model/clamp time. Male BALB/c mice age 8 - 
9 weeks were used for all pilot studies. 
In the bilateral ischemia pilot study, kidney function was assessed by transcutaneous 
measurement of FITC-sinistrin clearance at baseline and days 1, 3, and 7. Urinary albumin 
and KIM-1 excretion were measured in urine collected at baseline and days 1, 2, 3, and 7. 
Mice were culled on day 7 and tubular injury was scored for each kidney on PAS-stained 
paraffin kidney sections. 
In the unilateral ischemia with Nx pilot study, kidney function was assessed by 
transcutaneous measurement of FITC-sinistrin clearance at baseline (three repeated 
measurements) and days 1, 2, and 4. Mice were culled on day 4 and tubular injury was scored 
for each kidney on PAS-stained paraffin kidney sections.  
Subsequent experiments were carried out to further optimise the clamp time using the 
unilateral ischemia with Nx approach, eventually leading to an optimal clamp time of 31 
minutes in the final optimisation experiment (IRI, 31 min, n = 5; sham-operated, n = 5). Kidney 
function was assessed by transcutaneous measurement of FITC-sinistrin clearance at 
baseline and days 1, 2, and 4. Mice were culled on day 4, and blood was collected for SCr and 
BUN measurement. Tubular injury scoring was not performed due to time constraints, and 
instead immunofluorescence of tissue injury biomarkers, Ki67 for proliferation and KIM-1 for 
proximal tubule damage, was carried out on frozen kidney sections. 
Assessing the Efficacy of Cell Therapy 
27 male BALB/c mice age 8 – 10 weeks underwent unilateral ischemia (31 min clamping) with 
contralateral nephrectomy, and received either 7.5 x105 hKCs (n = 6), 7.5 x105 human 
umbilical cord-derived MSCs (hUC-MSCs; n = 6), 7.5 x105 human bone marrow-derived MSCs 
(hBM-MSCs; n = 6), or saline (n = 9) (all 100μl volume, IV) immediately after reperfusion. Mice 
were divided into three groups of nine mice, with six mice receiving one of the cell types and 
three mice receiving saline in each group. This experiment was carried out in a blinded 
fashion, and the treatment groups were not revealed until all analyses were complete. Kidney 
function was assessed by transcutaneous measurement of FITC-sinistrin clearance at 
baseline, and days 1, 2, and 4 after surgery. Mice were culled on day 4, blood was collected 
for SCr and BUN measurement. Tubular injury scoring was not performed due to time 
constraints, and instead immunofluorescence of tissue injury biomarkers, Ki67 for 





An additional 10 mice underwent unilateral ischemia (31 min clamping) with contralateral 
nephrectomy, and received either 7.5 x105 ZsGreen+/luciferase+ hKCs (n = 5) or saline (n = 5) 
(all 100μl volume, IV) immediately after reperfusion. Mice were imaged for bioluminescence 
after surgery (before recovering from anaesthesia) and at 24h. After imaging, mice were 
culled, organs imaged ex vivo, and blood was collected for SCr and BUN measurement. 
 
5.3 Results 
5.3.1 Optimising the IRI model 
The bilateral IRI model is more clinically relevant and more commonly used in research, 
however the unilateral with Nx model is reported to be associated with lower levels of 
variability. As such, pilot studies were carried out: (1) to determine whether the bilateral or 
unilateral with Nx approach was more suitable, and (2) to determine the optimal clamping 
time under each approach for inducing a moderate-severe, but survivable injury.  
5.3.1.1 Bilateral Ischemia Pilot Study 
The sham-operated mouse, and mice with 25 or 35 min bilateral ischemia lost less than 10% 
body weight by day 2, and subsequently put weight on; reaching or exceeding the starting 
weight by the end of the study on day 7 (Fig 5.1A). Mice with 30 or 40 min bilateral ischemia, 
however, lost a maximum of 15.4% and 21.1% body weight during the study. While weight 
gain in these animals was evident from days 5-6, body weight loss was still at around 10% by 
day 7. 
Renal function was assessed by transcutaneous measurement of FITC-sinistrin clearance at 
baseline and days 1, 3, and 7 following surgery (Fig. 5.1B). The sham-operated mouse and 
the mouse with 25 min bilateral ischemia displayed a decrease in FITC-sinistrin half-life over 
time, decreasing by over 5 min between baseline measurements and day 7 (Fig. 5.1B, Table 
5.2). Conversely, all other injured mice showed a peak in FITC-sinistrin half-life at day 1 
following surgery, with values returning towards baseline at day 3, and comparable to 
baseline levels by day 7. The FITC-sinistrin half-life tended to rise as clamp time increased, as 
the mouse with 40 min renal clamping displayed the highest FITC-sinistrin half-life at day 1, 
however the day 1 values for the mice with 30 and 35 min clamping were inverted based on 




Figure 5.1: Pilot bilateral IRI model – renal injury analyses. (A) Body weight change of animals following bilateral ischemia, with clamp times ranging 
from 25 – 40 min, or sham-operated with no renal ischemia. (B) FITC-sinistrin half-life was vastly increased over baseline levels at day 1, and decreased 
over time from day 3 to 7. The half-life at day 1 tended to increase as clamp time increased, however a clamp time of 30 min yielded a higher half-life 
than a clamp time of 35 min. (C) Tubular injury was scored for each kidney individually, and showed that the injury induced by each clamp time varied 
to a large extent between the left and right kidneys. (D) A plot of the correlation between the tubular injury score and FITC-sinistrin half-life at day 1 





 FITC-sinistrin half-life (min) Tubular Injury Score 
Clamp 
Time 






25 min 12.72 11.72 8.55 7.60 0 2 1 
30 min 12.03 30.60 20.93 13.47 12 23 17.5 
35 min 12.80 19.22 11.65 9.90 23 1 12 
40 min 15.83 56.92 23.50 14.17 22 16 19 
Sham 17.22 13.70 9.53 10.55 0 0 0 
 
PAS-stained paraffin kidney sections were analysed blinded by a veterinary pathologist, and 
tubular injury was scored for each kidney individually (Fig. 5.1C), with a maximum possible 
score of 50. Kidneys from the sham-operated mouse and the mouse with 25 min bilateral 
ischemia displayed little/no evidence of tubular damage. At least one kidney from the 30, 35, 
and 40 min bilateral ischemia mice showed signs of strong kidney damage, but the damage 
induced in both kidneys was not consistent, with one kidney showing weaker signs of damage 
than the other (Fig. 5.1C, Table 5.2). In the most extreme example of the variability in injury 
levels, the mouse with 35 min ischemia had a tubular injury score of 23 for the left kidney, 
and just 1 for the right kidney (Table 5.2). The tubular injury score for both kidneys was then 
averaged, and indicated a similar trend as the FITC-sinistrin clearance data, with respect to 
the relationship between length of clamping and degree of injury induced. The average 
tubular injury scores displayed a moderate level of correlation with the transcutaneous 
assessment of kidney function at day 1 (R2 = 0.68; Fig. 5.1D).  
Additionally, urine was collected to measure urinary albumin and KIM-1 excretion. Urine 
collection was found to be difficult in these animals, with many mice not producing urine at 
certain time points (denoted on the graph by ‘X’), and only one mouse producing urine at all 
time points (Table 5.3). When urinary albumin and KIM-1 levels were quantified, some 
samples yielded no detectable levels of either analyte (denoted on the graph by ‘O’), 
suggesting that the liquid collected from hydrophobic sand was in fact water from the water 
bottle, and not urine (Fig. 5.2A, B). As a result, there were very few data points available for 
analysis of urine biochemistry. Generally, urinary albumin and KIM-1 levels peaked at day 1, 
decreased over time from day 2 to 7, and tended to be more increased with longer clamp 
times. However, urinary KIM-1 excretion was reduced in the mouse with 40 min bilateral 
ischemia compared with the mice with 30 and 35 min bilateral ischemia. 







Day 0  
Day 0 
(Repeat) 
Day 0.5 Day 1 Day 3  
Urine Volume (μl) 
1.1 160 90 0 110 60 
1.2 <10 60 100 100 0 
1.3 0 80 0 130 50 
1.4 110 190 90 210 40 
1.5 0 140 0 50 70 
2.1 140 0 140 0 15 
2.2 40 0 210 260 0 
2.3 140 0 230 180 0 
2.4 0 100 0 0 0 
2.5 70 110 0 70 0 
 
5.3.1.2 Unilateral Ischemia with Contralateral Nx Pilot Study 
The sham-operated mouse, and mice with 25 or 30 min unilateral ischemia lost 10 - 12% body 
weight by day 2, and subsequently gained a small percentage of body weight over the next 
two days until the end of the study at day 4 (Fig 5.3A). Mice with 35 or 40 min unilateral 
ischemia, however, continued to lose weight throughout the study, to a maximum of 22% 
and 28% body weight loss, respectively, by day 4.  
Renal function was assessed by transcutaneous measurement of FITC-sinistrin clearance at 
baseline and days 1, 2, and 4 following surgery (Fig. 5.3B). The sham-operated mouse 
displayed a slight increase in FITC-sinistrin half-life at day 1 following surgery compared with 
baseline (Table 5.4), which returned towards baseline levels at days 2 and 4. All IRI mice 
displayed a strong increase in FITC-sinistrin half-life at day 1, with longer clamping times 
resulting in longer half-lives. For all mice with a clamp time of 35 min or less, the peak of FITC-
sinistrin half-life was at day 1, and measurements on subsequent days yielded decreasing 
values. However, the mouse with a clamp time of 40 min displayed a continued increase in 
FITC-sinistrin half-life at day 2, before decreasing at day 4. 
The tubular injury scores of PAS-stained paraffin kidney sections increased as clamp time 
increased (Fig. 5.3C, Table 5.4), and this correlated strongly with transcutaneous assessment 
of FITC-sinistrin clearance (R2 = 0.80; Fig. 5.3D).  
Table 5.3: Urine volumes produced throughout a typical experiment. The volume of urine 
collected from mice following 5h on hydrophobic sand was measured at various time points 
in the experiment. Instances where mice did not produce any collectable urine are 





This pilot study was then repeated with an additional cohort of five animals, and while similar 
trends with respect to clamp times were observed in the second group, the injury levels 
obtained were lower compared with the first group (Fig. 5.4A, B). The temperature of the 
heat mat during surgery for the second group was later found to have been unintentionally 
lower than that for the first group, leading to a reduced level of renal injury induced in all 
mice. 
Figure 5.2: Urine biochemistry and problems collecting urine. Urinary excretion of 
albumin (A) and KIM-1 (B) was difficult to analyse due to difficulties in collecting urine 
from mice. X = no urine collected; O = liquid collected from sand, but yielded no detection 
of the analyte, and it is likely that water and not urine was collected. Both albumin and 
KIM-1 levels were highest at day 1, and decreased back towards baseline levels at 
subsequent time points. At day 1, both urinary albumin (C) and KIM-1 (D) excretion 
increased as the clamp time increased, however after 40 min ischemia, urinary KIM-1 
excretion was reduced compared with 30 and 35 min ischemia. All data points represent 




Figure 5.3: Pilot unilateral with nephrectomy IRI model – renal injury analyses. (A) Body weight change of animals following unilateral ischemia with 
nephrectomy, with clamp times ranging from 25 – 40 min, or sham-operated with no renal ischemia. Weight loss was more severe for the 35 and 40 
min clamp times in the unilateral with nephrectomy model than in the bilateral model. (B) FITC-sinistrin half-life was vastly increased over baseline 
levels at day 1, and decreased over time at days 2 and 4. FITC-sinistrin half-life data shows that stronger injury levels were induced with the unilateral 
with nephrectomy model, than with the bilateral model. (C) Tubular injury was scored for each the injured kidney for each animal, and showed that 
as clamp time increased, tubular injury increased. (D) A plot of the correlation between the tubular injury score and FITC-sinistrin half-life at day 1 











Day 0 Day 1 Day 2 Day 4 Left Kidney 
Group 1 
25 min 8.76 21.31 15.18 10.16 12 
30 min 8.08 21.32 15.33 10.64 13 
35 min 8.51 55.00 29.78 15.31 20 
40 min 7.85 110.13 123.12 41.17 26 
Sham 7.73 12.65 10.85 8.70 2 
 
 
Table 5.4: Pilot unilateral IRI model – renal injury analyses.  
Figure 5.4: Highlighting the importance of careful temperature control. Surgery was 
performed on two groups of mice on two different days. In group 1 (same data as 
presented in Figure 5.2), the temperature of the heat mat was higher than for group 2. 
The cooler body temperature of mice in group two conferred a degree of protection from 
renal injury, as shown by FITC-sinistrin half-life (A) and histological assessment of tubular 
injury (B). The protective effect of temperature was more evident at the higher clamp 




As part of the analysis of the bilateral pilot study, it was noticed that the half-life of FITC-
sinistrin in the sham and 25 min ischemia mice decreased over time between baseline and 
subsequent measurements. In order to assess the stability of FITC-sinistrin half-life in healthy 
male BALB/c mice, baseline FITC-sinistrin clearance was measured three times (once every 
two days). Repeated measurements showed that FITC-sinistrin half-life was significantly 
higher on the first measurement, compared to the second or third measurements (paired t-
test, p < 0.001; Fig. 5.5A, B). The third measurement was significantly higher than the second 
(paired t-test, p = 0.03), however the difference in half-life was only around one minute, 
which is within normally observed fluctuations in clearance times and was not considered to 
be a problem.  
 
Following the initial pilot studies, the tubular injury scores assessed histologically showed 
that there were large differences in the injury induced in each kidney in the bilateral model, 
Figure 5.5: Repeated baseline 
measurements of FITC-sinistrin half-life. 
Transcutaneous measurements performed 
at three time points before surgery – 
baseline 1 was performed on the day of 
shaving, and baseline 2 and 3 were 
performed two and four days after shaving, 
respectively. (A) shows individual FITC-
sinistrin half-life data for each of 10 animals, 
and (B) shows the mean half-life at each time 
point. Baseline 1 was significantly higher 
than baselines 2 and 3. Error bars represent 
standard error. Paired t-test, p < 0.001 (***), 




most likely due to differences in effective clamp pressure resulting from slight differences in 
individual clamps and differences in the amount of connective tissue and fat surrounding the 
renal artery and vein. As a result, the unilateral with Nx model was selected for future studies.  
Furthermore, it is possible that the shaving procedure caused the half-life for FITC-sinistrin 
to be increased when the measurement was carried out on the same day as shaving, and as 
such, mice were shaved two days in advance of the baseline measurement in subsequent 
experiments.  
5.3.1.3 Finalising the Ischemia Time in the Unilateral Ischemia with Contralateral Nx Model 
Additional experiments were carried out to further optimise the ischemia time in the 
unilateral ischemia with contralateral Nx model (data not shown). Initial data suggested 34 
min ischemia would be optimal, however when the single heat mat used for all animals 
undergoing surgery at a time was replaced with individual infra-red mats that controlled 
individual body temperature more accurately, 34 min ischemia resulted in very severe injury 
(data not shown), and 31 min was instead determined as the optimal ischemia time. A final 
study was conducted to confirm that 31 min ischemia would induce renal injury that was 
severe enough for any efficacy by a cell therapy to be detected, with no mortality and 
acceptable variability between mice.  
Following 31 min ischemia, all five mice survived the four-day study, and lost up to an average 
of 16.7% body weight (Fig. 5.6A). Body weight loss in IRI mice was significantly greater than 
that in sham mice at days three and four (Supplementary Table S5.1A). Renal function was 
assessed by transcutaneous measurement of FITC-sinistrin clearance at baseline and days 1, 
2, and 4 following surgery. Sham mice displayed only a slight increase in FITC-sinistrin 
clearance one day following surgery, whereas IRI mice displayed a significant increase in FITC-
sinistrin clearance, averaging a half-life of around 49 min at day one, compared with 13 min 
for sham mice, and 9 min at baseline (Fig 5.6B, Table 5.5). As expected, FITC-sinistrin half-life 
in IRI mice decreased at day two, and was elevated but not significantly different to baseline 
levels by day four (one-way ANOVA, p < 0.001, see Supplementary Table S5.1B for results of 
post-hoc Tukey pairwise comparison test).  
Serum and tissue biomarkers were measured in IRI and sham mice. SCr and BUN were 
significantly elevated at day 4 in IRI mice compared with shams (SCr: Fig. 5.6C; two sample t-
test, p < 0.001. BUN: Fig. 5.6D; two-sample t-test, p = 0.013). Tissue expression of KIM-1 and 
Ki67 were analysed to assess injury and repair, respectively. KIM-1 tissue expression was 




Figure 5.6: Characterisation of the renal injury induced by 31 min unilateral ischemia with contralateral nephrectomy.  (A) Mean body weight change of 
mice with 31 min unilateral ischemia with contralateral Nx, and sham-operated mice. Sham mice lost a small percentage of body weight in the first few 
days after surgery, but began to put weight back on by days 3 and 4. Conversely, injured mice lost a large percentage of body weight during the experiment, 
and did not put weight back on before the end of the experiment at day 4. (B) FITC-sinistrin half-life increased significantly over baseline levels at day 1 in 
injured mice, and then decreased back towards baseline levels at days 2 and 4. Sham mice maintained a relatively constant FITC-sinistrin half-life 
throughout the study. SCr (C) and BUN (D) were significantly elevated in IRI mice compared to sham mice. Data points represent the group mean and error 
bars represent standard error (A - B). Data points represent individual animals, and bars represent mean (wide line) and standard error (short lines) (C – 





















1.1 8.55 54.78 33.19 19.51 92.11 7535.56 14.96 17.10 77.8 
1.2 9.15 50.94 34.24 16.87 99.75 11362.63 19.70 16.40 101.6 
1.3 10.23 47.73 32.06 17.13 89.93 10473.24 15.05 17.80 135.7 
1.4 10.24 32.82 24.70 15.80 94.29 11308.73 16.40 11.60 83.2 
1.5 7.97 59.30 27.45 20.08 96.48 5487.27 11.65 17.00 65.6 
Mean 9.23 49.11 30.33 17.88 94.51 9233.49 15.55 15.98 92.78 
SD 1.01 10.08 4.08 1.83 3.81 2612.18 2.90 2.50 27.27 
SE 0.45 4.51 1.82 0.82 1.70 1168.20 1.30 1.12 12.20 
Sham 
2.1 8.93 10.95 8.16 9.24 24.03 3680.13 0.12 9.10 2.4 
2.2 9.53 14.27 10.52 12.83 24.03 4016.43 0.11 7.50 2.3 
2.3 8.38 14.20 10.46 11.80 16.72 4160.57 0.11 14.60 2.7 
2.4 8.44 13.30 14.49 14.92 21.94 6226.43 0.11 8.20 3.5 
2.5 10.17 12.23 12.06 13.58 33.44 4352.74 0.11 7.20 0.7 
Mean 9.09 12.99 11.14 12.47 24.03 4487.26 0.11 9.32 2.32 
SD 0.76 1.41 2.34 2.14 6.05 1002.83 0.00 3.04 1.02 
SE 0.31 0.58 0.95 0.87 2.70 448.48 0.00 1.36 0.46 
 
magnification within the OSOM. KIM-1 staining was absent in sham mice (Fig. 5.7A), and 
significantly elevated in IRI mice (Fig. 5.7B, C; two-sample t-test, p < 0.001). Cell proliferation 
was assessed by counting Ki67-positive nuclei in ten FOVs at 40x magnification in each the 
cortex and the OSOM. There was a low level of cell proliferation in the cortex of both the 
sham and IRI mice (Fig 5.7D, E), which was significantly elevated in the IRI mice (Fig. 5.7H; 
two-sample t-test, p = 0.007). Cell proliferation in the OSOM was even lower than that in the 
cortex in sham mice (Fig. 5.7F; two-sample t-test, p = 0.008), but was vastly and significantly 
elevated in IRI mice (Fig. 5.7G, H; two-sample t-test, p = 0.002). 
Histological tubular injury was not analysed for the final optimisation study using 31 min 
ischemia due to time constraints, but was determined for previous optimisation studies. The 
data from multiple optimisation studies conducted using various clamp times and 
temperature conditions was pooled, and tubular injury scores were correlated with FITC-
sinistrin half-life on day one (n = 39), SCr on day four (n = 30), and BUN on day four (n = 30) 
(Fig. 5.8). Kidney function as assessed by transcutaneous measurement of FITC-sinistrin 
clearance correlated more strongly with histological assessment of kidney damage (R2 = 0.88, 
Fig. 5.8A) than either SCr or BUN (R2 = 0.69, 0.58, respectively, Fig. 5.8B,C), indicating FITC-
sinistrin half-life was a more accurate predictor of histological kidney damage than  





Figure 5.7: Expression of tissue biomarkers of injury and repair in IRI and sham mice. 
Representative images of KIM-1 expression in IRI mice (A) and sham mice (B). IRI mice 
displayed a significant upregulation of KIM-1 expression compared with sham mice (C). 
Representative images of Ki67 expression in the cortex of IRI mice (D) and sham mice (E), 
and the OSOM of IRI mice (F) and sham mice (G). Cell proliferation, assessed by the 
number of KI67+ nuclei (arrows), was modestly elevated in the cortex of IRI mice, and 
markedly increased in the OSOM, compared with sham mice. (H). Tubular casts were 
strongly autofluorescent (). Data points represent the group mean and error bars 
represent standard error (A - B). Scale bars represent 100µm. Data points represent 
individual animals, and bars represent mean (wide line) and standard error (short lines) 






either serum biomarker. As such, the transcutaneous measurement was used as the primary 
measure of kidney function in all subsequent experiments.  
Figure 5.8: Correlation of three measures of kidney function (FITC-sinistrin clearance, 
SCr, BUN) with histological evaluation of tubular injury. Transcutaneous assessment of 
FITC-sinistrin clearance (A) showed strong positive correlation with histological 
evaluation of tubular injury (R2 = 0.88), whereas SCr (B) and BUN (C) both showed positive 




5.3.2 Assessing the Efficacy of Human Cells in the IRI model 
5.3.2.1 Four-day study 
The efficacy of three different types of human-derived cells, hKCs, hUC-MSCs, and hBM-
MSCs, was assessed in IRI mice, and compared with IRI mice that received saline. All 27 mice 
survived the four-day study, and lost a similar proportion of body weight throughout the 
experiment (Fig. 5.9A). There were no differences in body weight loss between any of the 
treatment groups (Supplementary Table S5.2A). Kidney function was assessed by 
transcutaneous measurement of FITC-sinistrin clearance at baseline, and days one, two, and 
four. All mice showed a significant increase in FITC-sinistrin half-life at day one compared 
with baseline, which decreased back towards baseline levels at days two and four (Fig. 5.9B). 
However, there were no significant differences between treatment groups at any time point 
(Supplementary Table S5.2B). The degree of improvement in FITC-sinistrin clearance was also 
assessed, to determine whether cell-treated mice recovered faster than saline-treated mice, 
but there were no significant differences in the percentage of improvement between days 
one and two (Fig. 5.9C). SCr and BUN measured at the end of the experiment on day four 
were comparable in all treatment groups (SCr: Fig. 5.9D; one-way ANOVA, p = 0.501. BUN: 
Fig. 5.9E; one-way ANOVA, p = 0.936). To assess whether cell therapy had an effect on tissue 
injury and repair biomarkers, KIM-1 and Ki67 tissue expression were analysed. The 
percentage of KIM-1-positive area and the number of Ki67-positive cells were comparable in 
all treatment groups (SCr: Fig. 5.10A; one-way ANOVA, p = 0.772. BUN: Fig.5.10B; one-way 
ANOVA, p = 0.055), indicating that cell therapy had no effect on tubular cell injury or repair. 
5.3.2.2 One-day study 
The results of the four-day study suggested that none of the three cell types tested had any 
efficacy in improving kidney function in IRI mice. It was unclear whether this may have been 
due to an inability of the transcutaneous measurement to detect amelioration, and the late 
time point (day four) for detecting differences in serum biomarkers. In the IRI model, SCr and 
BUN tend to peak at day one, so a one-day study was carried out to compare the efficacy of 
hKCs with saline. Moreover, ZsGreen+/luciferase+ hKCs were administered in this study, and 
their biodistribution in vivo was assessed with BLI.  
As expected, hKCs were restricted to the lungs following IV administration (Fig. 5.11A) and 
there was no bioluminescence signal from mice that received saline (Fig. 5.11B). 




Figure 5.9: Efficacy of different types of human cells in the IRI model. (A) Mean body weight change of mice declined at approximately the same rate 
in all groups. (B) FITC-sinistrin half-life increased significantly over baseline levels at day 1 in all groups, and then decreased back towards baseline 
levels at days 2 and 4. There were no significant differences between treatment groups at any time point. The percentage of improvement in half-life 
between days 1 and 2 (C), and serum biomarkers at day 4 SCr (D) and BUN (E) were not significantly different between any treatment group. Data 
points represent the group mean and error bars represent standard error (A - B). Data points represent individual animals, and bars represent mean 




cell administration (Fig. 5.11A, C; paired t-test, p = 0.598). Furthermore, there were no 
significant differences in serum biomarkers at day 1 (SCr: Fig. 5.11D, two-sample t-test, p = 
0.096; BUN: Fig. 5.11E, two-sample t-test, p = 0.564). 
 
5.4 Discussion 
The overall aim of this chapter was to compare the efficacy of several cell types in a clinically-
relevant model of AKI. Initial pilot studies were carried out to decide whether to set up a 
bilateral or unilateral model of IRI, and the duration of ischemia was then optimised in the 
unilateral with Nx model before the therapeutic efficacy of three different cell types was 
investigated. The key findings were as follows: 
(i) Bilateral ischemia induced less severe injury than unilateral ischemia (with Nx) with 
comparable clamp times, however the injury induced in each kidney was highly 
variable. 
(ii) unilateral ischemia with contralateral nephrectomy after 31 minutes clamp time 
induced renal injury that was severe but survivable, with acceptable weight loss. 
(iii) The transcutaneous measurement of FITC-sinistrin clearance was a superior measure 
of kidney function in the IRI model, correlating with histological damage more 
strongly than either SCr or BUN. 
(iv) None of the cell types assessed in this model had any effect on kidney function or 
injury. 
Figure 5.10: Expression of tissue biomarkers of injury and repair following cell therapy. 
There were no significant differences in tissue expression of KIM-1 (A) or Ki67 (B) between 
any of the treatment groups. Data points represent individual animals, and bars represent 






Figure 5.11: Short-term cell tracking and efficacy of hKCs. Representative 
bioluminescence images of a hKC-treated (A) and a saline-treated (B) mouse immediately 
after cell/saline administration (day 0) and at day 1. Unexpectedly, bioluminescence 
signals persisted at the same intensity 24h after administration (C). Bars represent the 
group mean, error bars represent standard error. There were no significant differences in 
SCr (D) or BUN (E) between hKC- and saline-treated mice at day 1 Data points represent 




(v) hKCs remained in the lungs 24h following IV administration, which was an 
unexpected finding based on previous results, and may offer an insight into why the 
tested cell types had no ameliorative effect.  
Establishing the IRI model by unilateral clamping with contralateral Nx 
Several variables in the IRI model were decided upon before pilot studies began and were 
not modified throughout the experiments. These included the age, strain, and sex of the 
mice, surgical approach, and anaesthetic agent. Young adult male mice are commonly used 
in the IRI model and were chosen due to their increased susceptibility to renal injury over 
female mice. Whilst C57BL/6 mice are more commonly used in other studies, BALB/c mice 
were chosen here due to our familiarity with this strain, our preference for white mice for 
imaging experiments, and no need to genetically manipulate the mice. A dorsal surgical 
approach was chosen for its reported superiority in improving recovery and survival and 
reducing the risk of dehydration and infection, compared with the ventral approach. 
Isoflurane, an inhalation anaesthetic, is reported to exert a protective effect on the kidney, 
but was deemed preferable to injection anaesthetics (which are not renoprotective) due to 
faster recovery times and the ability to tune the depth of anaesthesia with isoflurane. The 
reason that many other groups choose injectable anaesthetics for the IRI model is likely due 
to the ability to perform surgery on multiple animals at once, which is difficult with inhalation 
anaesthetics due to the need for extra equipment (nosecones etc.). To overcome this 
problem, we commissioned the design of a multi-way nosecone system, which allowed 
surgery to be performed on four animals at once. 
Although not described in this thesis, many optimisation studies were carried out between 
the initial pilot studies and the final study characterising the injury induced with 31 min 
ischemia. These numerous studies taught many lessons about the IRI model, and its 
sensitivities to varying experimental conditions.  
First, it was not feasible to collect urine for biomarker analysis. Because of license restrictions 
it was not possible to use metabolic cages for 24h urine collection at multiple time points 
within a four-day post-surgery time frame. An alternative method of placing mice on 
hydrophobic sand was therefore tested, although this was associated with several problems, 
including the need to withhold food, accidentally collecting water that had dripped from the 
water bottle instead of urine, and mice not producing urine at all time points. Afternoon 
collections tended to yield a higher volume of urine than morning collections, however this 




mice that were more severely injured had not yet fully cleared FITC-sinistrin from their 
system, meaning that the urine collected was contaminated with FITC-sinistrin. This was a 
major problem for the quantification of urine creatinine, which was necessary for the 
normalisation of albumin and KIM-1 measurements, as the urine creatinine assay relied on a 
colorimetric measurement.   
Second, transcutaneous measurements were very well-tolerated by all mice after surgery. 
The incisions tended to be low enough that the transcutaneous device could be placed 
proximal to the sutures, and small sections of cotton swab could be used to protect the 
sutures from being pulled open by the adhesive plaster. The transcutaneous measurement 
of FITC-sinistrin clearance revealed greater changes in kidney function in the IRI model 
compared with the ADR model. The clearance curve showed a more drastic delay in clearance 
in IRI mice at day one (Supplementary Fig. S5.1) compared with week four in the ADR model 
(Fig. 3.2), where only a very subtle change in clearance could be observed in the clearance 
curve. Importantly, renal function as measured by transcutaneous measurement correlated 
much more strongly with histological assessment of renal damage than either SCr or BUN, 
indicating that this method is not only reliable, but that it is also superior to traditional 
measures of kidney function. Moreover, the transcutaneous measurement could identify 
mice that were likely in renal failure, by a lack of clearance of FITC-sinistrin during the 90-
minute measurement period (Supplementary Fig. S5.1C). Invariably, mice that showed an 
absence of FITC-sinistrin clearance at day one either died or did not improve at day two and 
had to be sacrificed early due to severe ill health and suspected renal failure. An interesting 
finding whilst carrying out baseline measurements in this model was that it was essential to 
shave mice prior to the first measurement. The half-life of FITC-sinistrin was significantly 
higher if the measurement was carried out on the day of shaving than if it was carried out 
two days later. This finding was exclusive to the male BALB/c mice used in the IRI model; it 
did not apply to the female SCID mice used in the ADR model.  
Third, the optimisation studies highlighted just how sensitive the IRI model is to subtle 
changes in temperature. As shown in Fig. 5.4, and in numerous published studies360,362,363, a 
slight decrease in temperature during surgery protects the kidney from injury. Initial 
experiments with the IRI model were carried out using a single large heat mat for all mice 
undergoing surgery, however the heat was not well-distributed across the mat, and surgeries 
carried out using this heat mat lead to variable responses in kidney injury. Subsequently, the 
single heat mat was switched for individual infrared feedback-loop heat mats, which 




temperature, leading to more consistent renal injury. An additional observation not 
described in this chapter was the effect of the kidney’s location during ischemia. The kidney 
was initially placed under the skin during the period of ischemia, but in the initial studies the 
kidney did not always reperfuse very well following the release of the clamp, and it was 
thought that the manipulation of the clamped kidney to place it under the skin may have 
been causing damage to the vasculature. As such, an alternative method of keeping the 
kidney out of the body but covered in saline-soaked swabs to prevent drying was tried. This 
of course led to the kidney being too cool during ischemia, and led to low levels of renal 
injury. Further optimisations regarding temperature control included waiting until the 
mouse’s body temperature was up to 37°C before starting surgery, and standardising the 
time spent recovering in the heat box after surgery to 30 minutes.  
Ultimately, an ischemia time of 31 minutes was optimised for the experimental conditions 
imposed in our laboratory, and was influenced by: 
(i) the strain, age, and sex of mice,  
(ii) the choice of isoflurane to anaesthetise the mice,  
(iii) the hydration status of mice during morning surgery, which is likely to be greater 
than if surgery was carried out in the afternoon, and is also influenced by the choice 
of dorsal surgical approach, and the volume of fluids given before surgery, and 
finally, 
(iv) the temperature, including core body temperature during surgery, temperature of 
the heat box during the initial period of recovery, and ambient temperature at which 
mice are maintained post-surgery. 
Assessing efficacy of human cells in the IRI model 
Following optimisation of the IRI model, the efficacy of three cell types, hKCs, hUC-MSCs, and 
hBM-MSCs, was assessed. These cell types were chosen in order to determine whether there 
were any differences in the efficacy of (i) kidney derived cells compared with MSCs, and (ii) 
MSCs depending on the source of the tissue that MSCs were isolated from. Unexpectedly, 
none of the cell types showed any efficacy in the IRI model. Efficacy was predominantly 
assessed by transcutaneous measurement of FITC-sinistrin clearance as a measure of kidney 
function. This method was chosen as the primary outcome due to its superiority over SCr and 
BUN as a measure of kidney function, and its value in detecting ameliorative effects of hKCs 
in a rat model of cisplatin-induced AKI134. However, there were no significant differences in 




Moreover, there were no significant differences between the treatment groups in body 
weight loss, as a measure of general health, or in the serum and tissue biomarkers analysed 
at the end of the study on day four. Tissue KIM-1 expression demonstrated that there were 
no differences in tubular injury, and tissue Ki67 expression showed that there was no 
difference in tubular cell proliferation, and therefore renal recovery, between any of the cell-
treated groups and the saline-treated group.  
To explain the lack of efficacy observed, the initial hypothesis included the following 
arguments: (i) the transcutaneous measurement was unable to detect kidney repair in the 
IRI model as it had not been reported before in this AKI model; (ii) the day four time point 
was too late to detect any differences in SCr and BUN. 
The levels of these serum biomarkers tend to peak at day one to two and then decrease at 
later time points110,118,352,356,357, and as such any differences between treatment groups may 
have been evident at an earlier time point, but undetectable by day four. However, in an 
additional experiment analysing day one biomarkers, the values of SCr and BUN were still not 
significantly different between treatment groups.  
An additional feature of the one-day study was the inclusion of bioluminescence imaging to 
track the in vivo biodistribution of ZsGreen+/luciferase+ hKCs. As expected, the 
bioluminescence signal was restricted to the lungs on the day of IV administration of hKCs, 
indicating that the cells were trapped in the lungs. However, 24h later the bioluminescence 
signal remained present in the lungs, but was not detectable in the kidney or any other organ. 
This was an unexpected result since it was assumed that the bioluminescence signal would 
decrease within 24h of cell administration, in line with previous results from this thesis (Fig. 
4.3A, 4.8A, 6.6A) and our general experience of imaging the biodistribution of various cell 
types. Surprisingly, the intensity of the bioluminescence signal persisted at approximately 
similar levels or even increased slightly, suggesting that the cells did not undergo cell death 
as usually occurs following in vivo administration, and possibly even proliferated. An 
explanation for the increase in bioluminescence signal in these mice could be a slight loss of 
body mass between day zero and day one, resulting in the appearance of a stronger 
bioluminescence signal; however, further studies to assess any proliferation of the cells 
would be required to determine this. 
Studies have shown that intravenously administered cells become trapped in the lungs due 
to their large size physically entrapping them in small pulmonary capillaries349,350, and also 




(VCAM-1)349, integrins369,370, and possibly also fibronectin370. It is also known that the cells do 
not persist in the lungs for very long after administration, with a half-life of about 24h371. This 
is supported by other studies in this thesis, which have shown that weak bioluminescence 
signals persist for several days following IV administration (Fig. 4.3A, 4.8A, 6.6A), suggesting 
that small numbers of cells do survive in the lungs for up to one week (Fig. 4.8A), however 
the vast majority of cells die very quickly following cell administration. Furthermore, 
Santeramo and colleagues have shown evidence of hKCs undergoing cell death in the lungs 
from as early as one hour following IV administration in a rat model of cisplatin-induced 
AKI134. However, it is not known what mechanisms initiate cell death, nor why the cells 
survived in the lungs of IRI mice for 24h after administration in the study described in this 
chapter. 
It is widely known that ischemic AKI is not a disease restricted to the kidney, and in fact causes 
widespread effects on distant organs372-375. Patients with AKI may suffer consequences to the 
lungs, heart, liver, and brain, and it is thought that the accumulation of deleterious effects 
on multiple organs may actually be responsible for the very high morbidity and mortality 
levels in patients with AKI372,373. In particular, renal IRI is known to cause injury to the lung376, 
and this may provide insights into the reason why the hKCs did not die following IV 
administration to mice with renal IRI, and further insights into the mechanism of action of 
cell therapy in vivo.  
Clinically, respiratory failure is a common complication in AKI patients377,378, and conversely, 
AKI is frequently diagnosed in patients requiring mechanical ventilation or following a lung 
transplantation379-381. Experimentally, AKI-associated acute lung injury (ALI) can be induced 
following renal IRI, however it is unclear whether ALI is a consequence of renal failure itself, 
or specifically the damage induced by ischemia. One research group has demonstrated that 
renal failure without ischemia, modelled by bilateral nephrectomy, resulted in negligible lung 
injury224,382,383, whereas another group has reported similar severities of ALI following both 
30 minutes bilateral IRI and bilateral nephrectomy384. This difference could be due to the 
different parameters of ALI measured by each group. A recent review on AKI-associated ALI 
suggested that the release of cytokines, inflammatory mediators, and products of cell death 
following ischemia may act to directly damage the lung endothelium to cause non-
cardiogenic ALI (pulmonary oedema as a result of direct damage to lung endothelium), 
whereas the systemic accumulation of uremic products and subsequent fluid accumulation 





Experimental data has demonstrated that renal IRI in rodents causes apoptosis of pulmonary 
endothelial, but not epithelial, cells, leading to microvascular dysfunction and subsequent 
increased pulmonary vascular permeability and pulmonary oedema224,383,385. Immune cells 
such as T cells386, neutrophils387, and macrophages388, in addition to various serum 
cytokines384,387,389,390, also play a role in the complicated pathogenesis of AKI-associated ALI.  
To the best of our knowledge, lung injury following renal IRI has not previously been reported 
to promote the survival of intravenously administered cells. However, BLI has been used in 
two publications to monitor the biodistribution of MSCs in mice with ALI, induced either by 
smoke inhalation injury279 or intranasal endotoxin administration280. Both studies showed 
greater bioluminescence signals in mice with ALI compared with healthy controls. However, 
the mechanism behind the survival of the cells is still unclear. One hypothesis could be that 
healthy pulmonary endothelial cells induce the death of cells that come into contact with 
their apical surface. This may occur via contact with a death receptor such as the Fas ligand 
(FasL), which is constitutively expressed on the pulmonary endothelium and initiates 
apoptosis in cells expressing Fas391,392. Gordon et al., (2007) have shown that activation of the 
Fas-FasL apoptosis pathway was involved in the lung clearance of pulmonary metastases, and 
that dysregulation of this pathway permitted osteosarcoma cells to persist and grow in the 
lungs392. The Fas-FasL apoptosis pathway may explain why intravenously administered cells 
undergo cell death soon after in vivo administration and do not persist in high numbers in 
the lungs, but it is not definitively known whether the hKCs administered in the studies 
described in this chapter express Fas. Fas is a cell surface protein belonging to the TNF 
receptor family, and is ubiquitously expressed in the body, with high abundance in the 
kidney, as well as the thymus, liver, and heart393. As such, it may be likely that hKCs express 
Fas, and that the Fas-FasL apoptosis pathway is activated when these cells are delivered to 
the lungs following IV administration, leading to rapid cell death. However, when the 
pulmonary endothelium is damaged, it may not be possible for the endothelial cells to carry 
out such a function of inducing the death of exogenously administered cells. Furthermore, 
the breakdown of the endothelial barrier leads to extravasation of fluid and, presumably, 
exogenously administered cells, into the interstitium, where the death of these cells may be 
less likely to be initiated. 
It has been suggested that the process of cell death stimulates anti-inflammatory cytokines 
to inhibit inflammation and reduce injury134,394-396, the so-called ‘dying stem cell 
hypothesis’394, and that death of the pulmonary-entrapped cells may therefore play a key 




et al., (2017) demonstrated the role of macrophages in clearing apoptotic debris from dead 
hKCs in the lungs, and showed that the infiltrating macrophages secreted the anti-
inflammatory cytokine, IL-10134. This hypothesis is supported by the fact that microvesicles 
derived from MSCs have been shown to improve organ function in a wide range of disease 
models397, including the kidney398. However, in contrast, the administration of apoptotic 
thymocytes to mice with ischemic IRI significantly worsened kidney function399, suggesting 
that the factors released by different cell types may have different effects on kidney injury. 
The results of this chapter, showing no efficacy of cell therapy on kidney injury alongside a 
lack of cell death in the lungs, may potentially support this hypothesis, as it suggests that cell 
death may be necessary for efficacy. However, it is unknown if the lack of efficacy of cell 
therapy in this chapter was due to the absence of cell death, or instead due to some other 
cause. The cell death hypothesis has not yet been widely investigated, and as such further 
work is required to elucidate the role of cell death in the ameliorative effect of cell therapies. 
These results open up a multitude of questions for further experimental investigation 
regarding the mechanisms behind the survival of hKCs in the IRI model, but not in healthy 
animals or the ADR model, and subsequently, the mechanisms behind cell efficacy in kidney 
injury. Important questions that should be addressed include: 
1. Is the survival of hKCs a direct consequence of lung injury induced by renal IRI? 
2. Is the survival of hKCs the reason for their lack of efficacy in improving kidney 
function and injury?  
a. If so, why do the cells need to die in order to have a beneficial effect?  
b. Will administering the cells before the onset or after the peak of lung injury 
lead to increased cell death and therefore improved efficacy?  
c. If the severity of renal injury, and therefore the severity of ALI, is reduced, 
will the cells have a greater ameliorative effect?  
3. Do hUC-MSCs and hBM-MSCs also survive in the lungs, and is that the reason why 
they also had no beneficial effect on kidney function or injury? 
4. If the cells need to die in order to have a beneficial effect on the kidney, and if they 
cannot die in the lungs of mice with ischemic AKI due to ALI, then why are there so 
many other papers that report beneficial effects of various cell types in models of 
IRI? What is different about the model described in this chapter that leads to such 




In summary, the results presented in this chapter identified the unilateral ischemia with 
nephrectomy model as a preferable model of renal IRI over the bilateral model, due to 
reduced variability, and an ischemia time of 31 minutes was optimised for the particular 
experimental conditions imposed in our laboratory. The results showed that the 
transcutaneous measurement of FITC-sinistrin was an appropriate and reliable method of 
measuring kidney function in the IRI model, with superior correlation with histological 
tubular injury compared with SCr and BUN. Importantly, the results demonstrated that hKCs 
administered to mice following reperfusion persisted in the lungs for at least 24h following 
administration, and this may be associated with the lack of amelioration of kidney injury. 
Further investigation is required to dissect out the mechanisms behind cell survival, and to 
determine what modifications to the therapy protocol would be required in order to achieve 
an ameliorative effect.  
5.5 Supplementary Figures and Tables 
 
A 
Body Weight Change (%) 
n Mean Grouping 
Day 0 
(Baseline) 
31 min IRI 5 0.00 A         
Sham 5 0.00 A         
Day 1 
31 min IRI 5 -3.51 A B       
Sham 5 -3.16 A B       
Day 2 
31 min IRI 5 -11.13     C D   
Sham 5 -7.45   B C     
Day 3 
31 min IRI 5 -15.00       D   
Sham 5 -5.30 A B C     
Day 4 
31 min IRI 5 -16.70       D   
Sham 5 -4.41 A B       
         
B 
 FITC-sinistrin half-life (min) 
n Mean Grouping 
Day 0 
(Baseline) 
31 min IRI 5 9.23       D   
Sham 5 9.09       D   
Day 1 
31 min IRI 5 49.11 A         
Sham 5 12.99     C D   
Day 2 
31 min IRI 5 30.33   B       
Sham 5 11.14     C D   
Day 4 
31 min IRI 5 17.88     C     
Sham 5 12.47     C D   







Body Weight Change (%)  B 
FITC-sinistrin half-life (min) 
n Mean Grouping  n Mean Grouping 
Day 0 
IRI + hKCs 6 0.00 A            
Day 0 
IRI + hKCs 6 9.86       D   
IRI + hUC-MSCs 6 0.00 A            IRI + hUC-MSCs 6 9.35       D   
IRI + hBM-MSCs 6 0.00 A            IRI + hBM-MSCs 6 9.54       D   
IRI + saline 9 0.00 A            IRI + saline 9 9.54       D   
Day 1 
IRI + hKCs 6 -6.81 A B C        
Day 1 
IRI + hKCs 6 55.76 A B C     
IRI + hUC-MSCs 6 -7.64 A B C D      IRI + hUC-MSCs 6 75.69 A         
IRI + hBM-MSCs 6 -6.58 A B          IRI + hBM-MSCs 6 45.88 A B C     
IRI + saline 9 -6.63 A B          IRI + saline 9 64.75 A B       
Day 2 
IRI + hKCs 6 -12.01   B C D E    
Day 2 
IRI + hKCs 6 42.34 A B C D   
IRI + hUC-MSCs 6 -15.88   B C D E F  IRI + hUC-MSCs 6 51.64 A B C     
IRI + hBM-MSCs 6 -13.86   B C D E F  IRI + hBM-MSCs 6 35.71   B C D   
IRI + saline 9 -14.59   B C D E F  IRI + saline 9 47.00 A B C     
Day 3 
IRI + hKCs 6 -17.41     C D E F  
Day 4 
IRI + hKCs 6 20.08     C D   
IRI + hUC-MSCs 6 -22.84           F  IRI + hUC-MSCs 6 25.38     C D   
IRI + hBM-MSCs 6 -16.18   B C D E F  IRI + hBM-MSCs 6 19.83     C D   
IRI + saline 9 -20.09         E F  IRI + saline 9 23.17     C D   
Day 4 
IRI + hKCs 6 -18.13     C D E F             
IRI + hUC-MSCs 6 -22.49       D E F           
IRI + hBM-MSCs 6 -17.44     C D E F           
IRI + saline 9 -18.92         E F           





Supplementary Figure S5.1: Example FITC-sinistrin clearance curves. (A) Baseline 
measurement, showing that the fluorescence levels returned to baseline within the 
measurement period, indicating that FITC-sinistrin was completely cleared from the 
system quickly (t1/2 = 8.41 min). (B) Clearance curve of the same mouse in (A), one day 
after IRI surgery. The clearance was much slower in the injured mouse, and fluorescence 
levels did not return to baseline within the measurement period (t1/2 = 94.04 min). (C) 
Clearance curve from a severely injured mouse one day after IRI surgery. There was no 
clearance of FITC-sinistrin during the measurement period, indicating complete renal 
failure. As there was no clearance, it was not possible to calculate an accurate half-life. 
Black data points represent raw data, blue lines represent the 3-compartment fit, and 











Preclinical imaging approaches for assessing the short- and long-term 





6.1 Introduction  
Regenerative medicine therapies have great potential to treat, and possibly cure, many 
different diseases and as such have gained considerable attention in recent years by 
scientists, medical professionals, and also the general public. Despite extensive research into 
the efficacy of various stem cell therapies for a wide range of health conditions, including but 
not limited to diabetes mellitus400, neurodegenerative disorders401, spinal cord injury402, 
human immunodeficiency virus (HIV)403 and diseases of the kidney342,343,404, liver405, heart406, 
and eye407, there are currently only three fully-approved stem cell therapies available to 
patients: 1) blood stem cells for the treatment of blood disorders/cancers, 2) s stem cells to 
produce grafts for burn victims, and 3) limbal stem cells for corneal replacement88. 
A major hurdle in the clinical translation of RMTs is a lack of robust safety data. While the 
efficacy of cell therapies is frequently investigated preclinically, the long-term safety of these 
therapies is often neglected. The primary concerns for the safe use of cell-based medicinal 
products in humans include90-92: 
1. Biodistribution – it is important to know where the cells go once they are 
administered to the patient, for example if they remain in the intended organ in the 
case of local administration, or if they are able to migrate to the target organ 
following systemic administration. It is also vital to know if cells migrate to non-target 
organs. 
2. Tumourigenicity – PSC-based therapies in particular have a risk of tumour formation 
if the cell product is contaminated with undifferentiated cells, or if the cells de-
differentiate back to a pluripotent state. 
3. Immunogenicity – allogeneic stem cells may evoke an immune response in the 
recipient, leading to graft rejection, or alternatively, transplanted cells may mount 
an immune response against the host, leading to graft-versus-host disease. 
Moreover, autologous stem cells may have the capacity to elicit an immune response 
following epigenetic changes during culture. 
It is vitally important to carry out extensive safety studies prior to clinical translation of a 
therapy, as severe complications in clinical trials not only endanger lives, but also negatively 
impact public confidence in stem cell therapies and hinder the overall progress in the 
development of regenerative medicine therapies. Recently, the fatal outcomes of tracheal 
transplants, which were performed in humans without adequate preclinical assessment of 




Traditionally, safety concerns would be investigated by sacrificing large numbers of animals 
at various time points, in order to analyse tissues ex vivo. This approach does not permit the 
responses of individual animals to be monitored over time, and may not allow for off-target 
effects to be detected in unexpected locations in the body. Alternatively, in vivo imaging is 
becoming more widely used in preclinical research. Administered cells can be tracked in vivo 
in a minimally invasive manner, allowing various parameters involving the biodistribution, 
tumourigenicity, and immunogenicity of cells to be monitored longitudinally in individual 
animals. 
In order to track cells in vivo, they must first be labelled in a manner appropriate for the 
intended imaging modality and required length of tracking time. Generally, cell labels can be 
split into two categories: (1) Genetic reporters, which require the genetic modification of 
cells to introduce reporter genes encoding proteins which generate signals either 
constitutively or following interaction with a substrate260,266,411; (2) Cell probes, which are 
small particles such as paramagnetic agents, nanoparticles, radionuclides, or fluorophores, 
which are taken up by the cells260,411,412. Each cell label has unique characteristics which will 
be ideally suited to only one or possibly two imaging modalities. While cell probes often 
provide a high signal-to-noise ratio, they suffer from the disadvantage that it is the probe, 
and not the cell which is being imaged, thus raising the possibility for false-positive detection 
if the labelled cell dies and the released probes are taken up by host cells412-414. Moreover, 
the probes will be divided between daughter cells during cell division, leading to signal 
dilution in proliferating cells411,412,414. On the other hand, genetic reporters are only expressed 
while the cell is alive and the reporter gene is passed on to daughter cells, making them useful 
for long-term tracking and tumour monitoring411,415-417. 
The two cell labels employed for cell tracking in this chapter are the bioluminescence 
reporter gene, firefly luciferase, and SPIONs, which are cell probes used in MRI. There are 
several different luciferases used in bioluminescence imaging, including firefly luciferase 
(Photinus pyralis, FLuc), Renilla luciferase (Renilla reniformis, RLuc), and Gaussia luciferase 
(Gaussia princeps, GLuc)265,266. Genes encoding the transcription of luciferase enzymes are 
introduced into the genome of the cell of interest, which can then be administered to the 
animal and tracked in vivo with bioluminescence imaging. The luciferase enzyme catalyses 
the oxidation of an exogenously administered substrate, resulting in light production. In the 
case of FLuc, the substrate is luciferin, and the oxidation process also requires ATP, 
magnesium ions, and oxygen265,266. Thus, only living cells are able to produce light, making 




Gaussia luciferases use the substrate coelenterazine, which does not require ATP, and thus 
permits imaging of extracellular biological processes265,266. FLuc is the most commonly used 
luciferase for BLI, largely due to its brightness, and the ease with which luciferin is handled. 
Luciferin can be administered intraperitoneally or subcutaneously, and has ‘slow glow’ 
kinetics, reaching peak light emission 10 - 15 minutes after administration and persisting in 
the body for some time, eventually being cleared around two hours after administration266. 
Coelenterazine, however, has very fast ‘flash’ kinetics and is rapidly cleared from the animal, 
and must be administered intravenously. This is technically more challenging, and limits 
imaging to just one animal at a time. Moreover, coelenterazine is prone to air oxidation, 
leading to non-specific background signals around the site of injection. Finally, each luciferase 
emits light at a characteristic wavelength: RLuc and GLuc emit blue/green light at around 
480nm, which is readily absorbed by endogenous chromophores such as haemoglobin, fat, 
and melanin, thus reducing the amount of light that can reach the detector, whereas FLuc 
emits red-shifted light at 562nm, which is less absorbed by endogenous chromophores, thus 
resulting in stronger signal detection of FLuc265,266.  
SPIONs are clinically-available contrast agents that were originally developed to enhance the 
contrast of organs for MRI, but have since been applied to cell tracking purposes412. 
Paramagnetic and superparamagnetic materials only become magnetised when placed in an 
external magnetic field, where they then disturb the local magnetic field homogeneity412. 
Paramagnetic agents, such as gadolinium, contain a metal lanthanide complex which alters 
the T1 (longitudinal) relaxation time of surrounding water protons, producing a bright, 
positive signal, whereas superparamagnetic agents contain an iron oxide core less than 20nm 
in diameter, and alter the T2 (transverse) relaxation time, producing dark negative contrast 
(loss of signal)292,412. Protocols for synthesising SPIONs are now well-established, and as they 
are also highly sensitive, biocompatible, and exhibit higher paramagnetism than T1 agents, 
SPIONs are now commonly used in preclinical cell tracking292. Cell labelling with SPIONs is 
very easy, simply requiring incubation in the cell culture media for 24 hours before 
administration to the animals293. 
The combination of firefly luciferase and SPIONs for cell tracking allows more information to 
be gained from a single animal. Luciferase cell tracking by BLI permits fast, whole body 
imaging and allows the assessment of cell survival, however the spatial resolution is poor, 
and inter- and intra-organ biodistribution cannot be assessed in vivo. SPION cell tracking by 
MRI provides images at higher spatial resolution with unlimited penetration depth, providing 




however MRI takes longer to perform for each animal, and is not suited for long-term 
tracking. Therefore, by employing a multi-modal imaging approach using two 
complementary imaging strategies, more data can be obtained than is possible with a single 
modality: high resolution, organ-specific biodistribution of cells with MRI, and longitudinal 
whole body assessment of cell survival with BLI.  
Various aspects of the safety of stem cells may differ not only with the stem cell type, but 
also with the route by which the cells are administered. The most common route of systemic 
administration of stem cell therapies in experimental animals is intravenous404. However, as 
discussed in Chapter 4, this injection route delivers cells via the venous circulation directly to 
the lungs where they become trapped as consequence of the pulmonary first-pass 
effect111,134,267,349-351,371. Despite the lack of renal engraftment of administered cells following 
IV administration, preclinical efficacy studies largely report therapeutic effects of cell 
therapies for ameliorating kidney injury89,105,110,111,139,145,352,353, suggesting a paracrine or 
endocrine role in efficacy. However, it is possible that delivery of cells to the kidneys may 
result in improved efficacy superior to that achieved by paracrine mechanisms alone. In such 
circumstances, it would be necessary to deliver cells to the kidney, and while direct 
administration to the renal artery is a commonly used method in rats and other large 
mammals111,127,418, this is not feasible in mice due to the small diameter of the renal artery. 
Alternatively, administration into the carotid artery is sometimes reported in mice267, 
however this method is invasive as it requires surgery. However, intracardiac (IC) 
administration provides a viable, less-invasive method of delivering cells to the kidneys in 
experimental mouse models. By administering cells directly to the left ventricle of the heart, 
cells will travel through the arterial circulation, passing through all organs of the body, 
including the kidneys, before entering the venous circulation and reaching the lungs. The IC 
administration route therefore permits cells to be delivered to the kidneys in mice, without 
the use of invasive surgical techniques. However, the IC administration route also delivers 
cells to all other organs of the body, and as such may pose a higher safety risk compared with 
IV administration which restricts cells to just one organ, the lungs. It is necessary to carry out 
comprehensive preclinical safety assessments using the most clinically-relevant 
administration route. While intracardiac administration is not intended to be used in 






This chapter utilises in vivo imaging strategies in order to address the following aims: 
1. Optimise an ultrasound-guided method of intracardiac cell administration in order 
to facilitate cell delivery to the kidneys 
2. Fully characterise cell delivery to the kidneys following intracardiac administration 
and compare with intravenous administration 
3. Compare the effect of administration route on the long-term safety of cell 
administration 
 
6.2 Experimental Design 
Optimising Intracardiac Cell Administration 
Three different methods of performing intracardiac cell administration (of 5.0 x105 
ZsGreen+/luciferase+ mKSCs in 100μl) were trialled in BALB/c mice: via the diaphragm, via the 
intercostal space, and ultrasound-guided. Success was assessed by BLI of the luciferase+ cells 
to determine if cells were correctly administered to the left ventricle and by evaluating the 
well-being of animals following IC injection.  
Comparing the immediate biodistribution of cells following IV and IC administration routes 
The biodistribution of ZsGreen+/luciferase+ mouse- and human-derived cells (mMSC, mKSC, 
hMSC, hKC) were each compared following IV and IC administration to BALB/c mice by BLI. 
Mice were culled on the day of cell administration and organs imaged ex vivo. 
Evaluating cell delivery to the kidney 
Increasing doses of 1.0 x105 – 1.0 x106 ZsGreen+/luciferase+ mKSCs were administered to 
BALB/c mice (1.0 x105, n = 2; 2.0 x105, n = 3; 4.0 x105, n = 3; 5.0 x105, n = 6; 6.0 x105, n = 5; 
and 1.0 x106, n = 3). Biodistribution of cells was assessed in vivo by BLI, and ex vivo by BLI of 
organs and analysis of ZsGreen reporter gene expression by fluorescence microscopy of 
frozen kidney sections. Ex vivo analyses were performed on mice sacrificed on the day of cell 
administration. 
MR imaging of cell biodistribution to the kidneys and brain 
1.0 x106 ZsGreen+/luciferase+/SPION+ mMSCs were administered to BALB/c SCID mice (IC, n 
= 2; IV, n = 2). BLI and MR imaging of the abdomen (kidneys) and brain were performed at 
baseline and immediately after cell administration. Mice were culled after imaging and 




1.0 x106 ZsGreen+/luciferase+/SPION+ mMSCs were administered to BALB/c SCID mice (IC, n 
= 5). BLI and MR imaging of the abdomen were performed at baseline (MRI only), and 0h, 
24h, 48h after cell administration. At least one mouse was culled at each time point for ex 
vivo imaging and histological evaluation of tissues.  
Long-Term Bioluminescence Imaging 
1.0 x106 ZsGreen+/luciferase+ mMSCs were administered to BALB/c SCID mice (IV, n = 3; or IC, 
n = 5), and to immunocompetent BALB/c, FVB, and MF1 mice (IC, n = 4). The biodistribution 
of the cells was monitored regularly by BLI up to day 30. At day 30, mice were sacrificed, and 
organs and any identifiable tumours were imaged ex vivo.  
To facilitate the comparison of bioluminescence images displaying different signal intensity 
scales throughout the longitudinal study, different coloured frames have been used to 
indicate the different scale ranges required to display bioluminescence signals of different 
intensities (Table 6.1).  
Table 6.1: Table of different bioluminescence scales used. 
Scale (p/s/cm2/sr) Use Frame colour 
1.0 x104 – 1.0 x105 Lower scale, used to display weaker signals Blue 
1.0 x105 – 1.0 x106 
Standard scale required for signals on the day of 
administration 
Green 
1.0 x107 – 1.0 x108 Higher scale, used to display stronger signals Orange 
1.0 x108 – 1.0 x109 Very high scale, used to display very strong signals Red 
 
6.3 Results 
6.3.1 Optimising Intracardiac Cell Administration 
In order to facilitate cell delivery to the kidneys, three methods of intracardiac cell 
administration were trialled. The first method attempted to ‘blindly’ administer cells into the 
left ventricle, via the diaphragm in a similar manner to the widely used cardiac puncture for 
terminal blood collection. This method was found to be highly inaccurate, as it was 
impossible to determine whether the needle was in the heart before cells were administered. 
The second method, described by Campbell et al. (2012), delivered cells to the heart by 
measuring the approximate location of the left ventricle, and administering cells via the 
intercostal space419. This method was somewhat more successful, as the pulsatile entrance 




a ‘blind’ method, and was associated with a high degree of failure, both in terms of mis-
injections and mouse mortality.  
The third method was an ultrasound-guided method420,421, where the left ventricle of the 
heart was directly visualised by ultrasound (Fig. 2.4), and correct placement of the needle 
could be confirmed prior to administration of the cells (Fig. 2.4G). This method was found to 
be superior, and led to the completion of over 150 IC injections with a success rate of over 
90%, where ‘success’ was defined as the presence of a typical distribution of bioluminescence 
signal over the body of the mouse, with no signs of mis-injection into the right ventricle or 
chest cavity (Fig. 2.5), and the absence of side-effects to the well-being of the mouse. A 
detailed description of the fully optimised ultrasound-guided method is provided in Chapter 
2 (General Methods).  
It was possible for adverse effects to occur following IC administration of cells. The least 
severe side effect was a loss of balance which resulted in mice leaning to one side (usually 
the left) and walking in circles for some time, however this was recoverable and generally 
wore off after 30 minutes to one hour. More severe side effects included:  
(i) Hind limb paralysis, where the mouse lost complete function of the hind legs, 
and function generally did not return. This therefore negatively affected the 
welfare of the mouse, but was not lethal.  
(ii) ‘Spinning’, where the mouse would twist and spin very violently. Mice never 
recovered from this behaviour and so had to be sacrificed immediately if 
‘spinning’ was observed.  
(iii) Death.  
Generally, adverse effects were either observed immediately after the mice woke from 
anaesthesia, or developed over the first hour. While it was difficult to know the exact cause 
of adverse effects and death, the most likely causes were embolism resulting from clumped 
cells lodged in vessels, or damage to the heart during the injection, resulting in fatal blood 
loss. Careful cell preparation to avoid cell clumping, and a steady hand during the injection 
to avoid damaging the heart, appeared to improve the outcome. It was found that increasing 
the volume administered to 200µl, and thus decreasing the density of the cell solution, did 
not have any effect on the outcome with regards to adverse effects, and as such further cell 




6.3.2 Comparing the Biodistribution of Mouse and Human Cells Following IV and IC 
Administration Routes 
To compare the biodistribution of cells following different administration routes, both mouse 
and human mesenchymal/stromal and kidney-derived cells (ranging in diameter from 15 – 
25 μm) were administered to healthy mice either IC, by using ultrasound-guidance to inject 
into the left ventricle of the heart, or IV, by injecting via the tail vein. All cells had previously 
been transduced to genetically express the ZsGreen/luciferase reporter gene construct, 
allowing cell tracking in vivo by bioluminescence imaging of luciferase, and ex vivo by 
fluorescence microscopy of ZsGreen. Invariably, IV administration of cells resulted in 
bioluminescence signals restricted to the lungs (Fig. 6.1A), regardless of cell type or size. In 
contrast, IC administration resulted in a whole-body distribution of bioluminescence signals, 
with stronger signals in the head and kidney regions of the animals. This pattern of signal 
distribution was consistent between all cell types investigated (Fig. 6.1A). Ex vivo imaging of 
organs within one hour of cell administration confirmed that bioluminescence signals were 
only detected in the lungs of IV-administered mice, but could be detected in the lungs, 
kidneys, heart, liver, spleen, and brain of IC-administered mice (Fig. 6.1B). Quantification of 
organ-specific bioluminescence signals ex vivo confirmed that following IV administration,  
on average 98.51% of the signal (SE: 0.58, n = 3) was found in the lungs, while following IC 
administration, the bioluminescent signal was found in the lungs at a lower percentage 
(mean: 62.24%, SE: 6.33), and also in the kidneys (mean: 11.73%, SE: 2.52), heart (mean: 
1.66% SE: 0.45), liver (mean: 8.53%, SE: 1.44), spleen (mean: 7.17, SE: 1.01), and brain (mean: 
5.96%, SE: 0.91; n = 3; Fig. 6.1C). Histological examination of frozen sections of the same 
organs under fluorescence microscopy confirmed the presence of ZsGreen+ cells in all 
assessed organs after IC administration, but only in the lungs after IV (Fig. 6.2). 
6.3.3 Quantification of Labelled Cells in the Kidneys using Bioluminescence and Histology 
Next, a detailed analysis of the cell biodistribution within the kidneys was performed 
histologically. ZsGreen+ mKSCs were only found in the glomeruli; none were located in 
tubules or the interstitium (Fig. 6.2, 6.3A). To determine whether the cell dose affected the 
number of cells found in the kidney, the percentage of glomeruli that contained ZsGreen+ 
cells was calculated in both coronal and axial sections of kidneys following IC administration 
of increasing doses of mKSCs: 1.0 x105, n = 2; 2.0 x105, n = 3; 4.0 x105, n = 3; 5.0 x105, n = 6; 






Figure 6.1: Biodistribution of cells following intravenous or intracardiac administration 
of various cell types. (A) Bioluminescence imaging showed that regardless of the cell type 
or size, cells were always confined within the lungs after intravenous (IV) administration, 
but distributed throughout the body after intracardiac (IC) administration. From top: 1M 
mMSCs, average diameter (d) 15 µm, BLI scale 1.0 x105 – 1.0 x106 p/s/cm2/sr; 1M mKSCs, 
d = 17 µm, BLI scale 1.5 x105 – 1.5 x106 p/s/cm2/sr; 1M hMSCs, d = 24 µm, BLI scale 1.0 
x106 – 5.0 x106 p/s/cm2/sr; 300K hKCs, d = 25 µm, BLI scale 1.0 x105 – 1.0 x106 p/s/cm2/sr. 
(B) Ex vivo bioluminescence imaging of organs within 1h after administration of mKSCs in 
(A) confirmed the in vivo cell biodistribution. Clockwise from top right: kidneys (K), spleen 
(S), liver (Li), lungs (Lu), heart (H), brain (B). BLI scale: IV, 5.0 x105 – 5.0 x106 p/s/cm2/sr; 
IC, 5.0 x104 – 5.0 x105 p/s/cm2/sr. (C) Quantification of the bioluminescence signal of 
organs ex vivo. Bars represent the mean signal expressed per organ as a percentage of 






Figure 6.2: Tissue biodistribution of mKSCs following intravenous or intracardiac 
administration. Fluorescence microscopy confirmed the presence of ZsGreen+ mKSCs in 
organs. After IC administration, cells could be detected in the lungs (arrows), the glomeruli 
in kidneys, heart, liver, spleen, and brain (arrows). After IV administration, cells were only 
present in the lungs (arrows), and were absent from all other organs. Glomeruli within 










The analysis of an average of 119 glomeruli in coronal sections, and 70 glomeruli in axial 
sections, showed that the percentage of glomeruli containing ZsGreen+ mKSCs increased as 
the cell dose increased, and that there was no difference in the percentage of glomeruli 
containing ZsGreen+ mKSCs in either orientation, suggesting a homogenous spread of 
administered cells throughout the kidney (paired t-test, axial vs coronal: 1.0 x105, p = 0.704; 
2.0 x105, p = 0.484; 4.0 x105, p = 0.974; 5.0 x105, p = 0.615; 6.0 x105, p = 0.954). Importantly, 
the analysis demonstrated a strong correlation (R2 = 0.97) between the number of cells 
administered and the percentage of glomeruli containing ZsGreen+ mKSCs following IC 
administration (Fig. 6.3C). In addition, quantification showed that after IC administration of 
1.0 x106 mKSCs, on average 61% of glomeruli contained ZsGreen+ mKSCs (SE: 5.64, n = 3), in 
comparison to 0% after IV administration (SE: 0.00, n = 3) (data not shown). 
Further, the relationship between the number of cells administered IC to the animal, and the 
number of cells identified within the glomeruli, was assessed by categorising cell-containing 
glomeruli as having one cell, or two or more cells. This revealed that when 2.0 x105 or fewer 
cells were administered, the percentage of glomeruli containing one cell was equal to or less 
than the percentage containing multiple cells. However, when doses of 4.0 x105 or more cells 
were administered, the majority of cell-containing glomeruli had multiple cells, and the 
percentage of glomeruli that contained two or more cells increased as cell dose increased, 
while the percentage of glomeruli that contained just one cell remained at around 10% for 
all cell doses (Fig. 6.3D).  
Finally, to determine whether there was a relationship between the in vivo bioluminescence 
imaging of luciferase+ mKSCs, and the percentage of glomeruli that contained ZsGreen+ cells, 
an ROI was drawn around the region of the kidneys (Fig. 6.3E), and the bioluminescence 
signal was correlated with (1) the percentage of glomeruli that contained ZsGreen+ cells for 
 Figure 6.3: Quantification of ZsGreen+ mKSCs in kidneys and correlation with BLI. 
(A) ZsGreen+ mKSCs localised exclusively to the glomeruli (dashed circles) of the kidneys 
after IC administration. Scale bar represents 50µm. (B-C) Quantification of ZsGreen+ 
mKSCs within the kidneys showed similar distribution of glomeruli containing cells in 
both the coronal or axial sections (B), and thus indicated a homogenous spread of cells 
throughout the kidney. (C) There was a strong correlation (R2 = 0.97) between the 
number of administered cells and the % of glomeruli containing ZsGreen+ mKSCs. (D) 
When 200,000 or fewer cells were administered, most cell-containing glomeruli had only 
one cell, however when 400,000 or more cells were administered, most cell-containing 
glomeruli contained multiple cells. (E) Region of interest (ROI) drawn around the kidneys 
of an animal injected IC with ZsGreen+ mKSCs. The total flux (photons/second) for the 
ROI was quantified for each animal and correlated with the percentage of glomeruli 




each mouse (Fig 6.3F), and (2) with the number of cells administered IC to the mouse (Fig. 
6.3G). These analyses revealed a moderate positive correlation (R2 = 0.66 and 0.77 
respectively) for both relationships. 
6.3.4 MR Imaging to Track Cell Biodistribution Within the Kidneys and Brain at Higher Spatial 
Resolution 
BLI of luciferase+ cells indicated a whole-body biodistribution of cells following IC 
administration, however the poor spatial resolution of BLI meant that animals had to be 
sacrificed and organs dissected and imaged ex vivo in order for organ-specific signals to be 
evaluated. MRI has a much higher spatial resolution than BLI, in addition to unlimited 
penetration depth, enabling organ-specific imaging. To assess the intra-organ 
biodistribution, ZsGreen+/luciferase+/SPION+ mMSCs were administered IV or IC, and imaged 
in vivo with BLI and MRI. Additionally, MRI scans of the brain were performed to assess 
whether BLI signals in the head resulted from cells within the brain, or simply the meninges 
or blood vessels surrounding the brain. 
BLI revealed typical cell biodistribution following IV and IC administration respectively, with 
cells restricted to the lungs following IV administration, and dispersed throughout the whole 
body following IC administration (Fig. 6.4A). FLASH T2* MR imaging revealed hypointensive 
signals in the cortex of the kidneys, and homogenously throughout the brains of mice that 
received an IC administration of SPION-labelled cells (Fig. 6.4B). These hypointensive signals 
were not present in baseline images of the kidneys and brain, indicating that they resulted 
from the SPION-labelled cells. In contrast, hypointensive signals were not detected in the 
kidneys or brain of IV-injected mice, and post-administration images were comparable to 
baseline images (Fig. 6.4B), confirming that IV-administration does not deliver cells to the 
kidneys or the brain.  
Ex vivo MR imaging of organs could be performed at higher resolution than that in vivo, and 
confirmed the presence of hypointensive signals in the renal cortex and throughout the brain 
of IC-injected mice, but not IV-injected mice (Fig. 6.4C). Isolectin staining of the blood vessels 
in frozen brain sections showed that ZsGreen+ mMSCs were restricted to the lumen of blood 
vessels, and were never detected in the parenchyma of the brain (Fig. 6.4D), suggesting that 




Figure 6.4: in vivo and ex vivo tracking of ZsGreen+/Luciferase+/SPION+ mMSCs in the kidneys and brain following IC or IV administration. (A) 
Representative in vivo bioluminescence images of mice following IC (top) or IV (bottom) administration of 1x106 mMSCs. BLI scale 1.0 x105 – 1.0 x106 
p/s/cm2/sr. (B) in vivo FLASH T2* MR imaging of the kidneys and brain at baseline, and following IC or IV administration of mMSCs, showing 
hypointensive signals in the cortex of the kidney and throughout the brain following IC, but not IV administration of SPION+ mMSCs. (C) FLASH T2* 
MR imaging of the dissected kidney and brain could be performed at higher resolution. (D) isolectin staining of blood vessels in the brain, showing a 
ZsGreen+ cell within the lumen of a blood vessel in the brain. Scale bar represents 50μm. (E) Histological tracking of cells by fluorescence imaging of 




Histological tracking of the ZsGreen reporter gene by fluorescence microscopy, and the 
SPIONs by Prussian Blue staining of iron, showed that labelled cells were located in the 
glomeruli within kidneys. Co-localisation of ZsGreen and Prussian Blue signals confirmed that 
the SPIONs were located within the ZsGreen+ mMSCs, and that in vivo hypointensive signals 
were unlikely to result from false-positive detection of free SPIONs at this time point (Fig. 
6.4E).  
6.3.5 Longitudinal MRI/BLI Tracking of Labelled Cells 
Nanoparticle-based cell tracking relies on the detection of the cell label, not the cell itself, 
and false positive cell tracking can occur if the cell label is released from the cell. Bi-modal 
imaging using BLI to detect live cells at low spatial resolution, and MRI to detect SPION-
labelled cells at high spatial resolution, can give more confidence in nanoparticle-based cell 
tracking results. To assess the relationship between the luciferase and the SPION signals in 
the kidney over time, mice were imaged with BLI and MRI at 0h, 24h, and 48h following IC 
administration of ZsGreen+/luciferase+/SPION+ mMSCs.  
MRI of the kidneys of IC-injected mice revealed extensive hypointensive signals in the cortex 
at 0h, fewer hypointensive signals at 24h, and by 48h the kidneys were comparable to 
baseline images, indicating that SPION-labelled cells were being cleared from the kidneys. BLI 
of mice at the same time points showed a decrease in overall bioluminescence signal over 
time, indicating that cells were dying. Fluorescence microscopy of ZsGreen+ cells in frozen 
kidney tissue supported in vivo MRI and BLI, as the number of ZsGreen+ mMSCs in the 
glomeruli decreased over time (Fig. 6.5A). 
Changes in the overall presence of hypointensive signals in MR images were quantified by 
calculating the T2* relaxation time in the cortex of the kidney, thus giving an indication of the 
relative quantity of SPION-labelled cells present at each time point. Hypointensive signals are 
associated with shorter T2* relaxation times, so the shorter the relaxation time, the greater 
the number of SPIONs present. The T2* relaxation time in the cortex of the kidney was 
statistically significantly lower on the day of cell administration (Fig. 6.5B; 0h, mean = 7.98 
ms, SE = 0.29) than at baseline (mean = 14.56 ms, SE = 0.32; One-way ANOVA, p < 0.001, see 
Supplementary Table S6.1A for Tukey pairwise comparisons). The T2* relaxation time then 
increased towards baseline levels at 24h (mean = 12.57 ms, SE = 0.50) and 48h (mean 13.19 
ms, SE = 0.23), and by 48h the difference compared with baseline levels was no longer 






Figure 6.5: Multi-modal imaging of ZsGreen+/luciferase+/SPION+ mMSCs in the kidneys 
for 48h following IC administration. (A) Tracking mMSCs in the kidneys of mice via MRI 
(left), BLI (middle), and fluorescence microscopy (right). MR imaging of the kidneys 
showed hypointensive signals in the cortex of the kidney immediately following IC 
administration of ZsGreen+/luciferase+/SPION+ mMSCs (0h). The amount of hypointensive 
signal decreased at 24h, and the kidneys were comparable to baseline by 48h, suggesting 
that the SPION-labelled cells were cleared from the kidneys within this time. This 
clearance corresponded with BLI data, where the bioluminescence signals in the region of 
the kidneys decreased over time. The in vivo imaging data was confirmed with 
fluorescence microscopy of fewer ZsGreen+ mKSCs in glomeruli over time. BLI scale: 1.0 
x105 – 1.0 x106 p/s/cm2/sr. Microscopy scale bar represents 50μm. (B-C) Quantification of 
T2* relaxation time in the kidney (B) and liver (C). T2* relaxation time decreased in the 
cortex of the kidney at 0h, due to the presence of SPION+ mMSCs. The T2* relaxation time 
then increased towards baseline levels at 24h and 48h, as SPION-labelled cells were 
cleared from the kidney. In the liver, there was a gradual decrease in T2* relaxation time 




Incidentally, due to the size of the region imaged, the liver was also included when imaging 
the abdomen for cell tracking in the kidneys. Although there were no obvious differences in 
the visual appearance of the liver following IC-administration of SPION-labelled cells (data 
not shown), quantification of the T2* relaxation time revealed a subtle but significant 
decrease in relaxation time between baseline through to 48h following cell administration 
(Fig. 6.5C; baseline, mean = 7.19 ms, SE = 0.29; 0h, mean = 5.48 ms, SE = 0.38; 24h, mean = 
5.10 ms, SE = 0.16; 48h, mean = 5.02 ms, SE = 0.94; One-way ANOVA, p = 0.006, see 
Supplementary Table S6.1B for Tukey pairwise comparisons) and suggested that SPION-
labelled cells may be cleared from the kidneys into the liver.  
6.3.7 Comparison of Administration Route on the Long-Term Biodistribution of mMSCs 
The long-term distribution of mMSCs following IV or IC administration was then assessed by 
BLI; (1) to determine whether entrapped cells were able to leave the lungs following IV 
administration, and (2) to determine whether cells persisted in any organs following IC 
administration. 1.0 x106 mMSCs, were administered IV or IC to immunocompromised mice 
(BALB/c SCID), and mice were monitored via BLI for 30 days.  
Unsurprisingly, cells became trapped in the lungs following IV-administration of mMSCs. 
Within 6h of administration the bioluminescence signal decreased, suggesting that the cells 
had started to die, and by 24h and for the remainder of the 30-day study, signals in two out 
of three mice could no longer be detected with the original signal scale used at 0h (1.0 x105 
– 1.0 x106 p/s/cm2/sr, green frame; Fig. 6.6A). In one mouse, weak signals in the lungs were 
detectable from day 14 when the signal scale was lowered (1.0 x104 – 1.0 x105 p/s/cm2/sr, 
blue frame; Fig. 6.6B), and these signals continued to increase at a slow rate for the 
remainder of the study, becoming detectable using the original scale by day 30 (1.0 x105 – 
1.0 x106 p/s/cm2/sr, green frame; Fig. 6.6C). In all three IV-administered mice, small foci of 
bioluminescence signal could be detected in the lungs ex vivo, but tumours were not visible 
by eye and could not be detected histologically, suggesting very small numbers of mMSCs 
were present. Changes in the bioluminescence signal over time were quantified by drawing 
an ROI around the body of each mouse, and this confirmed the observations from the images: 
that signals decreased rapidly within 6h, and remained very close to background levels for 
much of the study; increasing only towards the end of the 30-day experiment, with one 





Figure 6.6: Longitudinal cell tracking following IV-administration of mMSCs. (A) 
Representative bioluminescence images of a mouse administered with mMSC (IV) (BLI 
scale 1.0 x105 – 1.0 x106 p/s/cm2/sr, green frame) showed that cells were initially located 
in the lungs, but most of the signal was lost by 6h, indicating the majority of the cells had 
died, and in two out of three mice, the in vivo signal did not return by day 30. (B) Weaker 
signals could be displayed with a lower scale (BLI scale 1.0 x104 – 1.0 x105 p/s/cm2/sr, 
blue frame), showing that cells began to proliferate in the lungs from d14, and continued 
to grow at a slow rate until the end of the experiment (day 30), but the signals could only 
be visualised using the original scale (green frame) in one mouse (C). (D) Ex vivo organ 
imaging showed small foci of bioluminescence in the lungs, but no solid tumours were 
observable by eye, and could not be detected by microscopy. (E) Quantification of the 
bioluminescence signal from a region of interest drawn around the whole body of the 
mouse. The signals decreased in all mice between 0 - 6h, and were close to background 
levels by day 1. The signals had started to increase in all mice by day 30, but did not reach 





A typical whole-body biodistribution of cells was observed following IC-administration of 
mMSCs and, similar to the IV-administration, the signals decreased within 6h of 
administration, and were almost completely absent by 24h using the original signal scale (1.0 
x105 – 1.0 x106 p/s/cm2/sr, green frame; Fig 6.7A). Lowering the signal scale to 1.0 x104 – 1.0 
x105 p/s/cm2/sr (blue frame) showed that signals began to increase in the bodies of all IC-
injected mice from day 7, forming small foci of bioluminescence around the hindquarters 
(Fig. 6.7B). Signals then rapidly grew over the remainder of the study, with a mean fold-
change from day 0 of 680-fold (Table 6.2), becoming detectable using the original scale by 
day 14 (Fig. 6.7A), and by the end of the experiment requiring a signal scale that was two 
orders of magnitude greater (1.0 x107 – 1.0 x108 p/s/cm2/sr, orange frame) than the original 
scale (Fig. 6.7C). The development of bioluminescence signals was highly comparable in all 
IC-injected mice with respect to timing, location, and rate of increase. Ex vivo imaging of 
organs revealed small foci of bioluminescence in some organs, however this was less 
consistent between mice, with some mice having signals in the kidneys, heart, liver, or lungs, 
but no mouse had signals in all four organs (Fig. 6.7D). Bioluminescence signals were never 
observed in the spleen or brain. Note that the intensity of bioluminescence foci in the organs 
of IC-injected mice was weaker than those of the IV-injected mice, requiring a lower scale to 
display the signals. Quantification of the bioluminescence signals again confirmed the 
observations from the images, and showed that all mice were comparable in the timing of 
the onset of the increase in bioluminescence signal (Fig. 6.7E). Quantification is only shown 
up to day 14 in Fig. 6.7E, as the signal increase thereafter was so great that the signals from 
earlier time points would no longer be visible on the graph. Comparison of the 
 
Figure 6.7  : Longitudinal cell tracking following IC-administration of mMSCs. (A) 
Representative bioluminescence images of a mouse administered with mMSC (IC) (BLI 
scale 1.0 x105 – 1.0 x106 p/s/cm2/sr, green frame) showed a typical whole-body 
distribution of cells at 0h, but cells started to die within 6h and were almost completely 
absent by 24h. Bioluminescence signals then started to increase, forming foci in the 
hindquarters of the mice, and weak bioluminescence signals were detectable from day 7 
(B; BLI scale 1.0 x104 – 1.0 x105 p/s/cm2/sr, blue frame). Bioluminescence signals 
continued to increase throughout the experiment, requiring a very large scale (1.0 x106 
– 1.0 x107 p/s/cm2/sr, orange frame) to display strong signals by the end of the 
experiment (C). Ex vivo imaging of organs revealed weak foci of bioluminescence signal 
in some organs, but no solid tumours were observable by eye, and could not be detected 
by microscopy. (E) Quantification of the bioluminescence signal from a region of interest 
drawn around the whole body of the mouse. The signals decreased in all mice initially, 
but were clearly increasing by day 14. Each bar represents an individual mouse (n = 5). 
(F) Comparison of the mean bioluminescence signals of IV- and IC-administered mice 
shows that signals proliferated much more rapidly following IC-administration. Data 









highlighted the rapid proliferation of cells following IC-administration, surpassing the original 
level of bioluminescence at 0h by several orders of magnitude towards the end of the study. 
By contrast, signals following IV-administration increased slowly and remained below the 
original level of bioluminescence for the duration of the study (Fig. 6.7F, Table 6.2). 
 
  Bioluminescence Signal (p/s) 
Animal 
Route of Cell 
Administration 
Day 0 Day 30 Fold change 
Mean fold 
change 
Mouse 1 IV 3.68E+07 2.60E+07 -0.29 
-0.68 Mouse 2 IV 4.05E+07 8.80E+06 -0.78 
Mouse 3 IV 3.90E+07 2.01E+06 -0.95 
Mouse 4 IC 6.74E+07 9.83E+10 1457.08 
680.41 
Mouse 5 IC 5.31E+07 5.76E+10 1084.36 
Mouse 6 IC 7.84E+07 1.29E+10 163.71 
Mouse 7 IC 1.13E+08 2.99E+10 262.87 
Mouse 8 IC 1.30E+08 5.65E+10 434.03 
 
6.3.7.1 Analysis of MSC-derived tumours 
Ex vivo imaging of organs of IC-injected mice showed weak bioluminescence signals in some 
organs, but this did not account for the very strong signals imaged in vivo. Inspection of the 
carcasses of IC-injected mice revealed numerous solid tumours in the skeletal muscle, 
predominantly located around the femurs, hips, and lower spine (Fig. 6.8A), but also 
occasionally around the tibia, upper spine, ribs, and forelegs (data not shown). BLI of the 
dissected tumours confirmed that they were strongly bioluminescent (note the very large 
signal scale of 1.0 x108 – 1.0 x109 p/s/cm2/sr, red frame), confirming that they were derived 
from ZsGreen+/luciferase+ mMSCs, and not host tissue. Analysis of the border between 
tumour tissue and normal tissue by light microscopy (H&E-stained; Fig. 6.8C) and 
fluorescence microscopy (fluorescence of ZsGreen reporter gene, Fig. 6.8D) highlighted the 
difference in composition between the normal host tissue (*) and tumour tissue (**), and 
further confirmed that the tumour tissue was derived from ZsGreen+/luciferase+ mMSCs.  
Tumour samples were analysed by a qualified veterinary pathologist and were classified as 
osteosarcoma based on the presence of proliferating cancer cells (Fig. 6.8E) and both  
Table 6.2: Bioluminescence signal quantification. Table displays the total flux (p/s) 
measured from individual animals on the day of cell administration (day 0), at day 30, and 





mineralised and unmineralised osteoid formation (Fig. 6.8F). Further, the bone marrow of IC-
injected mice was extracted and analysed by FACS for the presence of ZsGreen+ cells. 
FACS analysis detected less than 1% fluorescent cells in the bone marrow of IC-injected mice, 
which was comparable to that of a control mouse which did not receive any cells (Fig. 6.9). 
Figure 6.8. Analysis of mMSC tumours formed 30 days after IC administration. (A) 
Photograph of the hindquarters of a mouse with multiple tumours, after removal of the 
skin. Red arrows indicate the location of the tumour foci, demonstrating their presence 
in the skeletal muscle close to the femurs, hips, and spine.  (B) Bioluminescence imaging 
of tumours dissected from an IC-injected mouse. Tumours were strongly bioluminescent, 
confirming that they originated from the administered mMSCs and not host tissue (BLI 
scale BLI scale 1.0 x108 – 1.0 x109 p/s/cm2/sr). (C - F) Histological examination of tumour 
tissue. H&E staining (C) and fluorescence imaging for the ZsGreen reporter protein (D) of 
similar regions of a tumour show the difference in cell composition between the tumour 
(**) and normal tissue (*). (E – F) Higher magnification of H&E-stained tumour tissue 
showing cancer cells (arrow) (in (E) showing a mitotic figure), un-mineralised osteoid 
(black arrowhead), and partially mineralised osteoid (red arrowhead). Scale bars 




This confirmed that the IC-injected mMSCs did not migrate to the bone marrow, and that the 
strong signals imaged in vivo resulted predominantly from osteosarcoma formation in the 
skeletal muscle, with only very weak foci of bioluminescence in some organs. Inspection of 
the carcasses of IV-injected mice did not reveal any solid tumours observable by eye (data 
not shown), suggesting that the bioluminescence signals imaged in vivo resulted exclusively 
from the small foci of signals observed in the lungs ex vivo.  
 
 
6.3.7.2 Comparison of tumour-forming potential based on genetic background and immune 
status of mice 
In order to determine whether the persistence and growth of mMSCs in the mice after IC 
injection was due to the fact that immunocompromised BALB/c SCID mice had been used, or 
because the mMSCs were derived from a BALB/c mouse, mMSCs were next administered IC 
into immunocompetent BALB/c, FVB (inbred strain), and MF1 (outbred strain) mice. The 
initial biodistribution of cells was similar to that in the BALB/c SCID mice, with a whole-body 
distribution of cells at 0h, and a decrease in bioluminescence signal at 24h. In the BALB/c 
mice, tumour growth was highly comparable to that in BALB/c SCID mice, with respect to the 
timing, location, rate of growth, and intensity of signals developed (Fig. 6.10A, B, E). While 
tumours formed at around the same time point in the FVB and MF1 mice as in the BALB/c 
and BALB/c SCID mice, these grew more slowly, and the distribution of tumours was not 
consistent between mice (Fig. 6.10C, D, E). 
Figure 6.9: Fluorescence Activated Cell Sorting (FACS) analysis of bone marrow.  FACS 
analysis of the bone marrow from the femurs and tibias of a uninjected control mouse (A) 
and a representative IC-injected mouse (B) showed that there were no ZsGreen+ mMSCs 





Figure 6.10: Comparison of tumour-formation potential in different mouse strains. 
Representative bioluminescence images of longitudinal tumour monitoring in four strains 
of mouse following IC administration of mMSCs; immunocompromised BALB/c SCID mice 
(A), and immunocompetent BALB/c (B), FVB (C), and MF1 (D) mice. BALB/c mice showed 
very similar tumour formation potential to BALB/c SCID mice, with respect to timing, size 
and location of tumour development (A-B), requiring a BLI scale two orders of magnitude 
greater (1.0 x107 – 1.0 x108 p/s/cm2/sr, orange frame) than that at 0h (1.0 x105 – 1.0 x106 
p/s/cm2/sr, green frame) in order to display the strong signals. FVB and MF1 mice displayed 
weaker foci of bioluminescence signals at d30, and not all animals displayed the same 
biodistribution of foci (C-D). (E) Whole-body quantification of bioluminescence signals over 
time showed that the intensity and timing of increase of bioluminescence signals was 
highly comparable in BALB/c and BALB/c SCID mice, whereas the signals in FVB and MF1 
mice increased at a slower rate. Data points represent the group means, error bars 





The experiments presented in this chapter were designed to answer a series of aims 
regarding the short- and long-term biodistribution of cells following intravenous or 
intracardiac routes of administration. The key findings were: 
(i) Intracardiac administration in mice successfully delivered cells to all major organs of 
the body, with a high degree of correlation between the number of cells 
administered and cell delivery to the kidneys. 
(ii) Multi-modal imaging using BLI and MRI allowed for the combination of whole-body 
and intra-organ imaging of cell biodistribution, and together showed that: (1) 
tracking SPION-labelled cells with MRI was reliable in the short-term, and (2) SPION-
labelled cells were cleared from the kidneys within 48h of administration. 
(iii) mMSCs had a far greater potential to form tumours in vivo following IC 
administration compared with IV, and this propensity to form tumours was affected 
by the mouse strain. 
As shown with BLI in Chapter 4, intravenous administration of cells does not result in cell 
delivery to the kidneys. As such, a key objective of these studies was to establish a method 
of reliably delivering cells to the kidneys. While the intracardiac injection route is commonly 
used in the cancer research field to monitor the metastasis potential of cancer cell 
lines419,422,423, it is rarely reported in regenerative medicine research.  
Because the method is seldom described in detail, making it difficult to learn, the feasibility 
of several IC injection methods were compared: (1) via the diaphragm, similar to cardiac 
puncture for terminal blood collection, (2) via the intercostal space419, and (3) ultrasound-
guided420,421. Of the three methods trialled here, the ultrasound-guided method was superior 
in terms of success of injection and animal health. Ultrasound guidance allowed the direct 
visualisation of the needle within the mouse heart (Fig. 2.4G), which provided the researcher 
with confidence in the correct placement of the needle before administering the cell solution, 
thus reducing the chance of mis-injections into the right ventricle, cardiac muscle, or chest 
cavity. This was an advantage over an alternatively described method of performing IC 
injections419, where the position of needle insertion was measured using anatomical 
features, but the needle was inserted into the heart blindly. Moreover, it was far less invasive 
than the method described by Arguello and colleagues, where the chest was surgically 




Following optimisation of the IC method of cell administration, the initial biodistribution of a 
range of cell types was assessed by BLI and histological detection of cells, and was compared 
with IV administration. IC administration of MSCs and kidney cells of both mouse and human 
origin consistently resulted in a whole-body distribution of cells, delivering cells to the 
kidneys, lungs, heart, liver, spleen, and brain, and while the intensity of the signal sometimes 
varied depending on the transduction efficiency of the different cell types, the pattern of 
distribution was always the same. Moreover, MRI of SPION-labelled MSCs showed 
hypointensive signals in the cortex of the kidneys of IC-injected mice, which was consistent 
with the exclusively glomerular location of MSCs as determined by fluorescence microscopy. 
Conversely, IV administration delivered cells to the lungs only, and long-term imaging 
showed that the majority of lung-entrapped cells died within 24h and did not migrate to any 
other organs within the 30-day study. These results were consistent with previously 
published reports, which showed that IV-administration of cells lead to their accumulation in 
the capillaries in lungs due to the pulmonary first-pass effect111,134,267,349-351,371. However, as 
discussed in Chapter 4, many preclinical studies assessing the efficacy of cell therapies in 
rodent models of kidney disease report migration of IV-administered cells to injured kidneys, 
and direct engraftment of administered cells into damaged tissues115,130,131,147,148,185. These 
conclusions were largely based on the tracking of cells by histological detection of cell 
membrane dyes such as PKH26 or DiI, which have been shown to be unreliable263. Moreover, 
multi-modal imaging of ZsGreen+/luciferase+/SPION+ cells by BLI and MRI in this chapter 
provided further evidence that cells did not reach the kidneys following IV administration.  
Despite many studies reporting beneficial effects on kidney structure and function following 
IV administration, it is possible that delivering cells to the kidneys may result in improved 
efficacy over delivering cells to the lungs with IV administration. While there are many studies 
assessing the efficacy of a cell therapy following arterial (either via the renal artery or carotid 
artery) administration of cells267,296,353,355,425-427, only a few reports provide a direct 
comparison between intravenous and arterial routes of administration on the efficacy of a 
cell therapy in rodent models of kidney injury, and the results are conflicting. While some 
studies reported no difference between intravenous and arterial administration111,127,418, 
others reported a beneficial effect of intra-arterial administration over intravenous426,428,429. 
However, a meta-analysis of 21 studies analysing MSC therapy for experimental kidney 
disease found that overall, arterial administration resulted in a greater reduction in serum 




It is important to note that all three of the studies that showed no difference in efficacy 
between the administration routes were carried out in rat models of AKI (either IRI111,418 or 
cisplatin127). A large body of work105,110,116,134,139,207,352,353,426,427,431-433, predominantly carried 
out in rodent models of AKI, suggests that the mechanism of action of a cell therapy is by 
paracrine/endocrine influences which reduce inflammation in acute injury. This is still poorly 
understood and much more work is required to further elucidate the mechanism of action of 
a cell therapy. However, it might be possible that the location of the cells within the body 
(i.e. renal vs lung-entrapped) may have no influence on the paracrine/endocrine signalling of 
the cells, and amelioration of AKI might be possible regardless of the route of administration. 
However, the amelioration of CKD represents a different challenge to AKI. While therapies 
for AKI are generally administered at the onset of injury and therefore act to prevent injury 
from occurring, in CKD the renal tissue is already damaged, and the replacement of damaged 
cells may be necessary for amelioration in CKD. As such it might be unlikely that immune-
modulation alone would result in amelioration of CKD, and direct engraftment and 
replacement of damaged renal cells may be a more viable therapeutic strategy for CKD.  
The intracardiac administration route can be used in mice to assess the regenerative capacity 
of stem cells with renal potential for integration and differentiation. Cells that have the 
potential to become functional renal cells, such as pluripotent stem cells (PSC), may be able 
to integrate into damaged renal tissue and generate new functional renal cells, and thus 
potentially restore normal structure and function to the damaged kidney. 
PSCs have the capacity to form any cell in the body, and are therefore an attractive cell type 
for regenerative medicine. The generation of renal cells from PSCs in vitro has gained a lot of 
interest in recent years, and there are now various established protocols for the directed 
differentiation of PSCs to renal cells434. Despite the advances in PSC technology for renal 
regenerative medicine, relatively few preclinical studies assessing the efficacy of these cells 
in vivo have been conducted, although the results so far have been promising. Renal 
progenitor cells derived from reprogrammed human bone marrow stromal cells435 or 
reprogrammed human fibroblasts135 have shown efficacy in mouse models AKI, while 
undifferentiated iPSCs had no effect in restoring kidney function135,357. iPSC-derived renal 
progenitor cells have been demonstrated to integrate into embryonic kidney rudiments in 
vitro and form tubular structures435, alluding to their potential capacity to engraft within 
damaged kidneys and form new renal tissue. The delivery of iPSC-derived renal progenitor 




improved efficacy over intravenous administration. Indeed, results from a research group in 
Taiwan have reported that in the same model of AKI (8-week old Sprague-Dawley rats; IRI 
induced by 45-minute unilateral renal ischemia with contralateral nephrectomy), adipose-
derived MSCs had equal efficacy when administered intravenously or arterially418, however 
arterially-administered iPSCs had improved efficacy over IV-administered iPSCs428. It is 
possible that the improved efficacy of arterially-administered iPSC resulted from 
engraftment and differentiation of pluripotent cells, however more robust cell tracking 
experiments are required in order to confirm the direct engraftment of renal progenitor cells. 
In many of these studies using iPSCs and their differentiated progeny, the authors reported 
engraftment of iPSC-renal progenitor cells in injured kidneys, however, as previously 
discussed, they primarily relied on cell membrane dyes and human nuclear staining to track 
the iPSC-derived cells in these studies, and any staining appeared to be sparse. Further 
investigation is therefore required to reliably track iPSC-derived cells in vivo and to further 
elucidate the mechanism of action of iPSC therapy. Moreover, as these studies were 
performed in cisplatin and IRI models of AKI, it will be important to determine whether a 
similar advantage of arterial administration could be observed in a model of chronic kidney 
disease. 
A major factor impeding the clinical translation of cell-based therapies for kidney disease is 
the lack of long-term safety data. Particularly for PSCs, whose defining characteristics include 
the ability to proliferate indefinitely, a serious concern is the risk for tumour formation. In 
the context of PSCs, the key factors involving tumour risk are: 
1. Contamination of the differentiated cell product (therapy) with undifferentiated 
PSCs, which may proliferate in vivo, forming teratomas  
2. The introduction of retroviruses for cell transduction, in the case of iPSCs; particularly 
the introduction of Klf4 and c-Myc, which are known oncogenes  
3. Epigenetic changes during reprogramming or culture in vitro65,436 
There are various measures that can be taken to reduce the risk of tumour formation90,92, 
however it is vital to carry out robust, long-term preclinical safety studies prior to clinical 
translation. While many investigators studying the efficacy of cell therapies do acknowledge 
the safety concerns surrounding tumour formation, relatively few studies follow the animals 
for an extended period of time. This chapter highlighted the importance of prolonged 
monitoring of mice. Following the administration of luciferase+ mMSCs, the bioluminescence 




at that time point, the formation of tumours at a later time point would not have been 
detected. Similarly, Kunter et al. published a report in 2006 describing the beneficial effects 
of MSCs on glomerular healing in a rat model of glomerulonephritis437. However, it was not 
until the following year when the authors tested the efficacy of the MSCs in a chronic version 
of the same model  that adverse effects were discovered426. 60 days following arterial 
administration of MSCs, the authors discovered that the MSCs had maldifferentiated to form 
adipocytes in the glomeruli; a complication that was not detected in the initial 10-day study. 
A relatively short period of only 30 days was used in the studies in this chapter. D1 mouse 
MSCs, a highly tumourigenic cell type438, were chosen specifically to investigate the effect 
that route of administration and genetic background of the host would have on tumour 
formation. As such, longer analysis was not possible due to the tumour burden on animals. 
However, when assessing the safety of cell therapies intended for the clinic, longer studies 
of six to twelve months are likely to be required92. 
One of the aims of this chapter was to determine whether route of administration had any 
effect on tumour formation. It was shown that IV administration led to the formation of very 
small, slow-growing tumours restricted to the lungs, while intracardiac administration 
promoted the rapid development and proliferation of multiple large tumours in mouse 
skeletal muscle. Additionally, there were some very small foci of bioluminescence in some 
organs following IC administration, but not after IV. These results were obtained from highly 
tumourigenic mMSCs, and as such are not intended to suggest that clinical MSC therapies 
pose such a high tumour risk. Rather, they highlight the importance that the route of 
administration may have on various aspects of RMT safety, such as tumour formation. It is 
therefore vital to carry out robust safety studies in a model that resembles the clinical 
scenario as closely as possible. This involves administering a clinically-appropriate dose, via a 
clinically-relevant administration route, and in an animal model that resembles the clinical 
disease as closely as possible92.  
A key feature of this chapter is the use of preclinical imaging to facilitate the monitoring of 
cells in vivo. Traditionally, preclinical research has largely involved the histological 
examination of tissues for a variety of purposes, including the analysis of tissue damage, 
degree of amelioration by a cell therapy, and the biodistribution of exogenously administered 
cells. Not only does this approach require the sacrifice of a large number of animals at many 
time points, and precludes the monitoring of individuals over time, it makes it difficult to 




administration of iPSC-derived renal progenitor cells for treatment of cisplatin-induced AKI, 
Imberti et al. inspected only the organ of interest - the kidneys - and reported no 
maldifferentiation eight weeks following cell treatment135. While this is good news for the 
kidney, it does not consider the possibility of off-target effects on other organs of the body.  
Imaging technologies are highly advantageous in preclinical research. However, each 
modality is associated with various advantages and disadvantages, and as such no single 
imaging technology alone is ideal. The combination of two or more imaging modalities can 
however strengthen the scientific data obtained in an experiment, with each modality 
complementing the other. As shown in this chapter, BLI is an excellent tool for whole-body 
imaging and is ideal for monitoring the biodistribution of cells over time. However, the spatial 
resolution is poor and it is not possible to definitively identify the organ in which the signals 
are located without sacrificing the animal and imaging the organs ex vivo. By incorporating 
MRI into the imaging regime, the inter- and intra-organ biodistribution of cells can also be 
ascertained, thus providing more information from each animal. Multi-modal imaging 
approaches are not limited to monitoring cell biodistribution, and are gaining increased 
interest in regenerative medicine research for a wide range of applications281,414,439. Notably, 
Ngen et al. developed a clinically-translatable, dual-modality cell imaging system, whereby 
live and dead cells could be distinguished in vivo using MRI, and the results were validated 
with BLI439, and Galisova et al. investigated the effect that MSCs had on the 
neovascularisation of subcutaneously implanted scaffolds, using MRI to monitor the scaffolds 
and image tissue perfusion and vessel permeability, and BLI to monitor the survival of 
MSCs281. 
In summary, the data presented in this chapter highlighted the importance of the route of 
administration and long-term safety assessment of RMTs. Arterial administration resulted in 
cell delivery to the kidneys, and thus may provide a therapeutic advantage over intravenous 
administration for chronic disease. Intracardiac cell administration provided a reliable 
method of delivering cells to the kidneys in mouse models, where renal artery administration 
is not feasible, and thus the IC method will be valuable for assessing the benefits of cell 
delivery to the kidneys in mouse models of CKD. Importantly, this chapter emphasised the 
need for long-term safety studies prior to clinical translation of RMTs, and preclinical imaging 
is a valuable asset for this purpose; reducing the number of animals required for long-term 
studies, increasing the data obtained from each animal by longitudinal imaging, and 





6.5 Supplementary Table 
 
A   n Mean Grouping 
Kidneys 
Baseline 10 14.56 A     
0h 6 7.98    C 
24h 6 12.57   B   
48h 4 13.19 A B   
              
              
    T2* Relaxation Time 
B   n Mean Grouping 
Liver 
Baseline 5 7.19 A     
0h 3 5.48   B   
24h 3 5.10   B   
48h 2 5.02   B   
 
Supplementary Table S6.1: Tukey Pairwise Comparisons. Two separate post-hoc 
statistical analyses following statistically significant results from separate one-way 
ANOVAs comparing the T2* relaxation time in the kidneys (A) and in the liver (B) Groups 












The experiments described in this thesis were designed to explore various aspects of the 
safety and efficacy of cell-based regenerative medicine therapies in models of kidney disease. 
Two models were utilised here, adriamycin nephropathy as a model of chronic glomerular 
kidney disease, and ischemia-reperfusion injury as a model of acute kidney injury, 
predominantly featuring tubular injury. The experiments focussed primarily on using novel 
imaging-based methods of assessing kidney function and tracking cells in vivo, rather than 
more traditional biochemical and histological techniques. There were several key findings 
and themes throughout this thesis: 
 
1. Novel methods of assessing kidney function in mice were superior to traditional 
biochemical assays.  
Two novel methods of monitoring renal function were explored in this thesis: transcutaneous 
measurement of FITC-sinistrin clearance, and photoacoustic imaging of IRDye clearance 
kinetics. The experiments in Chapter 3 demonstrated that both novel methods correlated 
very strongly with histological scoring of glomerular damage, whereas urinary albumin did 
not correlate as strongly with histological scoring, and both serum creatinine and BUN 
measured at week 5 did not show any statistically significant changes between injured and 
control mice. Even though both the transcutaneous device and the MSOT provided a reliable 
assessment of kidney function, the transcutaneous device was chosen as the method to be 
used in further studies as it had several practical advantages over the MSOT: 
a. Multiple animals could undergo the transcutaneous measurement at a time, making 
this method very high-throughput and time-effective. Conversely, only one animal 
could be imaged in the MSOT at a time, and there was significant preparation and 
temperature-equilibration time required, thus limiting the number of animals that 
could be imaged in a day. 
b. Data processing and interpretation from the transcutaneous device was very fast and 
simple, requiring only a few minutes to calculate the half-life, whereas data from the 
MSOT took several hours to process, reconstruct, and analyse, and analysis and 
interpretation could be more complicated.  
c. Required anaesthesia time was vastly lower for the transcutaneous measurement 
(less than 10 minutes) compared with MSOT imaging (approximately two hours). This 




was also better for the welfare of animals. This was particularly important in the IRI 
model, where multiple measurements in a short space of time was required. 
d. In the IRI model, the incision site/sutures interfered with the imaging data. MSOT 
imaging was carried out in IRI mice (data not shown), however it was found that the 
incision site/sutures, which were unavoidably directly above the kidney and 
therefore in the imaging plane, produced a photoacoustic signal which interfered 
with the signals in the kidney. Undyed suture material was used to try to avoid this, 
however the suture became dyed with blood, and the incision site would have 
contained small amounts of dried blood, which would have contributed to 
interference with the photoacoustic signal. This made it difficult to delineate the 
kidney and determine where to set the imaging plane, and also where to draw ROIs 
for signal quantification. Conversely, the sutures were not an obstacle for the 
transcutaneous device, as the location of the device could be altered to 
accommodate the sutures, without affecting the data. 
The transcutaneous device was therefore chosen as the primary method of measuring kidney 
function in IRI mice and was used to inform the choice of ischemia time in the initial 
optimisation studies whilst setting up the IRI model (Chapter 5). An additional advantage of 
the transcutaneous measurement in the IRI model was that data on the renal function of 
animals was available immediately after measurement, and thus animals in suspected renal 
failure could be identified in a timely manner, which was a particularly valuable tool whilst 
setting up a new model. Furthermore, the transcutaneous device proved to be sensitive and 
reliable in detecting kidney injury in IRI mice, correlating very strongly with histological 
assessment of tubular damage.  
Previous data have shown that the transcutaneous device is useful for monitoring kidney 
function in healthy animals, in addition to a range of kidney injury models, including 
unilateral nephrectomy234,237, polycystic kidney disease234,237, salt-sensitive hypertension242, 
diabetic CKD243, non-diabetic CKD244, sepsis245, and cisplatin-induced AKI134. The data 
presented in this thesis add to this list, demonstrating that the transcutaneous device is also 
useful in the adriamycin (Chapter 3) and IRI (Chapter 5) models. The transcutaneous device 
has been shown in Chapter 3 and by Cowley and colleagues to be more sensitive to changes 
in kidney function than serum biomarkers, with significant changes in FITC-sinistrin clearance 
but not in SCr or BUN242. Additionally, the transcutaneous measurement is minimally invasive 
and less stressful to the animals than repeated blood and urine sampling. Therefore, the 




preclinical models of kidney injury, especially in cases where longitudinal assessment of 
kidney function is required.  
Furthermore, the transcutaneous device is clinically translatable. MediBeacon (Missouri, 
USA) have developed a clinical version of the device440 to be used as point-of-care method of 
measuring GFR in real time in hospitalised patients. Clinical studies began in 2013, assessing 
the use of the device in healthy patients247. The next clinical study will enrol patients with 
impaired renal function, and the ultimate goal is to provide a new gold-standard for 
measuring renal function, and enable early detection of impaired renal function and thus 
rapid intervention440. 
Although the MSOT was not preferred as a method of measuring kidney function, it has some 
advantages over the transcutaneous device that must be acknowledged. The transcutaneous 
device only has one function, whereas the MSOT is capable of imaging multiple different 
physiological parameters, such as tissue perfusion and oxygenation status441, and kidney and 
liver function248, and can also be used to track appropriately-labelled cells in vivo. Thus, MSOT 
has multiplexing capabilities, and it is possible to monitor kidney function and track labelled 
cells in the same imaging session. Cells can be labelled with probes that maximally absorb in 
the near infrared, such as gold nanoparticles442-444 or carbon nanotubes445, or by transducing 
cells with reporter genes such as infrared fluorescent protein (iRFP)335 or tyrosinase332, thus 
allowing detection of administered cells in vivo by photoacoustic imaging. Recently, Nam and 
colleagues demonstrated the value of photoacoustic imaging in regenerative medicine444. 
The authors aimed to assess the therapeutic efficacy of adipose-derived stem cells to 
improve a burn injury. They used photoacoustic imaging to track gold nanorod-labelled cells 
in vivo, and to assess the severity of injury and the degree of tissue regeneration following 
cell therapy in a cutaneous burn model. Furthermore, an interesting study by Ricles and 
colleagues labelled cells with both gold nanorods and gold nanospheres in order to 
differentiate between live and dead cells in vivo, and also image the immune response to cell 
administration443. The peak absorption of gold nanospheres is changed when they are 
endocytosed by macrophages, allowing the differential identification of signals coming from 
live cells labelled with gold nanorods, and those coming from endocytosed cells labelled with 
the now-visible gold nanospheres. Using this sophisticated method, Ricles et al. could 
monitor the viability of administered cells in vivo and the rate of tissue macrophage 




In addition to cell tracking, photoacoustic imaging also has applications in preclinical 
regenerative medicine research through its ability to image tumours. Due to the high 
vascularisation of most tumours, endogenous haemoglobin contrast allows tumour 
imaging251. However, by using a contrast agent which passively accumulates in tumours, such 
as a fluorescent dye, indocyanine green, conjugated to human serum albumin446, the 
sensitivity and depth of tumour visualisation can be increased by up to 380%. More specific 
tumour targeting can be achieved by conjugating photoacoustic probes, such as gold 
nanoparticles, to antibodies specific to particular cancer cell antigens447. 
Photoacoustic imaging was previously limited to preclinical use, but it is now being developed 
for clinical applications, with a handheld MSOT scanner recently developed by iThera 
Medical448. The penetration depth limits clinical photoacoustic imaging to relatively 
superficial tissues, but recent work has demonstrated the potential of photoacoustic imaging 
for non-invasive assessment of Crohn’s disease activity259, in addition to imaging human 
vasculature258 and cancer257. 
 
2. Human kidney-derived cells showed a trend towards improved kidney injury when 
administered early (day one), but not when administered late (day 15) to mice with 
adriamycin nephropathy.  
The efficacy of cells derived from the human kidney has previously been shown in the 
rhabdomyolysis147-149,345 and cisplatin134 models of AKI, and the adriamycin model of CKD185. 
All studies report beneficial effects of hKCs in the various models, either with faster recovery 
of serum biomarkers of kidney injury148,345 or an earlier and/or lower peak in kidney 
injury134,147,149,185. In all of these reports, the hKCs were administered very early in the course 
of injury. The results of the acute study in Chapter 4 agreed with this, with attenuated weight 
loss and lower urinary albumin levels at day 10 in ADR mice administered hKCs on day one, 
compared with saline treated ADR mice. However, when treatment was delayed to a later 
stage in the progression of the disease (day 15), the hKCs no longer had a beneficial effect on 
urinary albumin excretion, and furthermore, had no effect on FITC-sinistrin clearance or 
histological scoring of glomerular injury.  
These results are somewhat similar to those described by Magnasco and colleagues who 
reported that when MSCs were administered to rats that the same time as ADR, the rats were 
protected from severe glomerulosclerosis, however when MSC treatment was delayed to 60 




administration time, the authors reported no differences in serum creatinine or proteinuria 
between MSC- and saline-treated rats. Furthermore, Caldas and colleagues reported that 
MSC therapy was less effective in the later stage of CKD, modelled by 5/6 Nx, compared with 
an earlier stage of CKD, modelled by 2/3 Nx219. 
The vast majority of published studies administered cells very early following the induction 
of injury, however this will not be possible for most human patients. The data presented in 
Chapter 4 and the results described by Magnasco and colleagues and by the team around 
Caldas highlight the importance of investigating the timing of therapeutic intervention, and 
indicate that cell-based therapies may offer no or limited amelioration to patients in the later 
stages of CKD. Very few preclinical studies have assessed the effect of late timing of 
administration, and importantly, relatively few studies used CKD models, rather than AKI 
models. Recent reviews have suggested that cell-based therapies hold great promise for 
treating CKD404,449, however further investigation is therefore required using models of CKD 
to assess the latest time point at which cell therapy may offer a beneficial effect to patients 
with CKD.  
 
3. Human kidney-derived cells had no beneficial effect on kidney function in the IRI 
model, and this may have been due to IRI-induced lung injury preventing cell death. 
There are a great number of published studies demonstrating ameliorating effects of many 
different types of cells in the IRI model. As such, it was a surprise when this was not the case 
in the experiments described in Chapter 5: none of the three cell types assessed, hKCs, hUC-
MSCs, or hBM-MSCs had a significant effect on FITC-sinistrin clearance throughout the course 
of the experiment, or on SCr, BUN, tubular injury (KIM-1 tissue expression), or tubular cell 
proliferation (Ki67 tissue expression) at days one (only hKCs assessed) or four (all cell types 
assessed). The results from bioluminescence imaging of luciferase+ hKCs 24h following cell 
administration were also unexpected. In previous studies using BLI to track cells over time, 
the signal was always markedly decreased 24h following cell administration, due to death of 
the luciferase+ cells in vivo. By contrast, the intensity of the bioluminescence signal was 
maintained over 24h in the experiments described in Chapter 5, and this was the first time 
that we had observed this in our laboratory.  
A possible explanation for the survival of the IV-administered hKCs could be IRI-induced acute 
lung injury376, and that the survival of the cells prevented the amelioration of AKI. There are 




however there are no reports describing this phenomenon following renal IRI. As such, the 
mechanisms behind pulmonary cell survival and the relationship with renal amelioration are 
unknown.  
Further, it is unclear why other studies on cell efficacy in the IRI model have not reported this 
phenomenon. It is possible that the renal injury induced in our laboratory is more severe than 
in others, and that this leads to more severe ALI. FITC-sinistrin clearance was shown to be a 
more reliable measure of kidney function than serum biomarkers, and as such, this was the 
primary parameter used to assess injury levels when setting up the IRI model. However, this 
meant that published FITC-sinistrin data in the IRI model were not available to compare to 
ours. Subsequent comparison of serum biomarker levels between our model and other 
published studies show higher SCr and BUN in our model, indicating more severe renal injury 
(Fig. 7.1, Table 7.1). It is difficult to directly compare different studies due to variations in the 
models, however Figure 7.1 gives an idea of the approximate injury levels induced in other 
models, and how the model described in this thesis compares. Jang et al., (2014) and Xing et 
al., (2014) used a bilateral model with 27 and 28 minutes ischemia respectively, and reported 
mean SCr levels at day one of approximately 2.4 and 1.1 mg/dL respectively105,110, compared 
with the much higher level of 5.71 mg/dL in the study in Chapter 5. Toyohara et al., (2015) 
used a model of IRI that is more similar to the one described here, with unilateral ischemia 
and a contralateral nephrectomy, but a much longer ischemia time of 40 minutes357. Despite 
the longer ischemia time, Toyohara et al., reported much lower SCr levels of approximately 
0.06 mg/dL at day four, compared with 1.14 mg/dL in Chapter 5. Ranghino et al., (2017) also 
used a unilateral ischemia with contralateral nephrectomy model, with a long ischemia time 
of 35 minutes120. They only reported SCr levels at day two, and therefore cannot be compared 
with the day one and four measurements reported in this thesis, however the levels they 
described at day two are roughly comparable to those reported by other studies at the same 
time point. The difference in BUN levels between those reported in Chapter 5 and in other 
studies follow a similar trend, with higher levels in the IRI model in this thesis (Fig. 7.1B, Table 
7.1).  
Therefore, it is possible that the more severe renal injury induced in the model described in 
Chapter 5 resulted in more severe ALI than would be seen in other IRI models. I propose that 
this increased lung injury could account for the lack of cell death following IV administration 
of hKCs. Consequently, if cell death is required for the ameliorating effects of cell therapy on 
kidney injury, then this may explain why we did not detect any beneficial effects following 






    SCr (mg/dL) BUN (mg/dL) 
  Model day 1 day 2 day 4 day 1 day 2 day 4 
Thesis 
male BALB/c mice 
unilateral w/Nx, 31 
min 
5.71 ND 1.14 342.6 ND 113.1 
Toyohara et 
al., (2015) 
male NOD/SCID mice 
unilateral w/Nx, 40 
min 
ND 0.05 0.06 ND 100 80 
Ranghino et 
al., (2017) 
male SCID mice 
unilateral w/Nx, 35 
min 
ND 1.40 ND ND 80 ND 
Jang et al., 
(2014) 
male C57BL/6 mice 
bilateral, 27 min 
2.40 2.60 ND 150 225 ND 
Xing et al., 
(2014)  
male BALB/c mice 
bilateral, 28 min 
1.16 1.54 ND 106.9 154.4 ND 
 
Figure 7.1: Comparison of the mean (actual or estimated from graph) SCr (A) and BUN (B) 
values in IRI mice between the model used in this thesis, and four other published models. 
Table 7.1: Comparison of the mean (actual or estimated from graph) SCr and BUN values 




These results have opened up a very interesting aspect of regenerative medicine research, 
and a great deal of further investigation is required to understand the role of ALI and cell 
death in the ameliorative capacity of a cell therapy for renal injury. 
4. Preclinical imaging methods are valuable tools for monitoring cell biodistribution in 
vivo, and this can inform the mechanism of action, in addition to the safety, of a cell 
therapy.  
Conventional methods of tracking exogenously-administered cells generally involve 
histological detection of cells labelled with fluorescent cell membrane dyes. As discussed 
throughout this thesis, this method is not ideal due to the likelihood of false positive cell 
identification, the inability to track cell biodistribution in individual animals over time, and 
the large number of animals that must be sacrificed for these types of experiment. 
Importantly, the high chance of false positive cell detection may not only lead to erroneous 
data, but may result in incorrect conclusions being drawn from the data. Alternatively, 
preclinical imaging offers a far more reliable method of tracking cells in vivo, allows 
longitudinal monitoring of individual animal, and thus reduces the number of animals 
required.  
There are several published studies that have used cell membrane dyes to track cells 
histologically and, upon detecting the dye in the kidney, have concluded that the therapeutic 
cells engrafted into the kidney147,148,185. Further, the cell membrane dye sometimes co-
localised with markers of specialised renal cells, such as the proximal tubule marker lotus 
tetragonolobus agglutinin (LTA)147,148, distal tubule marker dolichos biflorus agglutinin 
(DBA)147, and podocyte markers podocin, synaptopodin, Wt1, and nephrin185, and as such the 
authors further concluded that the administered cells differentiated in vivo, following their 
engraftment, and that this was how the cells exerted their beneficial effect on kidney injury. 
Importantly, Santeramo and colleagues have recently shown that this method of cell tracking 
results in false positive signals in the kidney134. Other studies have used slightly different 
methods to track cells histologically, for example by detection of male cells in female 
recipients130,215,352,433, or by immunostaining of human cell markers134,149. These methods are 
somewhat more reliable than cell membrane dyes, but still require the sacrifice of animals 
for histological analysis of tissues ex vivo and do not allow the differentiation between live 
and dead cells. Many of these studies have also reported the presence of administered cells 
in the kidney, however the number of cells detected must be taken into context when 




It must be noted that under certain conditions a very small number of cells may be able to 
bypass the lungs. Hypoxic conditions have been shown to recruit intrapulmonary 
arteriovenous anastomoses, which are large (at least 70μm in the rat) vessels that connect 
the pulmonary arterial and venous circulations, thus bypassing the capillary beds450,451. AKI is 
known to cause acute lung injury376, and the subsequent hypoxia may therefore lead to the 
recruitment of intrapulmonary arteriovenous anastomoses. Bates and colleagues showed 
that when one million 25μm microspheres were intravenously administered to rats under 
normoxic conditions, no microspheres were detected in the kidneys, but under hypoxic 
conditions, on average around 1,000 microspheres were detected in a single kidney450. 
Furthermore, this number was highly variable, ranging from 11 to 5,004 microspheres in a 
single kidney across five rats. This data may explain why cells are occasionally detected in the 
kidneys of some animals, but the very small number of cells that are able to reach the kidneys 
are highly unlikely to significantly contribute to the ameliorative effect89,134.  
The results of cell tracking studies in this thesis, and by other authors have demonstrated 
that intravenously administered cells predominantly remain trapped in the lungs134,349,350,371, 
and therefore renal homing, engraftment, and differentiation do not contribute to the 
ameliorative effect of the cells. Furthermore, recent data from our laboratory indicates that 
it may be essential for the cells to die in order to instigate the inflammatory response that 
leads to renal amelioration134. In this context, the results in Chapter 5 are important, as they 
suggest that the lack of cell death 24h following cell administration may be responsible for 
the lack of amelioration of kidney injury. This is in contrast to the results in Chapter 4, where 
the hKCs promptly died in the lungs of mice following IV administration, and led to a 
beneficial effect on kidney function. Thus, preclinical imaging is a useful tool for gaining 
insights into the mechanism of action of a cell therapy.  
Furthermore, the minimally invasive nature of preclinical imaging allows the long-term safety 
of cell therapies to be monitored in individual animals. Importantly, the data in Chapter 6 
highlights the need for long-term monitoring, as the bioluminescence signals initially 
decreased to near-background levels, and had imaging ceased at that timepoint, the high 
tumourigenicity of the mMSCs would not have been identified. Bioluminescence imaging was 
very useful for high throughput, whole body imaging of animals, and is highly recommended 
as a valuable tool for further preclinical safety assessment of RMTs in the future.  
However, a disadvantage of BLI is the poor spatial resolution, meaning that the exact 




useful to gain additional information on the biodistribution of cells in vivo. As shown in 
Chapter 5, by labelling cells in two ways, with a luciferase gene and with SPIONs, the cells 
could be tracked in vivo by both BLI and MRI. Thus, the benefits and limitations of each 
modality complemented the other, allowing sensitive whole-body imaging of live cells by BLI, 
and organ-specific, high resolution imaging of cells by MRI. It must be noted that cell labelling 
methods that involve probes such as SPIONs suffer from signal dilution when cells divide, and 
risk false positive cell detection if the probes are released from labelled cells, for example 
when they die or are phagocytosed, thus limiting the long-term monitoring of cells by this 
method. However, this particular multi-modal combination is highly useful for short-term 
analysis of cell biodistribution.  
 
5. Ultrasound-guided administration is a safe and feasible method of arterial cell 
administration in mice, which successfully delivers cells to the kidney, however the 
potential for tumour formation differs following intravenous and arterial 
administration. 
The vast majority of preclinical studies assessing the efficacy of cell therapies in animal 
models administer the cells intravenously. However, a meta-analysis of 21 studies found that 
arterial administration of MSCs resulted in improved efficacy over intravenous 
administration430. Despite this, individual studies directly comparing the effect of 
administration route on efficacy have yielded conflicting results111,127,418,428,429,437, and as such, 
further investigation is required to determine the optimal route of administration. Therefore, 
it is important to establish safe and reliable methods of arterial administration in mice. In 
Chapter 6, an ultrasound-guided intracardiac method of arterial cell administration was 
described. Once optimised, this method was found to be safe and highly reproducible, with 
limited side-effects and mis-injections. Further, this method successfully delivered cells to 
the kidneys, with a dose-dependent response in the number of cells found in the kidneys. 
Other methods of arterial administration for renal cell delivery include renal artery and 
carotid artery injections296,353,355,425-427, however both methods require surgery, and in 
particular, the renal artery injection is difficult in mice due to the small size of the vessel, and 
requires highly invasive surgery, with a large abdominal incision and manipulation of the 
intestines in order to access the renal artery. By contrast, intracardiac cell administration is 
a fast procedure that requires only brief anaesthesia, and the use of ultrasound imaging to 
guide the injection makes it highly reproducible and reliable. This method is commonly used 




regenerative medicine. This injection route is therefore recommended as a method of 
arterial cell administration in mice, and will be valuable in further assessments of the effect 
of route of administration on cell efficacy. 
In addition to affecting the efficacy of a cell therapy, the results of Chapter 6 demonstrated 
that the route of administration may also affect the safety of a cell therapy, with arterial 
administration of mMSCs leading to rapid and aggressive tumour formation, compared to 
limited and slow-growing tumour formation following intravenous administration. 
Furthermore, the strain of the animals used affected the tumour formation. BALB/c mice 
were highly susceptible to tumour formation, whereas FVB and MF1 mice were less 
susceptible. The increased sensitivity of BALB/c mice was most likely due to the fact that the 
mMSCs were derived from a BALB/c mouse, and the inbred nature of this strain meant that 
the mMSCs were unlikely to have been recognised by the immune system, allowing 
unrestricted tumour growth. Nonetheless, these results highlighted the need for extensive 
and robust safety assessment of stem cell therapies in animals prior to clinical translation. 
 
Taken together, many studies have shown that a range of cell types have a beneficial effect 
on kidney function, and that this beneficial effect is most likely mediated by paracrine effects 
which modulate the immune system to promote an anti-inflammatory microenvironment. 
However, there are some key questions that still need to be addressed. 
(i) If the cells have a paracrine action, can the same effect be achieved by administering 
only the appropriate cytokines/chemokines (i.e. conditioned medium), instead of the 
cells?  
(ii) If cells themselves are indeed necessary to achieve a beneficial effect, which is the 
best cell type to achieve maximum effect? 
(iii) Which is the best administration route?  
(iv) When is the best time to administer a cell therapy? 
(v) What is the ideal dose of cells? 
Several studies have assessed each of these questions individually, however the results 
between studies are conflicting, and there is not yet a general consensus on the efficacy of 
conditioned medium, nor on the most appropriate cells and administration regime. 




different types of kidney injury may have different requirements. Further work is therefore 
required to answer these questions.  
There are additional features of preclinical studies that must be considered and addressed in 
order to advance progress towards clinical translation. Almost all preclinical studies, 
including the studies described in this thesis, are conducted in animals that are inbred, young, 
of a single sex (generally male), and otherwise healthy. Whilst these conditions work in favour 
of the researcher, as controlling these factors leads to lower degree of variation in the 
response of the animals, and therefore a higher chance of obtaining statistically significant 
data, this is clearly not representative of human patients. As such, the promising results 
observed in preclinical studies may not be replicated when clinical trials begin. It is therefore 
imperative to assess the efficacy of a promising cell therapy in diverse models that use 
outbred animals, older animals, both genders, and animals with co-morbidities, such as 
underlying CKD, diabetes, or hypertension222. Moreover, the current publication bias towards 
only reporting positive results on surviving animals, and ignoring negative data, animal 
mortality, and side-effects221, ultimately impedes the overall progress towards clinical 
translation. As such, more emphasis should be placed on conducting carefully-designed 
studies that report on all outcomes, regardless of whether they are seen as positive or 
negative. This will provide the research community with a more comprehensive 
understanding of both positive and negative results, and will help to drive preclinical research 
to clinical translation. 
Overall, the experiments described throughout this thesis have demonstrated the use and 
value of novel methods of assessing kidney function and tracking cells in vivo with the 
ultimate aim of assessing the safety and efficacy of cell-based therapies. All methods 
described are minimally invasive, allowing individual animals to be monitored over time and 
reducing the number of animal required for experiments. Furthermore, all novel methods 
used are more reliable than conventional methods, thus delivering stronger and more 
accurate data, and provide important insights into the mechanism of action of cell therapy 
that are not confounded by false-positive results. Consequently, these novel methods of 
measuring renal function and tracking cells are recommended for widespread use in 
preclinical assessment of regenerative medicine therapies for kidney disease. By using more 
accurate and reliable methods, in addition to more diverse and robust experimental models, 
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